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Abstract 
 
 
 
IDENTIFICATION AND QUANTIFICATION OF PROTEIN CARBONYLATION BY MASS 
SPECTROMETRY 
 
By Qingyuan Liu, Ph.D. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
 
Director: Professor Scott Gronert, Department of Chemistry 
  
 
 
Accumulated evidence indicates oxidative stress plays important roles in disease and aging. 
Under oxidative stress, lipid peroxidation (LPO) leads to reactive carbonyl species (RCS) that 
can modify a wide range of biomolecules including protein, DNA and carbohydrate. In this 
dissertation, we investigate the modification of two model proteins, human serum albumin 
(HSA) and aconitase (ACO), by the LPO-relevant α, β-unsaturated aldehydes, acrolein (ACR) 
and 4-hydroxy-2-nonenal (HNE). The investigation is focused on the characterization and 
quantification ACR and HNE addition to the model proteins. A correlation between HNE 
modification and ACO activity is also determined. These results provide insights into the impact 
of oxidative stress at the molecular level and are relevant to aging and disease states. We finally
  
 
investigate protein carbonylation in ischemic mouse heart mitochondia, and develop a 
quantitative method for detecting carbonylated protein in this system. The research is based on 
liquid chromatography/mass spectrometry (LC/MS), Western Blots, and enzymatic assay.
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Chapter 1: Introduction
  2
Introduction 
Oxidative stress and disease 
Evidence of oxidative stress playing important roles in disease and aging has accumulated over 
many years. Oxidative stress is caused by an imbalance between the production of pro-oxidants 
and the anti-oxidant defense capacity of an organism.1 This imbalance is induced by one of three 
factors: 1) increased pro-oxidant generation, 2) decreased anti-oxidant protection, or 3) failure to 
repair oxidative damage.2 
Chemically, a substance that can accept electrons is an oxidant and one that can donate electrons 
is a reductant. In biological environments, they are identified as pro-oxidant and anti-oxidant.3 
Generally the pro-oxidants are referred to as reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). The ROS and RNS are generally oxidizing molecules and can be 
classified into two types of compounds, free radicals and nonradicals. The free radicals include 
compounds such as hydroxyl radical, superoxide ion radical, oxygen, peroxyl radical and nitric 
oxide radical.4 These compounds contain at least one unpaired electron. The unpaired electron 
makes these compounds highly reactive with a strong affinity to donate or obtain another 
electron to attain stability.5 The nonradicals include compounds such as hydrogen peroxide, 
organic peroxide, peroxynitrite, ozone, singlet oxygen, hypochlorous acid and aldehydes.4 Most 
of the ROS have a short life span, and often the half-life depends on the environment of the 
medium. In some cases, a relatively long life span for the ROS might imply a stronger toxicity 
because it provides adequate time to reach a biological target and cause damage far from the site 
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of production.6 
Generation of ROS and RNS can occur in response to diverse stimuli, which can come from both 
exogenous and endogenous sources.7 Exogenous sources mainly include exposure to ionizing 
and nonionizing irradiation such as ultrasound, UV and  irradiation,8, 9 exposure to xenobiotics 
and chemicals such as toxins, pesticides and alcohol,10, 11 or exposure to pollutants such as 
cigarette smoke, car exhaust and industrial contaminants.12 Drugs, food, bacteria and viruses are 
also major exogenous sources of ROS and RNS.13-16 Endogenous sources mainly include 
mitochondrial respiration,17 direct and indirect ROS producing enzymes such as NO synthase 
and xanthin oxidase,18 metabolism,19 and diseases such as metal disorders and ischemic 
processes.20 Generation of ROS and RNS from endogenous sources causes chronic problems 
because it is a constant process during the life of the cell.21, 22 
Anti-oxidants are substances that prevent or repair oxidative damage. In general, anti-oxidants 
include exogenous small molecule anti-oxidants such as ascorbic acid (vitamin C) and 
tocopherol (vitamin E),23 endogenous small molecule anti-oxidants such as glutathione (GSH),24 
small protein anti-oxidants such as thioredoxins and glutaredoxins,25 and enzymes such as 
catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPX).26 These 
different anti-oxidants all act to reduce oxidative damage in vivo, but their mechanisms of action 
are highly diverse. Based on their mode of biochemical action, anti-oxidants are divided into 
preventive and chain-breaking anti-oxidants.27-29 The preventive anti-oxidants prevent the 
generation of radical chain reactions by scavenging ROS directly or binding transition metals 
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needed to produce ROS. The chain-breaking anti-oxidants interrupt the reproduction of radical 
chain reactions by forming a stable product.30, 31 The pro-oxidant/anti-oxidant balance maintains 
physiological homeostasis and determines the degree of oxidant stress. Any disruption of the 
balance will lead to cell death or to the acceleration of ageing and age related diseases (Figure 
1-1).32 
 
Figure 1-1. Oxidative stress and ROS caused interference to the balance in biological system.32  
 
ROS and RNS react with various cellular components including proteins, DNA, lipids and 
carbohydrates. The reactions cause reversible or irreversible damage to these biological targets, 
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and thereby can lead to many cellular functional changes.3, 33 The effects of oxidative stress 
depend on the levels of these damages. Severe oxidative stress can even cause cell apoptosis and 
necrosis. Oxidative stress induced modifications have been involved in many diseases, such as 
Alzheimer’s disease, Parkinson’s disease, heart failure, lung disease, atherosclerosis, chronic 
fatigue syndrom, and aging.34, 35 
Direct determination of ROS/RNS concentration is difficult because they in general are too 
reactive and have too short lifetimes to be measured in vivo. However, the reactions of ROS/RNS 
with biomolecules typically generate specific products which are more stable than the reactive 
oxidants, i.e., aldehydes derived from oxidized lipids and carbonylated amino acids are more 
stable than the reactive species that cause these modifications. Thus the ROS/RNS measurement 
can be approximated by the determination of levels of their oxidation products.36, 37 On this basis, 
some biological molecules (biomarkers) will become available for determining general oxidative 
stress and oxidant levels. 
 
Protein oxidation 
Proteins are major targets for oxidative stress. Oxidative damage to proteins is caused either 
directly by ROS or indirectly by the reaction of “secondary” products from oxidative stress, such 
as aldehydes from lipid peroxidation.38-41 Oxidative damage to proteins can occur at protein side 
chains and the protein backbone. It leads to oxidation of the chains, protein cross-linking, and 
oxidation of the backbone resulting in protein fragmentation.33, 42-44 Protein fragmentation caused 
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by backbone cleavage is rarely used as a marker of protein oxidation in vivo because of the 
function of proteases in protein hydrolysis. In contrast, the oxidation of amino acid side chains 
produces stable products that can be used as potential markers of oxidative damage, and disease 
progression.37, 41, 44-46 
Protein oxidation caused by oxidative stress also can be divided into reversible and irreversible 
modifications (Figure 1-2).47, 48 Reversible modifications usually occur at sulfide-containing 
amino acid residues, such as cysteine and methionine. Cysteine can be oxidized to a disulfide 
and methionine can be oxidized to methionine sulfoxide (MeSOX). Oxidized cysteine and 
methionine can be converted back to unmodified formation by disulfide and MeSOX reductase 
containing in biological systems.33, 41, 42, 49, 50 Irreversible modifications can occur at the protein 
backbone or on various amino acid residues, leading to protein-protein cross-linking, protein 
fragmentation or the addition of oxidation sites on side chains, such as carbonyls. Irreversible 
modifications cannot be repaired and can lead to protein proteolytic degradation or aggregation, 
thus causing permanent loss of protein function.42, 44, 51Reversible modifications such as 
methionine oxidation can be used as a “built-in” ROS resistance system to prevent more 
damaging irreversible modifications that cannot be repaired.52 
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Figure 1-2. Intramolecular pathway of reversible and irreversible oxidized protein.47 
 
Lipid peroxidation (LPO) and LPO-derived aldehydes 
The peroxidation of lipids is commonly described as a ROS activated deterioration of 
unsaturated fatty acids, phospholipids, glycolipids, and cholesterol. The process can be an 
enzymatic or non-enzymatic reaction and involves the polyunsaturated fatty acids (PUFA).53 
Lipid peroxidation (LPO) generally goes through a free radical chain mechanism.54 This chain 
reaction for lipids involves three steps: initiation, propagation and termination, as shown in 
Scheme 1-1.53-55 In the initiation step, the lipid carbon-centered radical (L·) is formed by 
abstraction of a hydrogen atom from a bis allylic carbon in the PUFA, which is activated for 
attack by ROS. Next, the bis allylic carbon radical reacts with oxygen rapidly to form a lipid 
peroxyl radical (LOO·), which abstracts a bis allylic hydrogen atom from a neighboring PUFA to 
give a lipid hydroperoxide (LOOH) when an anti-oxidant does not mediate the process. At the 
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same time, a new carbon-centered radical is formed, and the propagation steps repeat. The 
propagation cycle can be terminated by reactions of the free radicals to form non-radical, stable 
products. Various free radical scavengers are able to cause chain termination.55 Monounsaturated 
and saturated fatty acids are much less likely to participate in LPO because peroxyl radicals have 
difficulty abstracting a singly allylic hydrogen.  
 
Initiation
LH
L
X
XH
LO2
LOOH
LH
O2
Propagation
IHLO2
Termination
Stable 
Products
Stable 
Products
 
Scheme 1-1. General LPO process proceeding by a free radical chain mechanism.55  
 
In the presence of transition metal ions, LOOH from the radical chain reaction can undergo 
decomposition and finally induces the generation of various secondary peroxidation products,38, 
56-58
 such as malondialdehyde (MDA),38, 56, 57 4-oxo-2-nonenal (ONE),38, 59 4-hydroxy-2-nonenal 
(HNE),38, 56, 57 2-octenal,60-62 2-hydroxyalkanal63 and so on (Scheme 1-2).56 These bifunctional 
aldehydes are reactive, relatively stable, and diffusible. They can act locally or diffuse from the 
site of origin and cause oxidative damage remotely. 
  9
 
R R'
HH
Hydrogen abstraction
Lipid
HO•
H2O
R R'
H
•
O2
Oxygen addition
R R'
OO•
Hydrogen 
abstraction
LH L-
R R'
OOΗ
H H
O O
MDA
C5H11
O
OH
C5H11
O
O
HNE ONE
 
Scheme 1-2. Common aldehydes generated from LPO under oxidative stress.56 
 
LPO has been considered as a major process in the production of oxidative damage from ROS.40 
Some hypotheses have been proposed to explain the connection between membrane LPO and 
cellular dysfunction that characterizes the process of aging and disease.64 One of these 
hypotheses is that LPO changes the fluidity of membranes, which interrupts essential functions, 
such as signal transduction or the selectivity of membrane permeability (Figure 1-3).40, 65-67 The 
other hypotheses involve the modifications of DNA and protein by LPO products. 43, 68-70 
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Figure 1-3. LPO induced modification to integral proteins in cell membrane under oxidative 
stress.71 
 
Protein carbonylation and LPO-derived protein modification 
Proteins can become modified by a large variety of reactive oxygen species under oxidative 
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stress, which can alter protein structure and function and finally cause cellular deterioration. 
Table 1-1 lists the common oxidations of amino acid residues of protein.42 Among these 
modifications, protein carbonylation has attracted much attention due to its irreversible and 
unrepairable nature.72 Many studies have shown that protein carbonylation plays a significant 
role in the development of various diseases and the aging of cells and tissues. Diseases involving 
increased protein carbonyl levels include neurodegenerative diseases, such as Parkinson’s 
disease and Alzheimer’s disease, cardiovascular diseases, such as atherosclerosis, chronic kidney, 
lung disease, cancer, cataractogenesis, diabetes, and aging process.46, 72-74 
 
Amino acid residues Oxidation products 
Cysteine disulfides, cysteic acid 
Methionine methionine sulfoxide, methionine sulfone 
Tryptophan 
 
2-, 4-, 5-, 6-, and 7-hydroxytryptophan, nitrotryptophan, 
kynurenine, 3-hydroxykynurinine, formylkynurinine 
Phenylalanine 
 
2,3-dihydroxyphenylalanine, 2-, 3-, and 
4-hydroxyphenylalanine 
Tyrosine 
 
3,4-dihydroxyphenylalanine, tyrosine-tyrosine cross-linkages, 
cross-linked nitrotyrosine 
Histidine 2-oxohistidine, asparagine, aspartic acid 
Arginine Glutamic semialdehyde 
Lysine α-aminoadipic semialdehyde 
Proline 
 
2-pyrrolidone, 4- and 5-hydroxyproline pyroglutamic acid, 
glutamic semialdehyde 
Threonine 2-amino-3-ketobutyric acid 
Glutamyl oxalic acid, pyruvic acid 
Table 1-1. Common oxidations of amino acid residues of protein.42  
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Protein carbonyl derivatives can be generated by four oxidative pathways:42, 58, 72, 75 The first 
pathway is direct oxidation of arginine, lysine, proline and threonine side chains by metal 
catalyzed oxidation (MCO) involving hydroxyl radicals. This leads to glutamic semialdehyde 
from arginine and proline, 2-aminoadipic semialdehyde from lysine, and 2-amino-3-ketobutyric 
acid from threonine.6, 42, 76 The second pathway is direct oxidation of the protein backbone, 
which can generate reactive protein carbonyl derivatives from cleavage of the protein backbone 
by either an -amidation pathway leading to an -ketoacyl derivatives, or a diamide pathway 
leading to an isocyanate (Scheme 1-3).42 The third pathway is involves glycation and 
glycoxidation reactions of the primary amino group of lysine residues with reactive carbonyl 
derivatives (ketoamines, ketoaldehydes, deoxyosones) generated from carbohydrates or their 
secondary oxidation products (advanced glycation end products).65 Finally, protein carbonylation 
also can be induced by adduction of reactive carbonyl derivatives generated during the 
peroxidation of PUFA. These LPO derived aldehydes include di-aldehydes such as MDA, which 
can react with lysine residues and form a Schiff-base product, ,-unsaturated aldehydes such as 
acrolein (ACR) and HNE, which can react with amino acids that have nucleophilic side chains 
(i.e., cysteine, histidine and lysine), and keto-aldehydes such as ONE, which also react with 
nucleophilic amino acid side chains by Michael addition.61, 77 The third and fourth pathways 
generate protein carbonyl derivatives from reactive carbonyl species (RCO). RCO are considered 
to be a major source of chemical modifications of proteins from oxidative stress. LPO-derived 
protein carbonyls play a key role in the development of Alzheimer’s disease and diabetes.78 
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Scheme 1-3. General pathways of protein backbone cleavage under oxidative stress.42 
 
Compared to ROS, LPO-derived RCO are more stable and diffusible. They can diffuse in or out 
of cells and attack targets far from the site of generation. LPO-derived protein carbonyls are 
more stable than ROS and more difficult to degrade by enzymes. Quantification of protein 
carbonyls can be used as a measure of the extent of oxidative damage. Various sensitive 
biochemical and immunological methods including Western blot, enzyme-linked immunosorbent 
assay (ELISA) and mass spectrometry have been developed for the identification and 
quantification of carbonylated proteins in cells, tissues and body fluids.73, 79, 80 LPO-derived 
protein carbonylation is becoming one of the best characteristic biomarkers of several diseases 
and aging under oxidative stress and damage. 
Protein carbonylation during disease development and aging is not random. Some proteins are 
more susceptive to be modified. However, the carbonylated proteins differ in different species.75 
The molecular cause for the evident selectivity of some proteins for carbonylation is not clear, 
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but some studies have suggested proteins binding with transition metals are more susceptible to 
undergo carbonylation by MCO,43, 81 probably because protein-bound transition metals are 
sources of MCO which could modify nearby amino acid residues in proteins.82 In addition, some 
proteins are more sensitive to be carbonylated, mainly because they are located close to the sites 
of producing ROS. 
Protein carbonylation is irreversible and unrepairable. It has been argued that protein 
carbonylation can cause protein misfolding, resulting in cell dysfunction and hence disease.75 
Misfolded proteins not only lose their normal function, but also form toxic species, including 
oligomers or aggregates. Generally mild carbonylation reduces or eliminates protein function and 
increases the rate of protein proteolytic degradation by proteasome.83 Heavily carbonylated and 
cross-linked proteins tend to aggregate in cells and eventually induce apoptosis.84, 85  
 
Mass spectrometry based proteomics 
In general, proteomics can directly determine the protein level of the large scale of gene and 
cellular function.86-91 Various approaches have been developed in this area, including 
biochemical methods, immunological methods, mass spectrometric methods and any 
combination of these methods.92-94 Compared to other available methods, mass spectrometry has 
been one of the most successful methods to analyze protein primary sequence, post-translational 
modifications (PTMs) and protein-protein interactions, especially for the analysis of low 
abundance and complex protein samples. Mass spectrometry provides more details about the 
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kinetics and mechanism of PTMs, as well as the stoichiometry and sites of modification.95-100 In 
addition, mass spectrometry can be combined with various separation technologies, such as high 
performance liquid chromatography (HPLC) and capillary electrophoresis (CE), to provide 
necessary purification and improved sensitivity.101-103  
Most recently, mass spectrometry based analysis approaches have been successfully applied to 
identify and quantify protein modification in both in vitro and in vivo experiments.104, 105 Finally, 
data analysis software and bioinformatics tools have been developed to rapidly process the large 
number of peptide MS/MS spectra for characterization of the peptide fragmentations which are 
used to identify specific sites of modifications.106-109 
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The long-term goal of the project 
Although protein carbonylation has been identified as an important factor in disease and aging 
processes, there is limited information available about the specific sites of carbonylation in the 
effected proteins. This knowledge gap hampers our ability to understand the mechanisms 
underlying the molecular changes that occur with oxidative stress. The key question is whether 
site selectivity can offer information about the nature of the disease state or the origin of the 
oxidative stress that caused the protein modification. This question only can be answered by 
gathering more data and establishing whether or not correlations exist between carbonylation 
patterns and disease states or environmental conditions. 
Our central hypothesis is that protein carbonylation does not occur randomly on reactive residues 
in a protein, but is localized at sites with vulnerable structural motifs and more inportantly, 
dependent on the nature of the oxidant. The research aims are to identify the sites of protein 
carbonylation both in vitro and in vivo by mass spectrometry. The data will test our hypothesis 
and provide critical information about the structural impacts of protein carbonylation and give 
insights into the functional ramifications of carbonylation. In the future, the modifications 
identified in this study could serve as biomarkers for disease states and aging processes. Finally, 
new analysis approaches aimed at improving the sensitivity and efficiency of identifying 
carbonylation sites will be developed. 
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Chapter 2: Identification of Acrolein Modified Human Serum Albumin 
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Background 
Acrolein (2-propenal, ACR) was first isolated from the distillation of glycerin in the presence of 
a dehydration agent by Redtenbacher in 1893.110, 111 Acrolein is a highly toxic, irritating and 
reactive molecule having two reactive centers consisting of a carbon-carbon double bond and an 
aldehyde group (Figure 2-1). In industry, acrolein has been an important intermediate in 
producing acrylic acid and plastic.111 Human exposure to acrolein can be grouped into exogenous 
and endogenous. Acrolein is mainly introduced to the environment from incomplete combustion 
of materials (such as petroleum, wood, coal and plastic material), automobile exhaust, tobacco 
smoke and cooking emission (from fried vegetable oil and animal fat).77, 111 112The main 
endogenous sources of acrolein are LPO of PUFAs, cleavage of dehydrated carbohydrates, 
enzyme-mediated degradation of amino acids (such as methionine and threonine) and 
polyamines (such as spermine and spermidine), metabolism of some allyl compounds, and the 
widely used anticancer drug cyclophosphamide.77, 111, 113 
 
O
 
Figure 2-1. The structure of acrolein 
 
Acrolein is one of the most electrophilic simple α, β-unsaturated aldehyde.114 It is capable of 
modifying nucleophilic side chains of cysteines, histidines, lysines and arginines in proteins by 
Michael addition (Scheme 2-1).111 A protein-ACR adduct can also be formed through a Schiff 
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base between the ε-amino group of the lysine residue and the aldehdye group of acrolein.115 The 
bi-functionality of acrolein gives the possibilities of intra- and intermolecular crosslinks through 
both Michael addition and Schiff base formation.116 Furthermore, a bis-adduct, 
Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine) can be formed on reaction with lysine 
residues by two, sequential Michael	
condensation and 
dehydration.115 Recently, a novel adduct, Nε-(3-methylpyridinium)lysine (MP-Lys) has been 
detected immunochemically using the oxidized B chain of insulin as a model peptide.58, 117 
Similar to adduction of the guanidine group of arginine, acrolein can react with deoxyguanosine 
(dG) in DNA.118, 119 It has been established that the relative reactivity of amino acid residues 
towards electrophilic aldehydes is Cys>>His>Lys. Histidine and lysine are considered as 
relatively weak nucleophiles and unlikely to be an immediate target for the soft acrolein 
electrophile.120 
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Scheme 2-1. Adduction of acrolein to amino acid residues in proteins.111 
 
Exposure to acrolein is highly toxic. The respiratory system is the most common target organ. 
Exposure can cause pulmonary edema, respiratory irritation and distress.112 Most of the cytotoxic 
effects of acrolein are involved in its high reactivity towards proteins. Irreversible acrolein 
adduction disrupts protein function and induces inhibition of protease activity and cell growth, 
disruption of metabolism and cell signaling, and modulation of cell apoptosis and necrosis.121-123 
Considering the relative reactivity of residues towards this electrophile, the toxic effects of 
histidine and lysine modifications are more likely under high dose intoxication or during the late 
stage of the chronic diseases when modifications on cysteine become saturated.120  
Acrolein can pass through membranes by passive diffusion. The major pathway for metabolism 
of acrolein is conjugation with glutathione (GSH) in the liver, followed by cleavage of the 
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glycine and γ-glutamic acid residues in the presence of enzymes.111 After enzyme induced 
N-acetylation and reduction, S-(3-hydroxy-propyl)-N-acetylcysteine (HPMA) is generated as the 
main metabolite of acrolein, and is found in urine.124, 125 
Human serum albumin (HSA) was chosen as a model protein in this project. HSA is a 66 kDa 
carrier protein that is important in physiological transport of many compounds, including free 
fatty acids, steroids, metals and metabolites.126-128 HSA is an attractive choice for biomarker 
studies because it is present in high concentration in serum, is known to form complexes and 
adducts with a variety of species, including acrolein and 4-hydroxy-2-nonenal (HNE), is a 
known target of oxidative stress, and is readily available.77, 129, 130 
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Experimental Procedures 
Chemicals 
Essentially fatty acid and globulin free HSA (Product A3782), (+) Biotin-hydrazide, 
iodoacetamide (IAM), N-ethylmaleimide (NEM), 1,4-dithio-DL-threitol (DTT), trifluoroacetic 
acid (TFA), sodium cyanoborohydride (NaBH3CN) and 10×phosphate buffered saline (PBS) 
concentrate were purchased from Sigma-Aldrich (St. Louis, MO). Ammonium bicarbonate was 
obtained from J.T. Baker (Phillipsburg, NJ) and acrolein was obtained from Cayman Chemical 
(Ann Arbor, MI). Sequencing grade modified trypsin was from Promega (Madison, WI).  
 
Experiments 
HSA modification 
HSA at 15 µM in 1× PBS buffer (pH 7.4) was incubated with acrolein at various final ACR:HSA 
molar ratios (1:4, 1:2, 1:1, 2:1, 5:1, 10:1). All reactions were carried out at 25°C with gentle 
shaking. The reaction time was 100 min for all experiments. 
1. Method A: acrolein adducts were labeled by incubation with Biotin-hydrazide at room 
temperature for 2 h. Labeled modifications were stabilized by adding NaBH3CN to 15 mM and 
incubating for 60 min at 0°C. Reaction mixture was repeated washes employing centrifugal filter 
devices (VWR, West Chestrt, PA) to remove reagents and to exchange to 50 mM ammonium 
bicarbonate buffer (pH 8.0) for enzymatic digestion; the molecular weight cut-off for the 
centrifugal filter devices used was 30 kDa. 
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2. Method B/C: acrolein adducts were directly stabilized by adding NaBH4 to 5 mM and 
incubating for 60 min at room temperature. Same centrifugal filter devices were employed to 
remove reagents and to exchange to 50 mM ammonium bicarbonate buffer (pH 8.0) for 
enzymatic digestion. 
 
Enzymatic digestion 
1. Method A: Modified HSA samples in 50 mM ammonium bicarbonate buffer were first 
reduced by incubating with 30 mM DTT for 20 min at 50°C and then alkylated by incubating 
with 55 mM IAM for 30 min at room temperature in the dark. Excess DTT and IAM were 
removed using the centrifugal filter devices (three washes were performed using 50 mM 
ammonium bicarbonate buffer). Sequencing grade trypsin (substrate to enzyme weight ratio 
40:1) was added and the mixture incubated for 16 h at 37°C. Digestion was terminated by adding 
1% formic acid (final pH = 2~3). 
2. Method B: Same procedure was performed, but no reagent was added to alkylate. 
3. Method C: Same procedure was performed, but NEM was used to alkylate instead of IAM. 
 
LC-MS/MS analysis 
Adduct identification was performed using a Thermo (San Jose, CA) LTQ XL linear ion trap 
mass spectrometer, equipped with electron-transfer dissociation (ETD). The LTQ XL was 
interfaced with a Thermo Surveyor capillary HPLC system. Peptides were separated on a 
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reversed-phase, C18 column (150 m × 10 cm, 5 m particles, 300 Å pores; Column 
Technology, Fremont, CA) at a flow rate of about 1 l min−1 using 0.1% formic acid in water as 
mobile phase A and 0.1% formic acid in methanol as mobile phase B. Approximately 2 µg 
peptides were injected and a Michrom (Auburn, CA) CapTrap trapping column was used for 
rapid sample injection. The gradient started from 2% B, then increased to 15% B over 5 min, 
then increased to 80% B over 70 min, and finally increased to 95% B over 15 min. The eluted 
peptides were introduced into the LTQ XL with a nanospray source operating at a spray voltage 
of 2.1 kV, a capillary voltage of 21 V, and a capillary temperature of 200°C. A full scan in the 
m/z range 300-2000 was performed to obtain precursor ions, followed by four data-dependent 
tandem mass spectrometry (MS/MS) scans (collision-induced dissociation, CID) for the three 
most abundant precursor ions in the full scan. Dynamic exclusion was used, that is, if the same 
precursor ion was picked for fragmentation twice within a 30 s window, it was excluded from 
further analysis for 180 s.  
 
Database searching and data processing 
Peptide sequences and modifications were identified using the BioWorks version 3.3.1, SP1 
implementation of Sequest (Thermo). No scan grouping was performed in preparing peak lists 
for database searching. The protein sequence database used consisted of the NCBI RefSeq 
version of the complete human proteome and the UniProt sequence for porcine trypsin 
(Accession Number P00761); reversed versions of all sequences were also included to permit 
false discovery rate estimation. Sequences were downloaded on November 20, 2010, and the 
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final database contained 68040 entries. Only fully-tryptic peptides were considered and up to 
three missed cleavage sites were allowed. Precursor ion tolerances were ±2 Da for linear ion trap 
measurements. According to method A, Fixed mass shifts were applied for IAM alkylated 
cysteines (+57 Da) while differential amino acid mass shifts were incorporated for 
NaBH3CN-reduced Biotin labeled Michael adducts at histidine and lysine (+298 Da) and at 
cysteine (+241 Da when the fixed mass shift at cysteine is considered), reduced Schiff base 
adducts at lysine (+40 Da), and oxidized methionines (+16 Da). According to method B, 
differential amino acid mass shifts were incorporated for NaBH4-reduced Michael adducts at 
cysteine, histidine and lysine (+58 Da), reduced Schiff base adducts at lysine (+40 Da), and 
oxidized methionines (+16 Da). According to method C, Fixed mass shifts were applied for 
NEM alkylated cysteines (+125 Da) while differential amino acid mass shifts were incorporated 
for NaBH4-reduced Michael adducts at histidine and lysine (+58 Da) and at cysteine (-67 Da 
when the fixed mass shift at cysteine is considered), reduced Schiff base adducts at lysine (+40 
Da), and oxidized methionines (+16 Da). In addition, MS/MS spectra for modified peptides were 
manually examined and any found to be inconsistent with the proposed identification were 
rejected. 
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Results 
The major mode of action of acrolein with proteins is Michael addition to the nucleophilic amino 
acid side chains of cysteine, histidine, lysine, and arginine to give stable adducts.111 Acrolein can 
also form a Schiff base with lysine and propano adducts with the guanidine group of arginine.131 
Furthermore, a bis-adduct, FDP-lysine, can be formed on reaction with lysine residues by two 
Michael additions, followed by an aldol
condensation and dehydration.115 All of the Michael 
additions lead to products bearing an aldehyde functional group whereas the Schiff base contains 
an imine instead. Modifications on arginine and FDP-lysine have been reported by 
immunochemistry.115 HSA is a 66 kDa protein with 35 cysteines, 16 histidines, and 59 lysines in 
its secreted form. There are 17 disulfide bridges, which leaves a single free cysteine in the 
protein.126 If the nucleophilic residue does not have reasonable surface accessibility or is located 
in an environment that is too sterically crowded to accept the added acrolein, some modifications 
would be highly unlikely.   
 
Sample preparations 
In this project, the mass shift of stabilized acrolein adducts by Michael addition is 58 and the 
mass shift of cysteine carboxyamidomethylation by IAM is 57. This 1 unit mass difference in the 
two shifts is not easily discriminated by the LTQ and can lead to incorrect modification 
assignments by the Sequest search. Therefore, three different sample preparation methods were 
applied. In method A, (+) biotin-hydrazide was used to label adducts of Michael addition 
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(Scheme 2-2).132 After stabilization by NaBH3CN, the mass shift became 298. In method B, no 
labeling reagent was used after the initial modification, and no carboxyamidomethylation step 
was applied before the trypsin digestion. In method C, no labeling reagent was used after initial 
incubation. NEM was applied as the alkylating agent instead of IAM after treatment by DTT. 
The mass shift of NEM alkylation at cysteines is 125. 
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Scheme 2-2. Acrolein adducts labeled by (+) biotin-hydrazide. 
 
Modification Sites 
Our goal was to identify the key modification sites when HSA is treated with acrolein. Starting 
with an HSA concentration of 15 µM, ACR:HSA ratios from 1:4 to 10:1 were surveyed and data 
are reported for the 1:1 and 10:1 ratios (Table 2-1). All site identifications are supported by CID 
data.  
Naturally, as the amount of acrolein was increased, it was possible to identify more modification 
sites. At a 1:1 ratio, a total of seven modification sites were identified in the three different 
sample preparations, but there were variations in the modification sites in the different 
preparations. In method A, five lysine residues (K51, K162, K262, K351 and K545) were identified as 
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Michael additions (the residue numbers are for the secreted protein; to convert to nascent protein 
numbering, add 24). In method B, one modified cysteine and histidine residue were found (C34 
and H338) as well as three lysine residues (K233, K525 and K545). In method C, one cysteine residue 
was found (C34) as well as three lysine and histidine residues (K233, K378, K545, H146, H288 and 
H388). At a 10:1 ratio, thirteen lysines and six histidines were modified in method A; one 
cysteine, fifteen lysines and three histidines were found modified in method B; one cysteine, 
eight lysines and three histidines were found in method C. The majority of the variability is due 
to the fact that we are operating at near detection thresholds. The different labeling procedures 
(A, B and C) introduce differences in the ionizability of the peptides and the quality of their CID 
spectra. Each of these can shift the detection threshold and affect the probability for detection. 
This effect is confirmed by the fact that modifications detected in a single preparation method at 
the 1:1 ratio are detected in multiple preparations at the 10:1 ratio in all but one case. 
 
Table 2-1. Modification site identifications from different sample preparations. Manual MS/MS 
spectrum validation was required in all cases. 
 
Modification Sitea Typeb 1:1c 10:1c 
Cys34 MA B/Cd B/C 
His67 MA not detected A 
His146 MA C A/B/C 
His242 MA not detected A 
His247 MA not detected A 
His288 MA C A/B/C 
His338 MA B/C A/B/C 
Lys12 MA not detected B 
Lys51 MA A A 
Lys73 MA not detected B 
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Lys137 MA not detected B/C 
Lys159 MA not detected B 
Lys162 MA A A/B 
Lys174 MA not detected A/B 
Lys205 MA not detected C 
Lys225 MA not detected B 
Lys233 MA B/C A/B/C 
Lys262 MA A A/B/C 
Lys351 MA A A/B 
Lys378 MA C A/B/C 
Lys414 MA not detected A/B/C 
Lys519 MA not detected A 
Lys525 MA B A/B/C 
Lys525 SB not detected B 
Lys545 MA A/B/C A/B/C 
Lys545 SB not detected B/C 
Lys545 FDP-Lys not detected B/C 
Lys574 MA not detected A/B 
a
 Secreted protein numbering; add 24 for nascent protein. 
b
 MA indicates Michael adduct formation; SB indicates Schiff base formation; FDP-Lys indicates FDP-Lys product 
generation. 
c
 Applied ACR:HSA ratio.  
d Sample preparation method: A represented biotin labeling method; B represented  method with no 
carboxyamidomethylation; C represented NEM alkylating method.  
 
Finally, the sequence coverage from the tryptic digestion is around 80%. Five histidines and 
sixteen lysines are not in the covered sequence. It is possible that modifications at these residues 
occurred, but were not detected with our LC-MS conditions. Very short or long peptides are the 
most challenging to detect with the LTQ. 
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Discussion 
Sample preparation methods  
In this project, three different sample preparation methods were applied, but the identified 
modification sites from them were not entirely same. At a 1:1 molar ratio of ACR:HSA, no 
cysteine and histidine modifications were detected with method A, and only one modified lysine 
(K545) was detected in all the methods. At a 1:1 ratio, methods B and C shared the most 
modification sites (C34, H338, K233 and K545). At a 10:1 ratio, six modified histidines along with 
twelve modified lysines were identified with method A, but the cysteine modification still was 
not observed. There again is more consistency between methods B and C at the 10:1 molar ratio. 
Thirteen modifications are in common between these methods. Overall more sites are detected 
by multiple methods at the higher molar ratio, which probably is because the modification levels 
were more generally above the detection threshold. The identifications from repeats of the same 
sample preparation method are relatively reproducible, which implies that different sample 
preparations do impact the ability of a modification to be identified. The total number of 
modifications identified with method A was 18, with method B was 22, and with method C was 
14. The greatest sensitivity was with the method with no cysteine blocking, method B.  
 
Modification Sites 
It has been accepted that Cys34 is the most reactive site in HSA because Cys34 is the only free 
cysteine and sulfur is known to be highly nucleophilic in Michael additions.77, 129, 133 In this 
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project, there is evidence for acrolein addition at Cys34 in HSA at both concentrations. For 
sample preparation method A, no adduct of Cys34 was identified even when the concentration of 
acrolein was increased. It may due to limited detectability caused by the poor ionizability of the 
corresponding peptide after biotin labeling or due to the poor quality of its CID spectrum. 
Only six modified histidines were identified and three of them were detected in all the sample 
preparation methods at a 10:1 molar ratio. Generally, the detection of modifications on histidines 
from the repeats on the same sample preparation were very reproducible even at a low acrolein 
concentration, which may imply that histidine modification occurs readily and gives peptides 
with robust detection characteristics. Using detection at the 1:1 molar ratio as a criterion, His146, 
His288, and His338 are viewed as the most reactive histidines towards acrolein. 
Comparing the lysine and histidine modifications, more modification sites at lysines were 
identified. However, some lysine modifications had low reproducibility, especially at a lower 
concentration of acrolein. This suggests that lysine modifications are less favorable and are 
present at lower concentrations. Of all the identified lysine modifications, Lys545 was the only 
one found at a low concentration of acrolein in all three sample preparations. Schiff base 
formation adducts and FDP-lysine products at Lys545 were also detected when the concentration 
was increased. Therefore, Lys545 is likely one of the most reactive lysines towards acrolein. 
Other lysines active at the 1:1 molar ratio are Lys162, Lys233, Lys262, Lys351, Lys378, and Lys525.  
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It has been reported that acrolein also could form a propano adduct with the guanidine group of 
arginine.115 However, no arginine adducts with acrolein were found in this project.  
 
Correlation between Local Environment and Modification 
The effect of local protein environments on acrolein modifications can be evaluated by 
examining the crystal structure of HSA.134 At a low concentration of acrolein, it was observed 
that some modification sites were on the surface of HSA, such as Lys51, Lys162, Lys233, Lys262, 
Lys351 and Lys378 (Figure 2-2); some were near the surface or seams on the surface, but the side 
chains were recessed in grooves of the protein, such as Cys34, His146, His288, His338, Lys525 and 
Lys545, (Figure 2-3). Meanwhile, some residues are on the very surface of HSA, such as His128, 
gave no evidence of modification even at higher concentrations. This phenomenon also can be 
quantified using a simple calculation of the solvent accessible surface area (SASA) associated 
with the residues.135, 136 It provides some insight into the local environments of the modified 
residues. The plots of side chain and backbone SASAs for the histidines and lysines in HSA 
were generated using the GETAREA program (Figure 2-4).137 Although this small data set is not 
sufficient for confirming an absolute pattern, general tendencies can be suggested. Checking the 
SASA plots of histidines and lysines, the general properties of the more reactive sites, such as 
His338 and Lys545 seem to be moderate accessibility on the side chain and relatively low 
accessibility on the backbone. This phenomenon is more obvious in the histidine modifications. 
Moreover, some highly exposed sites were not generally reactive. His128 is a good negative 
control for this measurement. It has a relatively high SASA value for its side chain (95.2 Å2) and 
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backbone (25.6 Å2), but no modification of this site was detected even at higher concentrations 
of acrolein. Overall, the data suggest that factors aside from surface accessibility are important in 
determining the modification site, but that these preferences lead to limited selectivity. 
 
 
Figure 2-2. Crystal structures showing modified sites (K51, K162, K233, K262, K351 and K378) on 
the very surface of protein. 
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Figure 2-3. Crystal structures showing modified sites (C34, H146, H288, H338, K525 and K545) 
recessed in the pocket of protein. 
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Figure 2-4. SASA in Å2 for histidines and lysines of HSA. Red bars are the backbones and blue 
bars are the side chains. Green arrows indicate sites that were identified as modified at a 1:1 
molar ratio of ACR:HSA. Orange arrow indicates a negative control. 
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Future Direction 
This project has identified histidines and lysines in HSA that are most reactive towards acrolein. 
The data suggest that surface accessibility is an important component in determining reactivity, 
but other factors are also affecting the reactivity. To explore this system is greater detail, a more 
quantitative approach, such as that used in the next chapter is needed. Nonetheless, the present 
results provide a baseline for comparison to the system explored in the next chapter, HNE 
reacting with HAS.   
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Conclusions 
The addition of a prototypical α, β-unsaturated aldehyde, acrolein, to HSA exhibits modest 
selectivity in this study. Modification sites were identified at the ACR:HSA molar ratios of 1:1 
and 10:1 using a linear ion trap mass spectrometer. 
Identified modifications were not entirely the same from three sample preparation methods, 
which suggests that different sample preparations impact the detectability of modified peptides 
by mass spectrometry. By examining the modification sites in the crystal structure of HSA, it 
appears that surface accessibility is important, particularly with lysine modifications. However 
this is not the only factor and many lysines with high surface accessibility were not modified. 
There is more limited data with histidine, but it appears that surface accessibility is less 
important. Finally, developing a quantification approach is necessary for analyzing reaction 
kinetics and accurately identifying the relative reactivity of the residues. 
 
  38 
Chapter 3: The Reactivity of Human Serum Albumin Towards 
trans-4-Hydroxy-2-nonenal 
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Background 
Since HNE (Figure 3-1) was recognized as a major product formed during CCl4-induced lipid 
peroxidation in the rat liver microsome,138 it has been identified as the most cytotoxic aldehyde. 
This initiated a large number of investigations about generation, quantitation and biological 
activity. 
 
H
O
OH
 
Figure 3-1. The lipid peroxidation product (E)-HNE. 
 
HNE is the end-product of peroxidation of -6 polyunsaturated fatty acids, particularly 
arachidonic acid and linoleic acid, the most common ones in biomembranes.139, 140 These 
peroxidation mechanisms have not been fully understood, although numerous pathways have 
been proposed, which include enzymatic and non-enzymatic pathways.140, 141 Two distinct 
non-enzymatic pathways were proposed by Schneider, C. et al. in 2001, based on an oxidation 
study of 9S and 13S-hydroperoxy-octadecadienoic acid (HPODE). However, the pathway though 
13S-HPODE has recently been disproved by the same group. The 9S-HPODE mediated pathway 
starts from a free radical intermediate formed at the bis-allyl position of linoleic acid, which is 
captured by molecular oxygen to generate 9-HPODE. The cleavage of 9-HPODE through a Hock 
rearrangement provides 3Z-nonenal - further oxidation and reduction gives HNE (Scheme 3-1). 
An example of an enzymatic pathway has been given for the fatty acid peroxidation in plants.141, 
  40 
142
 Linoleic acid is first oxidized by plant lipoxygenase (LOX), then cleaved by hydroperoxide 
lyase (HPL) to give 3Z-nonenal, which can be easily converted to 4-HNE through an 
non-enzymatic pathway (Scheme 3-2).141 Recently, a peroxyl radical initiated dimerization or 
polymerization pathway has attracted attention. In essence, the peroxide bridges in the dimer or 
oligomer are prone to breakage to release aldhedyes, including the 4-HNE precursor, 
4-hydroperoxy-2E-nonenal (4-HPNE).141 Other hypotheses have also been reported, but further 
validations are required. 
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Scheme 3-1. Proposed 9S-HPODE mediated mechanism of HNE formation from -6 
polyunsaturated fatty acids.140  
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Scheme 3-2. Proposed enzymatic pathway of HNE formation from Linoleic acid.141  
 
Studies have shown that basal levels of HNE (< 1 M) are present in cells.143, 144. HNE could 
behave as a signaling molecule at these basal levels. However, HNE concentration could become 
higher (< 15 M) under oxidative stress, causing unwanted modification of biological molecules 
and inducing a disease process. Some HNE concentrations may even reach the range of 100 M 
in regions near or in oxidizing membranes because they are strongly lipophilic, which could 
yield acute and unspecific cytotoxic effects and finally lead to cell death (Figure 3-2).77, 145, 146 
  42 
 
Figure 3-2. Toxicity of various aldehydes on growth arrested human fibroblasts.77 1: 
pentanal/hexanal; 2: 2-octenal; 3: 2-nonenal; 4: 2,4-nonadienal; 5: 2,4-decadienal; 6: 
4-hydroxynonenal 
 
Physiologically relevant concentrations of HNE could be detoxified by various enzymes in 
different cells and organs. These pathways include oxidation of HNE to 4-hydroxynon-2-enoic 
acid (HNA) by aldehyde dehydrogenase,147 reduction of HNE to 1,4-dihydroxy-2-nonene (DHN) 
by aldehyde reductase,148, 149 glutathione-S-transferase (GST) mediated addition of HNE with 
GSH to give a GS-HNE conjugate,150 or reduction of HNE to 4-hydroxynonanal (HAA) by 
alkenal oxidoreductase.146, 151  
Biological effects of HNE involve the capacity of HNE to act as an ,-unsaturated aldehyde and  
react with a wide range of cellular nucleophiles, including DNA bases and proteins.54, 77, 146 The 
protein-HNE adducts are mainly formed by Michael addition of the sulfhydryl of cysteine, the 
imidazole moiety of histidine, or the ε-amino group of lysine residues. The Michael adducts can 
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undergo cyclization to form a hemiacetal structure (Scheme 3-3A).152 A protein-HNE adduct can 
also be formed through a Schiff base between the ε-amino group of a lysine residue and the 
aldehdye group of HNE, which can be followed by dehydration and cyclization to give a 
2-pentylpyrrole moiety. Furthermore, the bi-functionality of HNE gives the possibility of intra 
and intermolecular crosslinks through both Michael addition and Schiff base formation (Scheme 
3-3B).152 Modifications by HNE are known to have wide-ranging biological effects including the 
attenuation of enzyme activity, apoptosis, and neurotoxicity.143, 153 The presence of HNE 
modifications correlates with many disease states including Alzheimer’s disease, diabetes, and 
atherosclerosis.154, 155 In addition, an increase in HNE protein modifications has been observed 
with aging.156 Finally, HNE has been implicated in signaling pathways, but details of its impact 
in this role are just emerging.157 Overall, HNE has been viewed as a prime, potential biomarker 
for diseases or processes that induce oxidative stress, and several mass spectrometric studies of 
HNE protein modifications have been investigated.152, 158-163 
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Scheme 3-3. (A) Reaction of HNE with the nucleophilic amino acid residues via Michael 
addition. (B) Proposed mechanism of protein crosslink by HNE addition.152 
 
For these modifications to become useful biomarkers, an important step is a careful 
characterization of the chemical processes involved, which includes an understanding of the 
selectivity and kinetics of the protein modification reactions. In 2006, Aldini and Liebler 
presented separate studies aimed at characterizing the reaction of HNE with HSA.164, 165 HSA is 
a natural choice for model studies because it is present in high concentration in serum, is known 
to form complexes and adducts with a variety of species, including HNE, is a known target of 
oxidative stress, and is readily available.126, 128, 129 In the studies by Aldini and Liebler, the site 
selectivity and kinetics of the HNE additions were evaluated using mass spectrometric methods. 
  45 
Different approaches were taken by the two groups, but generally the data were in accord; 
however, there were some noteworthy exceptions. Specifically, Aldini identified additional 
highly active modification sites not seen in the Liebler study. Furthermore, both groups assumed 
that the reactions were kinetically controlled and based their analyses on that assumption. 
However, it is possible that some processes reach equilibrium under the reaction conditions and 
this would have a significant impact on the interpretation of kinetic data. 
Since most studies suggest that HNE signaling is the result of addition reactions rather than the 
result of allosteric interactions,166 a better understanding of HNE adduction chemistry is clearly 
desirable. In the present work, we revisit the reaction of HNE with HSA and track the process as 
a function of time using an iTRAQ-labeling strategy.167-169 We find that the kinetics are more 
complicated than may have been appreciated in previous work and have evidence that some 
processes may be controlled by thermodynamics rather than kinetics under conditions typically 
used for in vitro studies.  
The iTRAQTM (Isobaric Tag for Relative and Absolute Quantitation) system (Figure 3-3) is a 
multiplexed set of reagents for quantitative protein analysis. iTRAQ reagent has an NHS ester 
derivative to modify primary amino groups of proteolytic peptides in a digest mixture and link a 
mass balance group and a reporter group via an amide bond simultaneously.167 When 
iTRAQ-tagged peptides are subjected to tandem mass spectrometry, the mass balance group is 
released as a neutral fragment, and reporter ions are used to quantify individual peptides in the 
digest mixture.167, 169 In the iTRAQ labeling approach, peptides derived from proteins subjected 
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to different conditions are tagged with a set of isobaric labeling reagents, one for each condition 
studied. The labeling reagents are identical, except for the distribution of isotopes in the tag. This 
difference leads to fragment ions (immonium) with unique masses that correlate with the 
conditions. The beauty of the approach is that peptides from each of the conditions will have the 
same mass and should co-elute together, but once selected and fragmented will give 
characteristic peaks that are suitable for relative quantitation. One drawback of the approach is 
that the characteristic ions appear at low mass (114-117 in our case).   
 
 
Figure 3-3. Structure of iTRAQTM reagents.167 
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Experimental Procedures 
Chemicals 
Essentially fatty acid and globulin free HSA (Product A3782), IAM, DTT and 10× PBS 
concentrate were purchased from Sigma-Aldrich (St. Louis, MO). Ammonium bicarbonate was 
obtained from J.T. Baker (Phillipsburg, NJ) and HNE was obtained from Cayman Chemical 
(Ann Arbor, MI). Sequencing grade modified trypsin was from Promega (Madison, WI). 
bicinchoninic acid assay (BCA) Protein Assay kits were purchased from Pierce (Rockford, IL) 
and iTRAQ reagent kits were obtained from Applied Biosystems (Foster City, CA). 
 
Experiments 
HSA modification 
HSA at 15 µM in 1× PBS buffer (pH 7.4) was incubated with HNE at various final HNE:HSA 
molar ratios (1:4, 1:2, 1:1, 2:1, 5:1, 10:1, 50:1, 100:1). All reactions were carried out at 37°C 
with gentle shaking. The reaction time was 3 h for all experiments except those in which the 
reaction time was intentionally varied. Modified proteins were stabilized by adding NaBH4 to 5 
mM and incubating for 60 min at room temperature. Repeated washes employing centrifugal 
filter devices (VWR, West Chester, PA) were used to remove reagents and to exchange to 50 
mM ammonium bicarbonate buffer (pH 8.0) for enzymatic digestion; the molecular weight 
cut-off for the centrifugal filter devices used was 30 kDa. 
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Enzymatic digestion 
Modified HSA samples in 50 mM ammonium bicarbonate buffer were first reduced by 
incubating with 30 mM DTT for 20 min at 50°C and then alkylated by incubating with 55 mM 
IAM for 30 min at room temperature in the dark. Excess DTT and IAM were removed using the 
centrifugal filter devices (three washes were performed using 50 mM ammonium bicarbonate 
buffer). Sequencing grade trypsin (substrate to enzyme weight ratio 40:1) was added and the 
mixture incubated for 24 h at 37°C. Digestion was terminated by adding 1% formic acid (final 
pH = 2~3). 
 
iTRAQ reagent labeling 
1. Effect of varying HNE:HSA molar ratio 
After digestion with trypsin, the concentrations of the HNE-modified peptide mixtures were 
measured using the BCA protein assay (error has been reported to be less than 5%). Peptide 
mixtures prepared under four conditions (50 g each) were placed in four different 
microcentrifuge tubes (two control samples, i.e., no HNE in prep, plus samples from 50:1 and 
100:1, HNE:HSA experiments). Peptide mixtures were then dried using a centrifugal evaporator 
and reconstituted in 25 l iTRAQ dissolution buffer. The iTRAQ reagents (114-117) were 
dissolved in 70 l ethanol separately. Each iTRAQ reagent aliquot was added to one of the 
peptide mixtures in the following sequence: 114 to a control sample; 115 to 50:1 ratio sample; 
116 to 100:1 ratio sample; and 117 to a control sample. After incubation for 3 h at room 
temperature, all four peptide mixtures were combined and then purified using a Waters (Milford, 
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MA) Oasis MCX solid phase extraction cartridge. The final sample was dried using a centrifugal 
evaporator and then resuspended in HPLC equilibration mobile phase for LC-MS/MS analysis. 
2. Effect of varying reaction time 
HSA was incubated with HNE at a HNE:HSA molar ratio of 100:1. The reactions were quenched 
by adding NaBH4 at 1, 3, and 24 h. After digestion, peptide mixtures from different time frames 
(containing 50 g total peptides) were labeled separately using the four iTRAQ reagents: 114 for 
the 0 h sample (control); 115 for the 1 h sample; 116 for the 3 h sample; and 117 for the 24 h 
sample. Labeling and subsequent processing were performed as described for the varying molar 
ratio experiment. 
 
LC-MS/MS analysis 
1. HNE adduct identification 
Adduct identification was performed using a Thermo (San Jose, CA) LTQ XL linear ion trap 
mass spectrometer, equipped with ETD, and a Thermo LTQ Orbitrap Velos mass spectrometer. 
The LTQ XL was interfaced with a Thermo Surveyor capillary HPLC system. Peptides were 
separated on a reversed-phase, C18 column (150 m × 10 cm, 5 m particles, 300 Å pores; 
Column Technology, Fremont, CA) at a flow rate of ~1 l min−1 using 0.1% formic acid in water 
as mobile phase A and 0.1% formic acid in methanol as mobile phase B. Approximately 2 µg 
peptides were injected and a Michrom (Auburn, CA) CapTrap trapping column was used for 
rapid sample injection. The gradient started from 2% B, then increased to 15% B over 5 min, 
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then increased to 80% B over 70 min, and finally increased to 95% B over 15 min. The eluted 
peptides were introduced into the LTQ XL with a nanospray source operating at a spray voltage 
of 2.1 kV, a capillary voltage of 21 V, and a capillary temperature of 200°C. A full scan in the 
m/z range 300-2000 was performed to obtain precursor ions, followed by six data-dependent 
MS/MS scans (consisting of CID and ETD scans) for the three most abundant precursor ions in 
the full scan. Dynamic exclusion was used, that is, if the same precursor ion was picked for 
fragmentation twice within a 30 s window, it was excluded from further analysis for 180 s. For 
the Thermo LTQ Orbitrap Velos system, separations were performed on a Waters 
nanoACQUITY reversed-phase, C18 column (100 µm × 10 cm; 1.7 µm particles). Elution was 
achieved using a gradient of 0.1% formic acid in acetonitrile (B) versus 0.1% formic acid in 
water (A) at a flow rate of 0.4 µL min−1. Approximately 2 µg peptides were injected, with the 
loading and equilibration mobile phase being 1% B. The linear gradient ran to 35% B over the 
first 30 min and then to 85% B over the next 5 min. The nanospray ion source was operated at 
3.5 kV. 
2. iTRAQ reagent-labeled peptide quantification 
For iTRAQ reagent-labeled samples, the linear ion trap-based system was operated largely as 
described above for HNE adduct identification except that pulsed-Q dissociation (PQD) replaced 
CID and ETD. The top four most abundant ions in each precursor ion scan were subjected to 
PQD fragmentation. Settings for PQD were normalized collision energy at 36%, activation Q at 
0.7, and activation time at 0.1 ms. A targeted mass list was used and, therefore, dynamic 
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exclusion was not enabled. Similarly, for the Orbitrap-based system, most operating parameters 
remained the same as those used for HNE adduct identification except that higher-energy C-trap 
dissociation (HCD)170 replaced CID. For HCD, the normalized collision energy was 40 and the 
activation time was 0.1 ms; the top eight most abundant ions in each precursor ion scan were 
subjected to HCD fragmentation. Dynamic exclusion was not enabled and the same targeted 
mass list was used. The chromatographic gradient was also lengthened; after loading at 1% B 
there was an initial increase to 15% B over 25 min, followed by an increase to 25% B over 
35 min, followed by an increase to 35% B over 40 min, followed by an increase to 85% B over 
20 min. 
 
Database searching and data processing 
Peptide sequences and modifications were identified using the BioWorks version 3.3.1, SP1 
implementation of Sequest (Thermo). No scan grouping was performed in preparing peak lists 
for database searching. The protein sequence database used consisted of the NCBI RefSeq 
version of the complete human proteome and the UniProt sequence for porcine trypsin 
(Accession Number P00761); reversed versions of all sequences were also included to permit 
false discovery rate estimation. Sequences were downloaded on November 20, 2010, and the 
final database contained 68040 entries. Only fully-tryptic peptides were considered and up to two 
missed cleavage sites were allowed. Precursor ion tolerances were ±2 Da for linear ion trap 
measurments and ±15 ppm for Orbitrap measurements. Fixed mass shifts were applied for 
alkylated cysteines (+57 Da) while differential amino acid mass shifts were incorporated for 
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NaBH4-reduced Michael adducts at histidine and lysine (+158 Da) and at cysteine (+101 Da 
when the fixed mass shift at cysteine is considered), NaBH4-reduced Schiff base adducts at 
lysine (+140 Da), and oxidized methionines (+16 Da). In searches with the iTRAQ labels 
present, fixed mass shifts of +144 Da were used for the peptide N-terminus and 
non-carbonylated lysine residues, which resulted in the differential mass shifts associated with 
HNE modification at lysine being changed to +14 Da (Michael adducts) and −4 Da (Schiff base 
adducts). Addition of the iTRAQ tag at tyrosine (+144 Da differential modification) was also 
considered, but was found not to be common. Mass shifts were added to Sequest parameters files 
at high-precision (see Appendix Table A1 for non-iTRAQ and Table A2 for iTRAQ experiments) 
for compatibility with highly accurate Orbitrap precursor ion measurements and a maximum of 
three variable modifications were permitted for each peptide. Sequest output was refined using 
the Trans-Proteomic Pipeline (version 4.4; Institute for Systems Biology, Seattle, WA) software 
package. Specifically, PeptideProphet was used,171 in semi-supervised mode,172 to improve 
identification confidence. A PeptideProphet score threshold of 0.9 was applied. In addition, 
MS/MS spectra for modified peptides were manually examined and any found to be inconsistent 
with the proposed identification were rejected. Intensity measurements for iTRAQ reporter ions 
(114-117) were processed using Microsoft Access. MS/MS spectra for which all four reporter 
ion intensities were zero were first rejected and then reporter ion counts for all MS/MS spectra 
supporting each peptide were combined by averaging. Depletion plots were scaled to 100% for 
the control to allow comparison on the same axes while accumulation plots were not altered. 
Reporter ion counts should only be used to obtain relative abundance information for the same 
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peptide under different conditions and should not be compared between peptides, even between 
modified and corresponding unmodified peptides. 
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Results 
As noted in the background, the major mode of action of HNE with proteins is Michael addition 
to the nucleophilic amino acid side chains of cysteine, histidine, and lysine to give stable 
adducts. HNE can also form a Schiff base with lysine. All of the Michael additions lead to 
products bearing an aldehyde functional group whereas the Schiff base contains an imine instead.  
The relevant reaction products, along with the final NaBH4-reduced products that were analyzed, 
are given in Scheme 3-4. HSA is a 66 kDa protein with 35 cysteines, 16 histidines, and 59 
lysines in its secreted form. There are 17 disulfide bridges, which leaves a single free cysteine in 
the protein.126 The net result is the possibility of 135 different single addition modifications by 
HNE; however, some would be highly unlikely if the nucleophilic residue does not have 
reasonable surface accessibility or is located in an environment that is too sterically crowded to 
accept the added HNE group. 
 
 
 
Michael addition at cysteine Reduced Michael addition at cysteine 
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Michael addition at histidine Reduced Michael addition at histidine 
 
 
Michael addition at lysine Reduced Michael addition at lysine 
 
 
Schiff base at lysine Reduced Schiff base at lysine 
Scheme 3-4. Reaction products for the Michael addition of HNE to cysteine, histidine and lysine 
residues, and for Schiff base formation with lysine. Initial products are shown in the left column 
while the results of NaBH4 reduction are shown in the right column. Hemiacetal structures are 
given for the non-reduced Michael adducts. 
 
Modification Sites 
Our first goal was to identify the key modification sites when HSA is treated with HNE. Starting 
with an HSA concentration of 15 µM, HNE:HSA ratios from 1:4 to 100:1 were surveyed and 
data are reported for the 1:1 and 10:1 ratios (Table 3-1). The exposure of HSA to HNE 
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experiment was repeated five times at the 1:1 and 10:1 ratios. These ratios result in HNE 
concentrations far in excess of those found in plasma, but they could be representative of HNE 
levels found transiently in membranes under oxidative stress conditions. Four repeats were 
analyzed using the linear ion trap system while one was investigated using the Orbitrap system.  
In all cases, three replicate LC-MS/MS runs were recorded for each preparation. Modifications 
found using the linear ion trap instrument and validated by manual inspection of the MS/MS 
spectra were regarded as medium confidence; those confirmed with complementary data from 
the Orbitrap system were regarded as high confidence. These data are also presented in terms of 
modified peptide (rather than modification site as found in Table 3-1) as Appendix Table A3, for 
counts of LC-MS/MS runs in which the modified peptides was detected. Most site identifications 
were supported by CID data, but numerous acceptable ETD detections were also obtained.  
For peptides modified with non-reduced HNE Michael adducts, CID, but not ECD, 
fragmentation patterns are dominated by the neutral loss of HNE.159 Neutral loss peaks provide 
good evidence that the modification of interest is present, but suppression of other fragment ions 
can prevent peptide identification. Alternatively, reduction of HNE Michael adducts with NaBH4 
results in MS/MS data that are not dominated by neutral loss peaks.173 Further advantages of 
reduction include (a) avoiding the close mass coincidence between non-reduced Michael adducts 
(156.1150) and arginine residues (156.1011) and (b) removing the possibility of the aldehyde 
reacting during later sample processing steps. Without the neutral loss, HNE-modified peptides 
did not seem to exhibit a characteristic fragmentation pattern. 
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Using the Sequest/Trans-Proteomic Pipeline approach, the initial survey data were also searched 
for non-reduced Michael adducts and Schiff bases. For Michael adducts, the monoisotopic mass 
shift was +156 while for Schiff bases it was +138. Orbitrap and linear ion trap data were 
analyzed. No convincing identifications of either type were obtained, indicating that the 
reduction and stabilization reaction had gone to completion or that the unstable, non-reduced 
adducts were in some way lost during sample processing. While the strong neutral losses 
expected for the non-reduced Michael adducts make modified peptide identification more 
difficult, it seems reasonable to assume that if numerous non-reduced adducts were present, at 
least some would generate MS/MS data of sufficient quality to pass the scoring threshold. 
Naturally, as the amount of HNE was increased, it was possible to identify more modification 
sites. At a 1:1 ratio, only three sites were identified at high confidence: His67, Lys199, and Lys525 
(the residue numbers are for the secreted protein; to convert to nascent protein numbering add 
24).  His67 and Lys199 were Michael adducts while Lys525 was a Schiff base. At 10:1, there are 
15 high confidence modifications at 13 different residues (Table 3-1). In general, the 
identifications were very reproducible, but it is clear that in some cases the peptides were at a 
concentration that was close to the threshold for our identification criteria. In Liebler’ s work, ten 
modifications were identified with an HNE:HSA ratio of over 600:1.165 Our full set (medium and 
high confidence) includes all of their set with the exception of Lys51 and His105. Michael addition 
at Lys51 was only detected in one out of ten experiments in Liebler’ s study while the presence of 
an alternative Michael addition site at Lys106 makes confident detection of addition at His105 
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challenging; however, modification at His105 can be confidently detected in experiments where 
iTRAQ labels are present and quantitative data were obtained for this site (see below). Aldini 
detected eleven modifications at their highest ratio (5:1).164 In our studies, at a ratio of 10:1, we 
detected the majority of them at high confidence with the exceptions being Michael additions at 
His242 and His510, which we detected at medium confidence, and Schiff base formations at Lys195 
and Lys199, which we did not detect. Identification of His242 is challenging because the 
underlying tryptic peptide contains a second addition site at His247, requiring very high quality 
MS/MS spectra for certainty in modification localization. Aldini’ s identification of Schiff base 
formation at Lys195 required a careful manual search for new peaks in the HNE-treated sample’ s 
chromatogram (searches were conducted in chromatograms covering a series of mass ranges).  
With our global approach for identifying modifications, the observation of this modification site, 
which appeared to be a minor one, was much less likely. 
It is not surprising that our approach apparently detected more modifications than the one used 
by Aldini, 15/34 (high/medium confidence) vs. 11, because we used a somewhat higher 
concentration (10:1 vs. 5:1) and a longer reaction time (3 h vs. 2 h). In addition, they relied to 
some extent on manual matching in the chromatograms so there was a possibility that some 
modification combinations were not considered, the full sensitivity of their instrument was not 
realized, or peaks were obscured in some way. On the other hand, their approach has advantages 
in some situations and led to identifications that we did not detect. It is more surprising that we 
identified significantly more sites than Liebler despite using methodologies that were fairly 
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similar. It is unclear why so few modifications were identified in their study given the high 
concentrations employed, but nonetheless, there is reasonable consistency across the three 
studies of HNE/HSA reactivity in terms of the preferred sites of modification. 
It is interesting to note that at a 1:1 ratio, the HNE addition appears to be relatively selective.  
Only two of the 59 lysines and one of the sixteen histidines are identified at high confidence as 
modified (considering both high and medium confidence identifications, there are four histidine 
and eight lysine modification sites at this concentration). It might be tempting to conclude that 
the reactions with histidine are less selective because a higher percentage of them are modified, 
but the larger number of modification sites is also driven by the fact that the reaction is more 
favorable (see below) and, therefore, at a given ratio, more of the HNE is naturally adducted to 
histidines. 
Finally, there is evidence for HNE addition at the single free cysteine in HSA (Cys34) at both 
concentrations. Although it has been accepted that Cys34 is the most reactive Michael addition 
site,129, 133 the MS/MS data for this site are not as consistent as those for other modifications. 
This does not appear to be the result of a low level of modification, but instead is probably due to 
cysteinylation at Cys34, a common post-translational modification that is often found in HSA 
preparations.174 However, for all sites, poor detectability could be due to the ionizability of the 
corresponding peptide as well as the quality of its CID fragmentation pattern. Therefore, some 
care needs to be exercised in analyzing data from these types of experiments because effects 
other than concentration can have a major impact on the ability to identify modifications. As a 
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result, more direct concentration measures, such as those from an iTRAQ-labeling scheme are 
needed for ranking reactivities.169  
 
Table 3-1. High (bolded) and medium (italicized) confidence modification site identifications. 
Medium confidence hits based on low mass accuracy precursor ion measurements (linear ion trap) 
while high confidence hits included high mass accuracy precursor ion measurements (Orbitrap). 
Manual MS/MS spectrum validation was required in all cases. 
Modification Sitea Typeb 1:1c 10:1c 
Cys34 MA 9/1/0 9/3/3 
His67 MA 12/0/3 12/5/3 
His128 MA 0/2/0 2/3/0 
His146 MA 12/11/0 12/12/3 
His242 MA 8/7/0 11/11/0 
His247 MA not detected 11/10/0 
His288 MA 10/0/0 12/1/3 
His338 MA 4/6/0 12/11/3 
His367 MA not detected 9/0/0 
His510 MA 1/8/0 12/11/0 
Lys73 MA not detected 3/0/0 
Lys106 SB not detected 0/1/0 
Lys137 MA not detected 1/0/0 
Lys159 MA not detected 0/2/1 
Lys162 MA not detected 12/2/2 
Lys162 SB not detected 10/1/0 
Lys199 MA 6/0/2 11/0/3 
Lys212 MA not detected 12/0/1 
Lys233 MA not detected 9/4/0 
Lys240 MA 8/0/0 3/0/0 
Lys262 MA not detected 5/3/0 
Lys351 MA 10/0/0 9/0/0 
Lys351 SB not detected 3/1/0 
Lys359 MA not detected 1/3/0 
Lys378 MA not detected 5/1/0 
Lys402 MA not detected 4/0/2 
Lys414 MA not detected 11/1/3 
Lys414 SB 8/0/0 12/1/3 
Lys475 MA not detected 1/0/0 
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Lys519 MA not detected 1/0/0 
Lys525 MA not detected 0/1/3 
Lys525 SB 3/0/3 8/3/3 
Lys545 MA 4/7/0 11/11/3 
Lys545 SB not detected 4/7/0 
a
 Secreted protein numbering; add 24 for nascent protein 
b
 MA indicates Michael adduct formation; SB indicates Schiff base formation 
c
 Applied HNE:HSA ratio. Values are counts of LC-MS/MS runs in which the modified site was 
identified using linear ion trap CID scans (maximum = 12)/linear ion trap ETD scans (maximum = 
12)/linear ion trap CID scans associated with high mass accuracy Orbitrap precursor ion mass 
measurements (maximum = 3) 
 
Relative Modification Levels Based on iTRAQ Labeling 
In a quadrupole ion trap, such as that found in the LTQ XL instrument used in this work, it is 
very difficult to simultaneously trap low-mass iTRAQ reporter ions and the b- and y-ions needed 
for peptide identification because the mass window is fundamentally limited. However, in the 
LTQ XL, PQD can be used in place of CID to significantly widen the window and to 
simultaneously trap high- and low-mass ions (the approach shifts the qz value during the 
activation and fragmentation timeframes).175 Although PQD allows implementation of the 
iTRAQ approach with ion trap instrumentation, the intensities of the label ions are rather low and 
extensive signal averaging is needed to obtain reproducible results (based on our results, single 
PQD scans for both peptide identification and reporter ion intensity measurements were more 
effective than collecting, for each precursor ion, a CID scan for identification and a PQD scan for 
reporter ion measurements). Consequently, the most efficient approach in these systems is to use 
a targeted mass list of anticipated peptides (modified and unmodified) rather than dynamically 
determining masses for fragmentation. By targeting masses and not employing a dynamic 
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exclusion protocol, many more MS/MS spectra containing iTRAQ reporter ions can be recorded 
and averaged during a chromatographic run. The mass list approach was also used with the LTQ 
Orbitrap Velos instrument, both to allow comparisons to be made and to improve accuracy by 
collecting as many measurements as possible. A list of the 21 modified peptides targeted in these 
studies is given in Table 3-2; 20 modifications at 18 residues were considered (two variants are 
present for one modification to take account of the possibility of methionine oxidation). In 
addition, unmodified versions of the listed modified peptides and peptides resulting from 
cleavage with trypsin of unmodified versions of the listed modified peptides were also targeted 
(a full list of all targeted peptides with m/z values used is given as Appendix Table A4). Since it 
was not practical to monitor all possible modification sites in HSA in this way (there are 
hundreds of potential peptide masses), sites that had been identified previously by other workers 
as well as sites identified in the present study whose spectra suggested significant modification 
levels were included. 
 
Table 3-2. List of modified peptides included in the targeted mass list. 
Modified Peptidea Modification Siteb Typec 
ALVLIAFAQYLQQC#PFEDHVK Cys34 MA 
SLH@TLFGDK His67 MA 
NECFLQH@K His105 MA 
VH@TECCHGDLLECADDR His242 MA 
VHTECCH@GDLLECADDR His247 MA 
SH@CIAEVENDEM*PADLPSLAADFVESK His288 MA 
SH@CIAEVENDEMPADLPSLAADFVESK His288 MA 
CCAAADPH@ECYAK His367 MA 
EFNAETFTFH@ADICTLSEK His510 MA 
LVNEVTEFAK^TCVAD Lys51 MA 
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YK^AAFTECCQAADK Lys162 MA 
LK^CASLQK Lys199 MA 
AFK^AWAVAR Lys212 MA 
AEFAEVSK^LVTDLTK Lys233 MA 
ADLAK^YICENQDSISSK Lys262 MA 
LAK^TYETTLEK Lys351 MA 
VFDEFK^PLVEEPQNLIK Lys378 MA 
K^VPQVSTPTLVEVSR Lys414 MA 
K~VPQVSTPTLVEVSR Lys414 SB 
K^QTALVELVK Lys525 MA 
K~QTALVELVK Lys525 SB 
a
 Unmodified versions of the listed modified peptides and peptides resulting 
from cleavage with trypsin of unmodified versions of the listed modified 
peptides were also targeted; C# indicates HNE Michael addition at Cys 
followed by reduction; H@ indicates HNE Michael addition at His followed 
by reduction; K^ indicates HNE Michael addition at Lys followed by 
reduction; K~ indicates Schiff base formation with HNE at Lys followed by 
reduction; M* indicates oxidation at Met 
b
 Secreted protein numbering; add 24 for nascent protein 
c
 MA indicates Michael addition; SB indicates Schiff base formation 
 
Effect of HNE Concentration on the Level and Distribution of Modifications 
Using 3 h incubations at 37°C, we report pilot data here on two HNE:HSA ratios: 50:1 and 
100:1. Linear ion trap data alone were collected for this comparison (more extensive data, 
including Orbitrap measurements, are provided in the next section). These ratios provide 
sufficient conversion at 3 h to limit the inherent uncertainty in using PQD to assess iTRAQ 
labels. The data are the result of three separate LC-MS/MS replicate runs on a single sample 
preparation. Using duplicate (no HNE present) controls allows the consistency between iTRAQ 
counts to be evaluated: the log10-transformed average 114:117 ratio (masses of the duplicate, 
control iTRAQ labels) was 0.0068, but the log10-transformed standard deviation was 0.33 (single 
standard deviation 114:117 ratio range is from 0.47 to 2.18). As noted above, a highly targeted 
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peptide list (Table 3-2) was used in the analysis to maximize the iTRAQ detection count 
obtained for each peptide. Although 20 modifications were targeted, useful data were obtained 
for only 15 of them. Furthermore, of the 15 identified modifications, detections counts for Cys34, 
Lys199, and Lys262 were very low (see Appendix Table A5). Results for the histidines and lysines 
are presented in Figure 3-4. In panels (a) and (c), depletion plots are shown for the unmodified 
histidines and lysines, respectively, scaled to 100% for the control samples. In panels (b) and (d) 
are the corresponding accumulation plots (average reporter ion intensities for each modified 
peptide are displayed; no scaling has been performed). The measurements supporting Figure 3-4 
are listed in tabular form in Appendix Table A5.  
 
(a) Depletion of unmodified peptides 
containing the indicated histidine modification 
site 
(b) Accumulation of modified peptides 
containing the indicated modified histidine 
residue 
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(c) Depletion of unmodified peptides 
containing the indicated lysine modification site 
(d) Accumulation of modified peptides 
containing the indicated modified lysine residue 
  
Figure 3-4. Effect of varying HNE:HSA ratio on reaction progress measured using iTRAQ 
reporter ion intensity (linear ion trap/PQD) for targeted histidine and lysine sites. The targeted 
mass list was used. Depletion plots are average reporter ion intensities scaled to 100% for the 
control while average reporter ion intensities are given unaltered in the accumulation plots. 
Relative abundance measurements were not obtained for His242, His247, His288, Lys51, and Lys212. 
MA indicates Michael addition while SB indicates Schiff base formation. When more than one 
unmodified peptide for a particular modification site was available, the most frequently-detected 
unmodified peptide was used. 
 
In Figures 3-4a and 3-4c, one sees a reasonable dose/response relationship for the unmodified 
histidines and lysines—as the HNE concentration increases, there is a consistent drop in the 
intensity of the parent peptides. Looking at Figures 3-4a and 3-4c, the data indicate that His67 and 
His510 are the most reactive of the histidines and that Lys199 and Lys525 are the most reactive 
lysines under these conditions. In Figures 3-4b and 3-4d, the accumulation plots present a 
somewhat different picture in terms of relative reactivity. First, it is clear that the peptides have 
very different ionization/detection properties, which leads to much greater variations in the 
response in the accumulation plots than is seen in the depletion plots (those are normalized 
relative to the control response). The variation in response suggests that much care must be taken 
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in evaluating relative reactivity on the basis of the detectability of products (i.e., methods that use 
titrations to identify relative detection thresholds and then equate them with relative reactivity).  
Since intensities alone provide no guide, we are left with curve shape—the most reactive sites 
would be expected to show a greater increase in reporter ion intensity between the 0 and 50:1 
points than between the 50:1 and 100:1 points because they would approach saturation (i.e., 
100% conversion to product). For the histidines, His67 remains a candidate for the most reactive 
site (reporter ion intensity at 50:1 is about the same as that at 100:1), in agreement with the 
depletion plots, but His510 now appears to be least reactive (the increase in intensity between 0 
and 50:1 is similar to that between 50:1 and 100:1), though the differences are modest.  In the 
accumulation plots for the lysine series, Lys199 stands out, but the jump between the 0 and 50:1 
points is only a little larger than that between the 50:1 and 100:1 points; furthermore, the peptide 
supporting this modification was only detected once (see Appendix Table A5). Lys525 appears to 
still be relatively reactive, but the signal is split between the formation of a Michael adduct and a 
Schiff base, complicating interpretation. Looking for the least reactive targeted lysines, the 
accumulation plots suggest Lys262 and Lys233 (most relative intensity is found for the 100:1 
HNE:HSA ratio data points), which is broadly in agreement with the depletion plots. In general, 
the availability of only curve shape for the accumulation plots makes then particularly hard to 
interpret; we have only relative abundances and no knowledge of how close the reaction is to 
completion. Furthermore, the accumulation plots contain high degrees of uncertainty because 
signals are often low for the modified peptides (especially for Lys378), particularly at low 
conversions (intensities appear to be systematically low for the HNE-modified peptides, 
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probably because they offer alternative fragmentation pathways). In contrast, the depletion plots 
are much easier to compare since the degree of modification (i.e., depletion) must be zero if no 
HNE has been added. Therefore, the depletion plots would seem to be the best measure of 
relative reactivity. A critical point with respect to the data in Figure 4 is the impact of whether or 
not the systems are reaching equilibrium in this time frame. This issue is addressed with a more 
comprehensive analysis in the following section. 
 
Effect of Incubation Time on the Level and Distribution of HNE Modifications 
Incubation times of 1, 3, and 24 h were used with an HNE:HSA ratio of 100:1. The linear ion 
trap- and Orbitrap-based instruments were used with the same list of targeted peptides (Table 
3-2) to maximize the number of MS/MS spectra collected for each peptide, thus enhancing the 
signal-to-noise ratio in the iTRAQ data. The data presented are the result of three complete 
repeat preparations, for each of which three replicate LC-MS/MS runs performed on each 
instrumental platform. We anticipated that the longest timeframe would lead to extensive 
modification and potentially an equilibrium mixture.  
Data for targeted histidines are shown in Figure 3-5. All targeted histidines were detected except 
His247, which is difficult to confidently identify because it is located on the same tryptic peptide 
as His242. Modified and unmodified peptides for the His288 site were detected both with and 
without an oxidized methionine; the non-oxidized form was detected more frequently and was 
used in constructing these plots. Figures 3-5a and 3-5b illustrate the depletion of parent peptides 
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and the accumulation of modified peptides, respectively, for the linear ion trap while Figures 
3-5c and 3-5d provide the same information for the Orbitrap. The same unmodified peptides 
were used in constructing depletion plots for both instrumental platforms (see Appendix Table 
A6). Looking first at the depletion plots, there is good agreement between the methods on the 
least reactive targeted histidines (His105 and His367). This result is in good agreement with the 
HNE:HSA ratio versus unmodified peptide depletion comparison given in Figure 1a. His67 and 
His510, which were most reactive in the concentration study, are again among the most reactive 
sites. However, the two additional detections, His242/7 and His288, appear most reactive, although 
His242/7, by both methods, shows a greater degree of depletion at 1 h than 3 h. Moving to the 
modified peptide accumulation plots, His105 and His367 are again confirmed as being among the 
least reactive targeted histidines (not approaching saturation). Again, in agreement with the 
depletion plots, His67, His288, and His510 are confirmed as being the most reactive targeted 
histidines (saturated by 24 hours). His242 displays a more confusing picture, but this is probably 
caused by the low number of identifications obtained. This is due, as mentioned above, to two 
modification sites (His242 and His247) being present on the same tryptic peptide (very high quality 
MS/MS spectra are required to unambiguously identify one particular site when another site on 
the same peptide must also be considered). Taking all Figure 3-5 plots together, it appears that 
the modification reaction is moving towards completion, but a reaction time of greater than 24 h 
is required. 
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(a) Linear ion trap measurement of the 
depletion of unmodified peptides containing the 
indicated histidine modification site 
 
 
(b) Linear ion trap measurement of the 
accumulation of modified peptides containing 
the indicated modified histidine residue 
  
 
(c) Orbitrap measurement of the depletion of 
unmodified peptides containing the indicated 
histidine modification site 
 
(d) Orbitrap measurement of the accumulation 
of modified peptides containing the indicated 
modified histidine residue 
  
Figure 3-5. Effect of varying reaction duration, at a fixed HNE:HSA ratio of 100:1, on reaction 
progress measured using iTRAQ reporter ion intensity for targeted histidine sites. Linear ion 
trap/PQD and Orbitrap/HCD data are presented. The targeted mass list was used. Depletion plots 
are average reporter ion intensities scaled to 100% for the control while average reporter ion 
intensities are given unaltered in the accumulation plots. Relative abundance measurements were 
not obtained for targeted site His247, although this site shares the same unmodified peptide with 
His242. MA indicates Michael addition while SB indicates Schiff base formation. When more than 
one unmodified peptide for a particular modification site was available, the most 
frequently-detected unmodified peptide was used. 
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The data for the lysines are presented in Figure 3-6. Eleven of twelve targeted modifications 
were identified using the Orbitrap, with the exception being Lys51; with the linear ion trap, Lys51 
and Lys212 were missed. Figures 3-6a and 3-6b show the depletion of parent peptides and the 
accumulation of modified peptides, respectively, for the linear ion trap while Figures 3-6c and 
3-6d provide the same information for the Orbitrap. The same unmodified peptides were used in 
constructing depletion plots for both instrumental platforms (see Appendix Table A7); 
furthermore, the same unmodified peptides were used in constructing Figures 3-4, 3-5, and 3-6. 
The lysines present a different picture to the histidines. Not only are the extents of depletion 
lower, but the plots indicate that lysine modifications become saturated and level off at what 
appear to be equilibrium levels. The curve shapes for the lysine depletion plots are clearly 
different to those observed for the histidine depletion plots. A group of three sites, Lys233, Lys262, 
and Lys378, show very little depletion by both instrumental methods and appear to represent the 
set of least reactive targeted lysines (Lys212, although only detected on the Orbitrap platform, 
could also be added to this group). The most reactive targeted lysine is clearly Lys199 while the 
second most reactive is Lys525. The accumulation plots again provide a roughly complementary 
picture, but they tend to suggest that there is a slow accumulation in some modification sites in 
the 3-24 h time frame that is not reflected in the depletion plots. This is most evident for Lys233 
and it is unclear why there is a substantial increase in modified peptide signal here despite the 
small drop in parent peptide intensity for this site; however, it is important to note that what 
looks like a large change at the level of reporter ion intensity may only represent a small change 
in concentration. In any case, the drift up in the 3-24 h range for the all of the other peptides 
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suggests a rate that is well below that indicated for the first three hours and suggests the process 
is slowing, presumably to an equilibrium level. Interestingly, the Schiff base products show 
reduced relative abundance at longer reaction times, possibly indicating that the Michael adduct 
is the thermodynamically favored product. 
These experiments were not designed to provide quantitative kinetic data—the iTRAQ system 
employed provides too few data points and the uncertainties are significant. However, it is 
possible to extract crude rate constants from the data in Figures 3-5 and 3-6. In this analysis, a 
pseudo first-order approach was used, focusing on the first three hours of reaction. PQD and 
HCD measurements were averaged at equal weight when calculating rate constants. For the 
slowest targeted histidines, His105 and His367, rate constants of 0.027 ± 0.004 and 0.025 ± 
0.001 M−1 s−1, respectively, were obtained. For the pair of histidines that showed intermediate 
reactivity, His67 and His510, the respective rate constants calculated were 0.088 ± 0.009 and 0.083 
± 0.004 M−1 s−1 (the listed uncertainties only consider the precision of the kinetic 
plots—including other experimental factors, uncertainties in the 10-20% range are expected). For 
the most reactive histidines, His242/7 and His288, the errors were much larger in the kinetic plots 
and the rate constants for both sites are probably best expressed as 0.2 ± 0.1 M−1 s−1. Errors were 
perhaps more significant because very low intensity reporter ions were being masked by noise in 
the mass spectrum. This approach is not possible with the lysines because they are approaching 
equilibrium and we do not have enough data points at early times. Nonetheless, the plots suggest 
that the most reactive lysine, Lys199, has a rate constant comparable to His242/7 and His288. 
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(a) Linear ion trap measurement of the 
depletion of unmodified peptides containing the 
indicated lysine modification site 
(b) Linear ion trap measurement of the 
accumulation of modified peptides containing 
the indicated modified lysine residue 
    
 
(c) Orbitrap measurement of the depletion of 
unmodified peptides containing the indicated 
lysine modification site 
 
(d) Orbitrap measurement of the accumulation 
of modified peptides containing the indicated 
modified lysine residue 
    
Figure 3-6. Effect of varying reaction duration, at a fixed HNE:HSA ratio of 100:1, on reaction 
progress measured using iTRAQ reporter ion intensity for targeted lysine sites. Linear ion 
trap/PQD and Orbitrap/HCD data are presented. The targeted mass list was used. Depletion plots 
are average reporter ion intensities scaled to 100% for the control while average reporter ion 
intensities are given unaltered in the accumulation plots. Relative abundance measurements were 
not obtained for Lys51 by either instrumental approach and were obtained for Lys212 only using the 
Orbitrap approach. MA indicates Michael addition while SB indicates Schiff base formation. 
When more than one unmodified peptide for a particular modification site was available, the most 
frequently-detected unmodified peptide was used. 
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Discussion 
Comparison to Previous Work 
Our strategy for the initial identification of HNE-modified sites was similar to Liebler’ s, with 
some differences being found in the computational details (for modified peptide identification 
Liebler used Sequest and P-Mod while we used Sequest and Trans-Proteomic Pipeline software). 
However, we were able to add high mass accuracy precursor ion measurements, obtained using 
an Orbitrap mass spectrometer, significantly improving identification confidence. Moreover, 
Liebler used a very high HNE:HSA ratio, 640:1, while we report the use of two much lower 
ratios, 1:1 and 10:1. 
Aldini’ s approach resulted in a similar list of identified modified peptides, but it was distinct and 
comprehensive. Briefly, a tryptic digest of untreated HSA was analyzed using an LC-MS/MS 
with Sequest searching approach to build a list of detectable unmodified peptides. Reductions in 
selected ion chromatogram peak areas for HNE-exposed HSA versus control HSA, for each 
peptide, were then used to locate putative modification sites. These sites were then confirmed by 
collecting MS/MS data for the expected modified peptides. Chymotrypsin and 
chymotrypsin/trypsin hybrid digests were added in some cases to aid in distinguishing between 
two sites located on the same tryptic peptide. Furthermore, a search was made for additional 
peaks found in the HNE-exposed but not in the control total ion chromatogram that could 
indicate modified peptides for which the associated unmodified peptides had not been detected. 
However, this resulted in the identification of only one additional site, Lys195. Figure 3-7 shows 
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the divided and shared modification sites obtains from Aldini’ s, Liebler’ s, and our experiments 
at respectively highest HNE concentrations. 
 
 
Figure 3-7. Divided and shared modification sites from Aldini’ s, Liebler’ s, and our experiments. 
A (red): Aldini’ s approach; L (yellow): Liebler’ s approach; G (blue): our approach. 
 
Aldini also used depletion of unmodified peptides, again measured by precursor ion selected ion 
chromatogram peak area, to rank site reactivity. MS/MS data was not employed. At an 
HNE:HSA ratio of 1:4, only the tryptic peptide containing site Cys34 showed significant 
depletion, making Cys34 the most reactive site. At an HNE:HSA ratio of 1:2, His146 and Lys199 
were added, with comparisons of the degree of depletion used to identify Lys199 as second most 
reactive site. MS/MS data was required to determine whether the depletion at site Lys199 was due 
to the Michael adduct or to Schiff base formation. No attempt to monitor reaction progression 
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over time or to rank the remaining sites was reported. Using selected ion chromatograms of 
precursor ions can be problematic when interfering species are encountered. Moving to the 
monitoring of characteristic MS/MS transitions would significantly improve confidence. 
Furthermore, excellent reproducibility is essential when comparing separate LC-MS/MS runs; 
methods, such as iTRAQ, where the peak areas to be compared are taken from the same 
spectrum are more robust. 
In contrast, Liebler’ s strategy for ranking site reactivities is more similar to our iTRAQ approach 
than Aldini’ s. Liebler employed a self-developed system where phenylisocyanate (PIC) was used 
as a peptide N-terminus tag. Time point samples are labeled with 12C6-PIC and are compared 
with a duplicate of the final time point labeled with 13C6-PIC. Time point and standard samples 
are mixed and then subjected to LC-MS/MS analysis. Using 13C-labeling ensures that light and 
heavy versions of each labeled peptide will co-elute and will therefore experience the same 
ionization environment. Liebler’ s approach uses a targeted mass list to ensure that both the light 
and heavy tagged peptides are selected for fragmentation, and then uses selected ion 
chromatogram peak areas for three characteristic fragment ions for each peptide as a measure of 
relative abundance. However, Liebler only monitored modified peptides; the depletion of 
unmodified peptides was not considered. Assigning the 24 h time point as a standard made it 
easy to regard this time point as representing the reaction going to completion, whereas our study 
indicates that this is not always the case. Finally, Liebler’ s method required targeting two masses 
for MS/MS spectra to provide relative quantification fro each peptide, so all other things being 
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equal, twice as many sites can be monitored with and iTRAQ approach where a single MS/MS 
spectrum provides the needed relative quantification.  
As noted above, the present data share many of the same features as those obtained by Aldini in 
terms of modification sites. Comparisons focused on the relative reactivity of the sites are more 
difficult to make because the most reactive sites reported in the study by Aldini were difficult 
sites to quantify with our methods as well as with Aldini’ s methods. Aldini reports the following 
order of reactivity: Cys34 > Lys199 > His146. In the case of Cys34 and His146, they were not able to 
identify the modification products in tryptic digests, but had to rely on trypsin/chymotrypsin 
combination digests to identify them. Their conclusion was based on a combination of depletion 
data, comparisons of selected-ion chromatograms, and titrations identifying initial adducts at low 
HNE:HSA ratios. More recently, Aldini determined a rate constant of 30 M−1 s−1 for the reaction 
of Cys34 with HNE,133 a value about two orders of magnitude greater than our approximate value 
for the most reactive histidines, suggesting that the free cysteine is exceptionally reactive. While 
we were able to identify adducts at Cys34, His146, and Lys199 at high confidence in our initial 
survey, there were problems with each of these sites. His146 was not included in the targeted mass 
list because this modification was observed in control runs where no HNE had been added and 
was not detected in initial Orbitrap test runs performed without a mass list; however, the chief 
peptide supporting His146, RH@PYFYAPELLFFAK, is supported by convincing MS/MS 
spectra, with peak intensities conforming to the ‘proline effect’ .176 Cys34 and Lys199 were added 
to the mass list, but for both residues relatively small numbers of acceptable MS/MS spectra 
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were obtained. Lys199 has been included in the accumulation and depletion plots, but Cys34 was 
not due to the probable presence of extensive cysteinylation at this site in HSA as mentioned 
above. Although Aldini did not rank the reactivity of their other modification sites, the limited 
quantitative data that they provide is consistent with the more extensive results shown here in 
Figures 3-(4-6). 
Comparisons with Liebler’ s data are more difficult because the detected sites are somewhat 
different than those presented here. First, at an HNE:HSA ratio of 10:1, we find 15/34 
(high/medium confidence) modifications whereas Liebler reports only ten at an HNE:HSA ratio 
of 640:1. The differences in the kinetic data are also significant. Liebler obtained the following 
order of reactivity for the histidines: His242 > His67 ~ His510 > His367 > His247. Their rate constants 
vary by a factor of 600, from 0.0005 for His247 to 0.3 M−1s−1 for His242
 
(Sigma HSA numbers); in 
contrast, using the depletion of unmodified peptides, we see a much smaller variation in rate 
(from 0.02 for His105 to circa 0.2 M−1s−1 for His242/7 and His288). Due to the requirement for very 
high quality MS/MS spectra to confidently identify isobaric modifications on the same peptide 
and the consequent low numbers of detections for His242 and His247, we can only realistically use 
the depletion of the unmodified peptide to provide a combined rate for His242 and His247. Our 
results indicate the following ranking that is broadly in agreement with Liebler: His242/7 ~ His288 
> His67 ~ His510 > His105 ~ His367. Liebler identified but did not provide kinetic data for His105 
and did not detect His288. Overall, the major difference in the kinetic data centers on the rate 
constant of the less reactive histidines, which were found to be much slower in the Liebler study. 
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The origin of this difference is probably rooted in the methodologies that were used. In the 
Liebler study, the intensity of the HNE addition product was tracked as a function of time with 
the assumption that at 24 h there would be 100% modification at each site. The danger in this 
approach is that if the modification does not go to completion for some reason, such as 
equilibrium formation, or if the kinetics is more complex than expected, the approach can be 
skewed by the use of an errant reference point (i.e., assumption of 100% conversion at longest 
reaction time). In addition, if the modification site undergoes any secondary reactions, it is not 
included as a productive reaction and would lead to underestimation of the reaction rate. In our 
approach, we have based our kinetics on the disappearance of the unmodified peptide. In this 
case, the reference point (i.e., 0% conversion in the control) is well defined.  However, it is 
possible to overestimate the rate of a particular reaction if there are hidden pathways depleting 
the signal for the unmodified peptide. As a result, the present data should be viewed as 
upper-limits on the rates. In any case, neither our accumulation of modified peptide nor depletion 
of unmodified peptide data are consistent with His242 having exceptional reactivity among the 
histidines. Liebler gives kinetic data for only one lysine, Lys233, which like in our results, they 
identify as being a relatively less reactive site. Overall, the present data are broadly consistent 
with those from Liebler, but suggest that other histidines compete much more effectively with 
His242 than the previous data indicated. 
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Reactivity of Amino Acids 
As noted above, it has been established that Cys34
 
is the most reactive site in HSA. This is not 
surprising in that it is the only free cysteine and sulfur is known to be highly nucleophilic in 
Michael additions.77 Comparison of the lysines and histidines is more complicated because the 
lysines do not react to completion and are under a mix of kinetic and thermodynamic control 
with our reaction conditions. Nonetheless, some general conclusions can be drawn from the data 
at 1 h because the reactions, for the most part, have not reached equilibrium or completion at this 
point. If we look at the three most reactive lysines that were characterized, averaging the linear 
ion trap and Orbitrap data at equal weight, we see approximately 95% (Lys199), 65% (Lys525), 
and 27% (Lys351) depletion at 1 h. For the four most reactive histidines, again combining linear 
ion trap and Orbitrap data, we see approximately 85% (His242/7), 85% (His288), 49% (His67), and 
46% (His510) depletion at 1 h. These data indicate that histidines and lysines exhibit roughly the 
same kinetic reactivity with HNE and that local, specific interactions are mainly responsible for 
the variation in their rates of addition. However with lysine, some sites are thermodynamically 
unfavorable and therefore will not be competitive because their reactions do not proceed to 
completion despite having reasonable intrinsic addition rates (i.e., they must also have fairly high 
off-rates). The next question is what local environmental factors control the reactivity of the 
histidines and lysines. 
 
Relative Histidine Reactivity 
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The targeted histidines divide clearly into a fast set (His67, His242/7, His288, and His510) and a 
slower set (His105 and His367). His464 is a site at which no evidence of modification was found, 
making it suitable as a negative control for environmental factors that affect HNE reactivity. In 
examining the crystal structure of HSA,134 one finds that in general the most active sites have 
good, but not exceptional, surface accessibility. This can be quantified by a simple calculation of 
the SASA associated with the residue.135, 136 Although not a perfect measure of the environment, 
it provides some insight. Using the GETAREA program,137 a plot of side chain and backbone 
SASAs for the histidines in HSA can be generated (Figure 3-7a). Although there is not an 
absolute pattern in this small data set, the general tendency is for moderate accessibility on the 
side chain and low relative accessibility on the backbone. This corresponds with sites that are 
near the surface, but recessed in pockets or seams on the protein surface. The obvious exception 
is His242. In fact, His242 matches the characteristics of the negative control, His464. Liebler and 
co-workers noted the unusual location of His242 and suggested its reactivity was linked to it being 
buried in a hydrophobic pocket with its imidazole having very low basicity. We cannot clearly 
separate the reactivity of His242 and His247 in our data so definite conclusions cannot be made. Of 
all the modification sites we have identified (His and Lys), none has exhibited a side chain 
SASA as low as His242 (see below), so high reactivity here would be unique for the protein. 
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(a) 
 
 
(b) 
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Figure 3-8. SASA in Å2 for the (a) histidines and (b) lysines of HSA. Grey bars are the 
backbones and black bars are the side chains. Arrows indicate sites that were identified as being 
particularly reactive. In panel (b), the data is too extensive to include residue numbers, but highly 
reactive sites are labeled.   
 
Relative Lysine Reactivity 
The lysines are more interesting in that we have identified larger variations in rate/equilibrium 
constants and a larger data set is available. A similar pattern emerges in the plot of SASAs 
(Figure 3-7b). The most stable lysine adducts that we identified are Lys162, Lys199, Lys351, Lys414, 
and Lys525. These residues follow the same general pattern as the histidines—one sees well to 
moderate accessibility on the side chains and very low accessibility on the backbone in the more 
reactive sites. Lys414 appears to be an exception, but it is in a groove and will have reasonable 
accessibility in some side-chain conformations. In fact, Lys414 is known to play a role in fatty 
acid binding (see below); in a crystal structure with myristic acid,177 its SASA rises to 31.6 Å2, a 
value consistent with other reactive lysines. It is interesting to note that of the 12 lysines that the 
GETAREA algorithm defines as exposed on the basis of their SASA values (side chain SASA > 
82 Å2 for lysine), only two were found to be modified in this study, Lys262 (a low reactivity site) 
and Lys351, suggesting that high accessibility poorly correlates with the probability of HNE 
modification. 
 
Overall Reactivity Patterns 
Comparisons of relative site reactivity were made from experiments where HNE was used at 
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1.5 mM, a concentration almost certainly higher than any occurring naturally. It must be 
remembered that extensive protein modification could have occurred at long reaction times and 
caused changes in protein conformation that exposed normally unavailable residues to the 
solution. Furthermore, undetected modifications, which would enhance depletion of the 
corresponding unmodified peptide, could exist. Since rates were estimated from unmodified 
peptide depletion data, undiscovered pathways would result in an overestimation of the rate. 
However, for some of the lysines, alternative depletion pathways caused by modification of 
nearby residues might be detectable. Since modification at lysine prevents cleavage by trypsin, 
there is often more than one unmodified peptide that can be used to determine the rate (i.e., either 
of the peptides flanking the missed cleavage point in the modified peptide). If the calculated rate 
was significantly different between these unmodified peptides, it would imply that another 
depletion pathway existed for the more rapidly depleted unmodified peptide. Comparative data is 
available for Lys233, Lys262, Lys351, Lys414 and Lys525. All except the unmodified peptides for 
Lys414 are similar, which given the supporting peptides, implies that there may be some reactivity 
at Lys413. 
We have a relatively small sample set, but it is possible to draw some general conclusion about 
the factors that control the relative reactivity of histidine and lysine residues of HSA with HNE.  
As noted above, some degree of surface accessibility is necessary, but highly exposed sites are 
generally unreactive. The presence of nearby hydrophobic grooves or patches is a common 
theme in the more reactive residues identified in this study. This is not completely surprising 
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given the fact that HNE does have a moderately hydrophobic tail and could benefit from 
hydrophobic interactions. Liebler noted this in his study and suggested a strong link between the 
hydrophobicity of the environment and reactivity.165 It is well known that HSA has multiple 
binding sites for fatty acids and crystal structures are available for complexes.177, 178 These 
binding sites provide a guide for locations that offer favorable hydrophobic interactions linked to 
a salt bridge interaction with a basic site. Interestingly, two of the strong lysine HNE binding 
sites, Lys414 and Lys525, correspond directly with myristate binding sites (the carboxylate of a 
myristate binds to the ammoniums of these lysine residues).177 In addition, two other strong HNE 
binding sites, Lys162 and His288, are located adjacent to the hydrophobic pockets occupied by 
myristic acid. There certainly is not a one-to-one correspondence between the HNE and 
myristate binding sites (and one should not be expected given the differences in 
structure/binding), but the overlap that we have observed is at least suggestive and indicates that 
hydrophobicity might be playing a significant role in the HNE binding preferences. Liebler also 
suggested that the pKa of a histidine played an important role in its relative reactivity.165 This 
conclusion was driven by their identification of His242 as the most reactive histidine and an 
estimate of its imidazolium’ s pKa that indicated that it was unusually acidic. As shown above, 
although we see evidence of high reactivity in the peptide containing His242 and His247, the 
consensus of our data is not consistent with His242 being exceptionally reactive among the 
histidines (His288 is similar); therefore, the low, predicted pKa does not appear to be a strong 
predictor of HNE reactivity. 
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Comparison to acrolein induced modifications 
The overall modification sites in HSA induced by both aldehydes (acrolein and HNE) do not 
entirely overlap. Cys34 was detected as modified when both aldehydes were incubated with HSA. 
More modified histidines were identified from HNE treated HSA at a 1:1 molar ratio of aldehyde 
to HSA than with the acrolein treated HSA. All of the identified histidine modifications (His146, 
His288 and His338) found in the acrolein treatment was also found in the HNE treatment. However 
the His128 and His510 modifications found with HNE were not detected with acrolein treatment 
even at higher concentrations. The results are more diverse for lysine modifications. More 
modified lysines were identified with acrolein treated HSA than with HNE at the lower 
concentration of aldehydes. Only three lysine modifications (Lys351, Lys525 and Lys545) of the 
eight from the acrolein treatment were identified with HNE. The Lys51 modification was detected 
in acrolein treated HSA but not in HNE treatment; Lys199 and Lys240 were found to be modified 
by HNE but not by acrolein, even at a 10:1 molar ratio of aldehyde to HSA. A major, general 
difference is that acrolein tends to target lysines with greater surface accessibility than HNE. 
This is most likely a result of HNE being more hydrophobic and preferring sites near 
hydrophobic patches on the protein. 
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Conclusions 
The addition of a prototypical ,-unsaturated aldehyde, HNE, to HSA exhibits relatively high 
selectivity with only three of the potential 135 single addition modifications being identified at 
high confidence at an HNE:HSA ratio of 1:1. Even at high HNE:HSA ratios (100:1), our data 
suggests that only ten sites reach modification levels of 50% or more (assuming that most of the 
depletion of the unmodified peptide containing His242 and His247 is due to the generation of 
His242). Our data indicate that aside from the highly reactive Cys34, the next most kinetically 
reactive sites are Lys199, His242/7, and His288. Although this reaction system has been studied in 
the past, it has not previously been recognized that the lysine modifications are under 
thermodynamic rather than kinetic control under typical in vitro experimental conditions and do 
not go to completion even with HNE:HSA ratios as high as 100:1. This result suggests that 
lysine modifications by HNE will only have biological relevance when local HNE concentrations 
are anomalously high or if secondary reactions make the additions irreversible. In contrast, the 
monitored histidine reactions in the study appeared to be going to completion under our 
conditions. Finally, the work demonstrates that care must be taken in the quantification of HNE 
modified residues by mass spectrometry because the modification can greatly alter the 
ionization/detection efficiency of the peptide. In this respect, the iTRAQ approach, with 
monitoring of both the modified and unmodified peptides, offers a powerful tool for quantifying 
the reaction progressions. 
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Chapter 4: trans-4-Hydroxy-2-nonenal Induced Aconitase Carbonylation 
and Its Impact to Enzyme Activity 
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Background 
Aconitase (ACO) is a Krebs cycle (tricarboxylic acid cycle) dehydratase, which catalyzes the 
stereospecific conversion of citrate to isocitrate via the intermediate formation of cis-aconitate 
(Scheme 4-1).179 It was first reported by Carl Martius in 1937.180 Aconitase is present in both 
mitochondria and the cytosol of cells.181, 182 Mitochondrial aconitase (m-aconitase) and 
cytoplasmic aconitase (c-aconitase) are associated, however obviously different enzymes. They 
have about 30% amino acids sequence similarity. M-aconitase is abundant in heart, but 
c-aconitase is abundant in liver. Both types of aconitase contain an ion-sulfur cluster. The cubic 
iron-sulfur cluster is essential for their catalytic activities in the active state. C-aconitase can be 
converted to an iron-regulatory protein (IRP) by disassembling its iron-sulfur cluster when the 
iron is insufficient. IRP binds to iron-responsive elements (IRE) on either the 5’  or the 3’  
untranslated region of various mRNAs that encode proteins related to iron storage and 
transport.179, 183-185 The two forms of the protein coexist in vivo depending on the iron level of 
cells. M-aconitase is similar to the c-aconitase form as an enzyme, containing an iron-sulfur 
cluster as well, but it does not act as an IRP. 
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Scheme 4-1. Conversion of citrate to isocitrate via the intermediate formation of cis-aconitate by 
aconitase in a Krebs cycle.179 
 
The porcine heart m-aconitase precursor consists of 781 amino acids (the first 27 residues is a 
mitochondrial targeting sequence) and an iron-sulfur cluster which plays the critical role in the 
enzymatic reaction.186-188 In the active state of aconitase, the iron and inorganic sulfur are 
organized as a cubic [4Fe-4S]2+ cluster.189 An aconitase can be inactivated by oxygen damage 
resulting in the loss of the forth iron (Fe) from a specific site in the cluster and reform a new, 
stable [3Fe-4S]+ cluster.190-192 But inactivated aconitase can be rapidly reactivated by addition of 
Fe2+ and a reducing agent such as DTT, resulting in the formation of the [4Fe-4S]2+ cluster.193, 194 
Each of three iron atoms in the iron-sulfur cluster forms a coordinate bond with one cysteine 
sulfur (C358, C421 and C424) of the protein backbone (Figure 4-1).182, 186, 195 The Fe is ligated to 
inorganic sulfur and bound to hydroxyl from solvent.187, 196 
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Figure 4-1. The formation of cysteine ligand with iron-sulfur cluster and transformation from 
[3Fe-4S]+ to [4Fe-4S]2+.195 
 
During the tricarboxylic acid cycle, the Fe in the [4Fe-4S]2+ cluster directly participates in the 
binding of the substrate to the enzyme by coordinating to hydroxide and the C carboxyl of 
citrate (Figure 4-2).195, 197 The coordination number of Fe increases to six from the 
substrate-free state. The intermediate product, cis-aconitate, binds with Fe in two ways, a citrate 
mode and an isocitrate mode. The two binding conformations transform by a 180° rotation 
around a perpendicular axis of the cis-aconitate double bond. The isocitrate coordinates with Fe 
by the hydroxyl and the Cα carboxyl.192, 198-200 
 
 
Figure 4-2. Binding of citrate with [4Fe-4S]2+ and some residues in the active site region.   
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Although the fourth Fe could be considered as the critical active site of participating in substrate 
binding and catalysis, the cluster function is also controlled by the constraints imposed by the 
protein structure through the amino acid ligands and the amino acid residues surrounding the 
cluster.200 The crystal structure has revealed that the active site region of aconitase involves the 
iron-sulfur cluster as well as 21 key amino acids side chains from all four domains of the protein 
(Figure 4-3).182, 201 Active site residues are considered as such if they are in contact with the 
cluster or bound substrate, or are involved in hydrogen bonding with residues that directly bind 
with substrate.182 The active site residues can be sorted into seven groups: cluster ligand 
cysteines (Cys358, Cys421 and Cys424); asparagines hydrogen bonding with inorganic or cysteine 
sulfur (Asn258 and Asn446); histidines with aspartic acid or glutamic acid pairs (His101/Asp100, 
His147/Asp165 and His167/Glu262); arginines in contact with substrate carboxyl groups (Arg447, 
Arg452, Arg580 and Arg644); the catalytic base serine (Ser642); serines and glutamine hydrogen 
bonding with substrate (Gln72, Ser166 and Ser643); isoleucine (Ile425), which has a significant 
hydrophobic contact with the cluster; and an aspartic acid (Asp568), which is hydrogen bonded to 
active site residues Arg452 and Arg644.182 Overall, the active site region is a mixed combination of 
residues which forms hydrogen-bonding network with the iron-sulfur cluster, substrate, water 
molecules and other residues etc..182, 200 The involvement of 21 residues may provide a partial 
explanation of why aconitase is a large protein.182 Mutational studies of some of the active site 
residues have proved that these residues are essential for the catalytic activity of aconitase.202 
The mutation of ligand cysteines to serines caused complete loss of activity. The mutations of 
Ser642 to alanine and Arg580 to lysine showed a 10 5 fold decrease in activity. The mutation of 
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His101 to asparagine and Asp100 to serine caused enzymatic activity to drop 3 orders of 
magnitude.182, 202 
     
Figure 4-3. The active site region in mitochondrial aconitase. The side chains of 14 key active 
residues, iron-sulfur cluster and bound isocitrate are shown with labels.201 
 
It was reported that m-aconitase is sensitive to reactive oxygen and nitrogen species.203 
Superoxide anion (O2-), hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) have been shown 
to inactivate mitochondrial aconitase through disturbing the [4Fe-4S]2+ cluster.196, 204-207 During 
this reaction, iron (II) is released from the cluster resulting in an inactive [3Fe-4S]1+ form. The 
oxidation of m-aconitase plays an important role in mitochondrial oxidative damage, which is 
related to several diseases and aging.208-210 However, there is not much details related to 
modulating aconitase activity through the oxidative modifications of amino acids. 
As a reactive carbonyl species, HNE may modulate m-aconitase activity by modifying amino 
acids in the active site of the enzyme. In this project, we investigate the reaction of HNE with 
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m-aconitase in vitro. The reaction also was tracked as a function of time using an iTRAQ 
labeling strategy.  
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Experimental Procedures 
Chemicals 
Mitochondrial aconitase from porcine heart (Product A5384), IAM, DTT, urea, 10×PBS and 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) concentrate were purchased from 
Sigma-Aldrich (St. Louis, MO). HNE and enzymatic assay kits were obtained from Cayman 
Chemical (Ann Arbor, MI). Sequencing grade modified trypsin was from Promega (Madison, 
WI) and chymotrypsin was from Roche Diagnostics (Indianapolis, IN). Laemmli sample buffer 
was from Bio-Rad (Hercules, CA). Anti-HNE monoclonal antibody was purchased from Japan 
Institute for the Control of Aging (Haruoka, Japan). Enhanced chemiluminescence (ECL) kits 
were obtained from GE Healthcare (Pittsburgh, PA). BCA Protein Assay kits and Imperial 
protein stain were purchased from Thermo Fisher Scientific (Rockford, IL) and iTRAQ reagent 
kits were obtained from Applied Biosystems (Foster City, CA). 


Experiments 
Aconitase modification 
Aconitase at 12 µM in 1× PBS buffer (pH 7.4) was incubated with HNE at various final 
HNE:ACO molar ratios (1:1, 2:1, 10:1, 50:1, 100:1). All reactions were carried out at 37°C with 
gentle shaking. The reaction time was 2 h for all experiments except those in which the reaction 
time was intentionally varied. Excess HNE were consumed by reacting with 10 times DTT at 
room temperature for 30 min. Modified proteins were denatured by adding 6 M urea and 
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stabilized by adding NaBH4 to a final concentration of 5 mM and incubating for 60 min at room 
temperature. Repeated washes employing centrifugal filter devices (Millipore, Billerica, MA) 
were used to remove reagents and concentrate the sample for sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation; the molecular weight cut-off 
for the centrifugal filter devices used was 50 kDa. 


SDS-PAGE and in-gel enzymatic digestion 
Modified protein was heated at 95°C for 5 min after mixing with the same volume of 2×Laemmli 
sample buffer. Aliquota of the mixture were loaded into each well and then separated by a 
homemade 4% stacking gel and 8% running gel. The final gel was stained using Imperial protein 
stain. The molecular weight of the different proteins in the sample was indicated by a protein 
ladder. The gel band containing aconitase was carefully cut out and washed. Prior to digestion, 
proteins in the sliced gel band were reduced with DTT and alkylated with IAM. The tryptic and 
chymotryptic digestion was carried out overnight at 37°C. Digestion products were extracted 
from the gel using 0.1% formic acid/5% acetonitrile and 0.1% formic acid/50% acetonitrile 
followed by centrifugal evaporation.      
     
Western Blot 
A similar amount of nonreducing, modified aconitase (40 µg) from various HNE to ACO molar 
ratios (0:1, 1:1, 5:1 and 10:1) was loaded on an 8% SDS-PAGE gel, and then transferred to a 
polyvinylidene difluoride (PVDF) membrane. The membrane was blocked for 1 h at room 
  96 
temperature with 5% milk in tris-buffered saline with tween 20 (TBST) and incubated with 
anti-HNE in 5% bovine serum albumin (BSA) (1:1000) overnight at 4°C. The blocked 
membrane was then washed with TBST and incubated with horseradish peroxidase (HRP) 
conjugated anti-mouse in 5% BSA (1:5000) for 1 h at room temperature. Following washing 
with TBST, the signal was developed with ECL detection reagents.  
  
iTRAQ reagent labeling 
Aconitase was incubated with HNE at a HNE:ACO molar ratio of 10:1 at 37°C. The reactions 
were quenched by adding DTT, urea and NaBH4 in turn at 0, 1, 2, and 6 h. After SDS-PAGE 
separation and in-gel tryptic digestion, the concentrations of the HNE-modified peptide mixtures 
were measured using the BCA protein assay. Peptide mixtures were desalted using C18 
MicroSpin columns (The Nest Group, Southboro, MA) and dried using a centrifugal evaporator. 
Solid peptide mixtures (containing 25 ug total peptides) were then reconstituted in 25 ul iTRAQ 
dissolution buffer. Four iTRAQ reagents (114-117) were dissolved in 70 l ethanol separately. 
Each iTRAQ reagent aliquot was added to one of the peptide mixtures in the following sequence: 
114 for the 0 h sample (control); 115 for the 1 h sample; 116 for the 2 h sample; and 117 for the 
6 h sample. After incubation for 2 h at room temperature with gentle shaking, all four peptide 
mixtures were combined and then purified using a Waters (Milford, MA) Oasis MCX solid 
phase extraction cartridge. The final sample was dried using a centrifugal evaporator and then 
re-suspended in HPLC equilibration mobile phase for LC-MS/MS analysis. 
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Enzymatic assay 
Aconitase at 12 µM in 1× HEPES buffer (pH 7.4) was incubated with HNE at various final 
HNE:ACO molar ratios (1:0, 1:1, 10:1, 50:1) for 2 h or at a HNE:ACO molar ratio of 10:1 with 
various reaction time frames (0 h, 1 h, 2 h, 6 h). All reactions were carried out at 37°C with 
gentle shaking. Modified proteins were precipitated and washed with 80% (NH4)2SO4 on ice. 
The concentrations of the HNE-modified proteins from different molar ratios or time frames 
were determined using the BCA protein assay. Aconitase activity assay was performed following 
the manufacture’s protocol. Modified aconitase from different preparations were activated by 
incubating with activation solution (50 mM cysteine hydrochloride and 1 mM ferrous 
ammonium sulfate in 1× Tris-Cl buffer) for 1 h on ice. Activated samples, nicotinamide adenine 
dinucleotide phosphate (NADP+), isocitric dehydrogenase and citrate were added into wells of an 
assay plate in the order, followed by incubation at room temperature for 30 min. All the samples 
were assayed in triplicate in the presence and absence of inhibitor. The absorbance was 
monitored once every other minute at 340 nm for 30 min by a plate reader.  
    
LC-MS/MS analysis 
1. HNE adduct identification 
Adduct identification was performed using a Thermo (San Jose, CA) LTQ XL linear ion trap 
mass spectrometer, equipped with ETD, and by a Thermo LTQ Orbitrap Velos mass 
spectrometer. The LTQ XL was interfaced with a Thermo Surveyor capillary HPLC system. 
Peptides were separated on a reversed-phase, C18 column (150 m × 10 cm, 5 m particles, 300 
  98 
Å pores; Column Technology, Fremont, CA) at a flow rate of ~1 l min−1 using 0.1% formic 
acid in water as mobile phase A and 0.1% formic acid in methanol as mobile phase B. 
Approximately 2 µg of peptides were injected and a Michrom (Auburn, CA) CapTrap trapping 
column was used for rapid sample injection. The gradient started from 2% B, then increased to 
15% B over 5 min, then increased to 80% B over 70 min, and finally increased to 95% B over 15 
min. The eluted peptides were introduced into the LTQ XL with a nanospray source operating at 
a spray voltage of 2.1 kV, a capillary voltage of 21 V, and a capillary temperature of 200°C. A 
full scan in the m/z range 300-2000 was performed to obtain precursor ions, followed by four 
data-dependent CID MS/MS scans for the four most abundant precursor ions in the full scan. 
Dynamic exclusion was used, that is, if the same precursor ion was picked for fragmentation 
twice within a 30 s window, it was excluded from further analysis for 180 s. For the Thermo 
LTQ Orbitrap Velos system, separations were performed on a Waters nanoACQUITY 
reversed-phase, C18 column (100 µm × 10 cm; 1.7 µm particles). Elution was achieved using a 
gradient of 0.1% formic acid in acetonitrile (B) versus 0.1% formic acid in water (A) at a flow 
rate of 0.4 µL min−1. Approximately 2 µg peptides were injected, with the loading and 
equilibration mobile phase being 1% B. The linear gradient ran to 15% B after loading at 1% B 
over 25 min, followed by an increase to 25% B over 35 min, followed by an increase to 35% B 
over 40 min, and followed by an increase to 85% B over 20 min. The nanospray ion source was 
operated at 3.5 kV. 
2. iTRAQ reagent-labeled peptide quantification 
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Analysis of iTRAQ reagent-labeled samples was performed only by a Thermo LTQ Orbitrap 
Velos mass spectrometer. For the Orbitrap-based system, most operating parameters remained 
the same as those used for HNE adduct identification except that HCD replaced CID.170 For 
HCD, the normalized collision energy was 40 and the activation time was 0.1 ms; the top eight 
most abundant ions in each precursor ion scan were subjected to HCD fragmentation. A targeted 
mass list was used and, therefore, dynamic exclusion was not enabled. 
 
Database searching and data processing 
Peptide sequences and modifications were identified using the BioWorks version 3.3.1, SP1 
implementation of Sequest (Thermo). No scan grouping was performed in preparing peak lists 
for database searching. The protein sequence database used consisted of the NCBI RefSeq 
version of the complete porcine proteome and reversed versions of all sequences. Reversed 
sequences permit false discovery rate estimation. Sequences were downloaded on October 1, 
2009, and the final database contained 43958 entries. Only fully-tryptic peptides were considered 
and up to three missed cleavage sites were allowed. Precursor ion tolerances were ±2 Da for 
linear ion trap measurments and ±15 ppm for Orbitrap measurements. Fixed mass shifts were 
applied for alkylated cysteines (+57 Da) while differential amino acid mass shifts were 
incorporated for NaBH4-reduced Michael adducts at histidine and lysine (+158 Da) and at 
cysteine (+101 Da when the fixed mass shift at cysteine is considered), NaBH4-reduced Schiff 
base adducts at lysine (+140 Da), and oxidized methionines (+16 Da). Mass shifts were added to 
Sequest parameters files at high-precision (see Appendix Table A1 for non-iTRAQ and Table A2 
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for iTRAQ experiments) for compatibility with highly accurate Orbitrap precursor ion 
measurements and a maximum of four variable modifications were permitted for each peptide. In 
searches with the iTRAQ labels present, fixed mass shifts of +144.104 Da were used for the 
peptide N-terminus and non-carbonylated lysine residues, which resulted in the differential mass 
shifts associated with HNE modification at lysine being changed to +14.027 Da (Michael 
adducts) and −3.984 Da (Schiff base adducts). MS/MS spectra for modified peptides were 
manually examined and any found to be inconsistent with the proposed identification were 
rejected.  
Intensity measurements for iTRAQ reporter ions (114-117) were processed using Microsoft 
Access. MS/MS spectra for which all four reporter ion intensities were zero were first rejected. 
Reporter ion counts for all MS/MS spectra supporting each identified peptide were combined by 
averaging and then normalized by dividing the combined intensity of relative reporter ion from 
the targeted internal standard peptide (WVVIGDENYGEGSSR). Depletion plots were scaled to 
100% for the control to allow comparison on the same axes while accumulation plots were not 
altered. Accumulation plots were simply the normalized raw intensity or the logarithm of it. 
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Results 
HNE is a reactive carbonyl species and a byproduct from lipid peroxidation. The major mode of 
reaction of HNE with proteins is Michael addition to the nucleophilic amino acid side chains of 
cysteine, histidine and lysine to give stable adducts. HNE can also form a Schiff base with 
lysine’ s side chain.77, 146 All of the Michael additions lead to products bearing an aldehyde 
functional group whereas the Schiff base contains an imine instead. The m-aconitase is an 82 
kDa protein with 12 cysteines, 25 histidines and 53 lysines. There are no disulfide bridges, but 
side chains of three cysteines are coordinated with the iron-sulfur cluster as ligands.186, 187 Some 
mutation studies of active site residues in m-aconitase have confirmed that changes in the active 
site can reduce or eliminate the catalytic activity of the enzyme.182, 202 HNE may modulate 
m-aconitase activity by modifications of amino acids in the active site of the enzyme. 
 
Western Blotting 
To confirm the modification of the protein, monoclonal anti-HNE was used to detect HNE 
modifications in samples of aconitase treated with HNE. The anti-HNE is particularly sensitive 
to modified histidines in proteins. Both reduced and unreduced samples were analyzed (i.e., 
treated or not treated with NaBH4 after HNE modification). HNE-modified proteins were 
detected only from an unreduced sample. This is not surprising because the antibody is designed 
for the unreduced form of the HNE modification. An increased modification level was observed 
at the higher molar ratios of HNE to aconitase (Figure 4-4). The band position of aconitase only 
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could be determined roughly because the anti-aconitase antibody used to identify it was only 
weakly responsive in this study. The other present bands having steady blotting with the 
increased HNE concentrations are mostly caused by the unspecific binding of antibody. 
 
 
Figure 4-4. Western blot of HNE modifications. A: reduced modifications with increasing molar 
ratios of HNE to aconitase (control, 1:1, 5:1 and 10:1); B: non-reduced modifications with 
increasing molar ratios of HNE to aconitase (control, 1:1, 5:1 and 10:1). 
 
Modification Sites 
The first aim of the project was to identify the key modification sites when m-aconitase was 
treated with HNE. Starting with an aconitase concentration of 12 µM, HNE:ACO ratios from 1:1 
to 50:1 were surveyed and data are report in Table 4-1. The experiment was repeated four times 
at each of the different ratios. Three repeats were analyzed using the linear ion trap system while 
one was investigated using the Orbitrap system. Results from trypsin and chymotrypsin 
digestions were combined together. Only one LC-MS/MS run was recorded for each sample 
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preparation due to the limited amount of sample from the in-gel digestion. Modifications 
detected using the liner ion trap instrument and validated by manual inspection of the MS/MS 
spectra were regarded as medium confidence; those confirmed with complementary data from 
the orbitrap system were regarded as high confidence. These data are also presented in terms of 
modified peptide (rather than modification site as found in Table 4-1) as Appendix Table A8. 
Site identifications were supported only by CID data. ETD was not used in this study. 
It was possible to identify more modification sites when the amount of HNE was increased. At a 
1:1 ratio of HNE to aconitase, five sites were identified: Cys358, Cys421, Cys565, His13 and His98 
(the residue numbers are for the secreted protein; to convert to nascent protein numbering add 
27). Only Cys358 and Cys565 were identified at high confidence. As the molar ratio increased to 
2:1, eight modifications were detected. Four of them are at high confidence. At a ratio of 10:1, 
there are 22 identified modifications and 14 of them are at high confidence. When the molar ratio 
was raised to 50:1, more modified histidine and lysine residues were detected, but the four 
cysteine modifications found at lower ratios became less apparent and gave less confident 
identifications. In general, the identifications were very reproducible, but the concentration 
dependence indicates that in some cases, the peptides were at a concentration that was close to 
the threshold for our identification criteria. The combined sequence coverage is around 78% for 
the LTQ analysis and 68% for the Orbitrap analysis. It is possible that some peptide fragments 
having modification sites were not detected. Schiff base formation of lysine adducts were found 
only on Lys384 and Lys564. However, they were not investigated further. 
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Three of the five modifications that were identified at the lowest HNE concentrations were 
cysteines. Two of these, Cys358 and Cys421 are in the active site and involved in the iron-sulfur 
cluster. This result matches previous research that showed that cysteine is the most reactive 
Michael addition site in proteins, but it is noteworthy that the iron-sulfur cluster is available for 
modification by HNE. As the amount of HNE increases, first more histidines appear as modified, 
then more lysines. It might be tempting to conclude that the reactions with histidine are less 
selective because a higher percentage of them are modified, but the larger number of 
modification sites is also driven by the fact that the reaction is more favorable and more of the 
HNE is naturally adducted to histidines at a given ratio. However, effects other than 
concentration also can have a major impact on the ability to identify modifications. Some care 
needs to be employed in analyzing data from these types of experiments. Therefore, a more 
direct quantification method, such as iTRAQ reagent labeling is needed for ranking reactivities.  
It is also interesting to note that the solubility of the incubated sample declined as the amount of 
HNE or incubation time increased. Furthermore, some of the identified modification sites at the 
low molar ratios were not detected at higher ratios. The quantity of corresponding MS/MS 
spectra also dropped. This is possibly explained by cross linking between HNE-modified 
residues and lysine side chains by Schiff base formation, leading to peptides that could not be 
identified by our SEQUEST approach. This cross-linking is also expected to reduce solubility 
and potentially inhibit digestion by trypsin and chymotrypsin. 
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Table 4-1. List of identified modification sites based on linear ion trap data (represented by 
number) and Orbitrap data (represented by *). Bolded with underscore sites represent active site 
residues. Manual MS/MS spectrum validation was required in all cases. 
Modification 
Sitea 
Enzymeb 1:1c 2:1c 10:1c 50:1c 
Cys99 T 0  1* 1* 2 
Cys305 C 0 1 2 0 
Cys358 T 3* 3* 3* 3* 
Cys421 T 2 1 3* 1 
Cys424 T 0 0 3* 1* 
Cys565 T 3* 3* 3* 3* 
His9 T 0 0 0 1 
His13 T 1 1 3* 3*   
His46 T 0 0 3* 3* 
His46 C 0 0 3* 3* 
His98 T 1 1 2 3* 
His101 T 0 0 3* 3* 
His147 C 0 0 0 1 
His321 C 0 0 2* 3* 
His379 T 0 0 0* 0* 
His460 T 0 1* 3* 3* 
His460 C 0 0 3 3* 
His519 T 0 0 3 3* 
His569 T 0 0 2 2* 
His668 T 0 0 1* 2* 
His717 T 0 0 1 1 
His729 T 0 0 0 1* 
Lys23 T 0 0 1 2 
Lys117 T 0 0 3* 3* 
Lys218 T  0 0 1 2 
Lys490 T 0 0 0 3 
Lys496 T 0 0 2 3 
Lys674 T 0 0 0 1* 
a Secreted protein numbering; add 24 for nascent protein 
b
 T indicates Trypsin digestion; C indicates Chymotrypsin digestion 
c
 Applied HNE:ACO molar ratio. Values are counts of LC-MS/MS runs in which the modified site 
was identified using linear ion trap CID scans (maximum=3) and linear ion trap CID scans 
associated with high mass accuracy Orbitrap precursor ion mass measurements (*) 
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Relative Modification Levels Based on iTRAQ labeling 
In a quadrupole ion trap, such as that found in the LTQ XL instrument used to identify 
modification sites, it is very difficult to simultaneously trap low mass iTRAQ reporter ions and 
the b- and y-ions needed for peptide identification because the mass window is fundamentally 
limited. Although PQD technology175 has partially alleviated this limitation, in this project, the 
signal of iTRAQ reporter ions from PQD analysis was still low. Thus, the LTQ Orbitrap Velos 
instrument was applied to improve accuracy. A targeted mass list of anticipated peptides 
(modified and unmodified) was used. A list of the 12 modified peptides targeted in these studies 
is given in Table 4-2; 17 modifications at 12 residues were considered. In addition, unmodified 
versions of these peptides were also targeted (a full list of all targeted peptides with m/z values 
used is given as Appendix Table A9). In some cases, more than one unmodified version was 
needed because the modified peptides contained a missed cleavage – a version with and without 
the missed cleavage was included in the list. A peptide with no HNE addition sites was put in the 
list as an internal standard (WVVIGDENYGEGSSR) for normalizing the intensity of reporter 
ions. Since the methods in this project may impact the stability of imines formed between HNE 
and lysine, Schiff base formation of lysine adducts was not included in the iTRAQ analysis 
(actually, the detected Schiff base formation was very limited). By targeting masses and not 
employing a dynamic exclusion protocol, many more MS/MS spectra containing iTRAQ reporter 
ions can be recorded and averaged during a chromatographic run. However, it was not practical 
to monitor all the potential HNE modifications in m-aconitase in this way (there are too many 
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potential peptides masses). Only the sites identified at significant modification levels were 
included. Most of the modification sites from Table 4-1 were included. 
 
Table 4-2. List of modified peptides included in the targeted mass list. 
Modified Peptidea Modification Siteb 
VAVPSTIHC@DHLIEAQLGGEK Cys99 
VAVPSTIH^C@DHLIEAQLGGEK Cys99 /His98 
VAVPSTIHC@DH^LIEAQLGGEK Cys99 / His101 
VAVPSTIH^C@DH^LIEAQLGGEK Cys99 / His98 / His101 
VAVPSTIH^C*DHLIEAQLGGEK His98 
VAVPSTIHC*DH^LIEAQLGGEK His101 
VAVPSTIH^C*DH^LIEAQLGGEK His98 / His101 
VGLIGSC@TNSSYEDMGR Cys358 
VGLIGSC@TNSSYEDM#GR Cys358 
DVGGIVLANAC@GPC*IGQWDR Cys421 
DVGGIVLANAC*GPC@IGQWDR Cys424 
DVGGIVLANAC@GPC@IGQWDR Cys421 / Cys424 
C@TTDHISAAGPWLK Cys565 
C@TTDH^ISAAGPWLK Cys565 / His569 
C*TTDH^ISAAGPWLK His569 
VAMSH^FEPHEYIR His9 
VAM#SH^FEPHEYIR His9 
VAMSHFEPH^EYIR His13 
VAM#SHFEPH^EYIR His13 
VAMSH^FEPH^EYIR His9 / His13 
VAM#SH^FEPH^EYIR His9 / His13 
IVYGH^LDDPANQEIER His46 
NDANPETH^AFVTSPEIVTALAIAGTLK His460 
AEFDPGQDTYQH^PPK His519 
AK~DINQEVYNFLATAGAK Lys117 
FNPETDFLTGK~DGK Lys490 
FK~LEAPDADELPR Lys496 
K~QGLLPLTFADPADYNK Lys674 
a
 Unmodified versions of the listed modified peptides were included in the 
list. If the modified peptide contains a missed cleavage, an additional 
peptide (without the missed cleavage) was also included. A peptide 
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(WVVIGDENYGEGSSR) without HNE modification sites was also 
included as an internal standard; C* indicates carboxyamidomethylation at 
Cys; C@ indicates HNE Michael addition at Cys followed by reduction; H^ 
indicates HNE Michael addition at His followed by reduction; K~ indicates 
HNE Michael addition at Lys followed by reduction; M# indicates oxidation 
at Met 
b
 Secreted protein numbering; add 27 for nascent protein 
 
Effect of Incubation Time on the Level and Distribution of HNE Modifications 
Incubation times of 1, 2, and 6 h were used with an HNE:ACO ratio of 10:1. The Orbitrap-based 
instruments was employed with the list of targeted peptides (Table 4-2) to maximize the number 
of MS/MS collected for each peptide, thus enhancing the signal-to-noise ratio in the iTRAQ data. 
The data presented are the result of three replicated LC-MS/MS runs from a single preparation. 
In this study, higher HNE concentrations and longer incubation times cannot be applied due to 
the poor solubility of aconitase under these experimental conditions. One unmodified peptide 
was chosen as an internal standard (WVVIGDENYGEGSSR) to correct for declining overall 
signal intensity caused by possible protein precipitation during long incubations. The 
measurements are listed in tabular form in Appendix Table A10. 
Data for targeted cysteines are shown in Figure 4-5. All the targeted cysteines were detected 
except Cys424, which is difficult to confidently identify because it is located on the same tryptic 
peptide as Cys421. Very high quality MS/MS are required to unambiguously identify one 
particular site when another site on the same peptide must also be considered. In this case, strong 
evidence was only found for Cys421. Tryptic peptides having both Cys421 and Cys424 modified 
were not found. In the listed sites, Cys99/His(98/101) and Cys565/His569 also share the same tryptic 
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peptides. In these cases, all the possible modifications share the same unmodified parent peptide 
and cannot be distinguished in plots of parent peptide depletion rates. Modified and unmodified 
peptides for the Cys358 site were both detected, with and without an oxidized methionine; the 
oxidized and non-oxidized forms had a similar contribution in constructing these plots. Figures 
4-5a and 4-5b illustrate the depletion of parent peptides and the accumulation of modified 
peptides from Orbitrap measurements. Generally, the depletion plots are easier to compare 
because the starting and end points are well defined - 100% intensity at time zero and 0% 
intensity at reaction completion. In contrast, we have no information about the expected absolute 
intensity at 100% conversion (standards are not available). As a result, it is not possible to relate 
the intensity of the modified peptides to relative concentrations. In addition, the modified 
peptides often give low signal intensities due to low concentrations in some cases and potentially 
poor ionization properties in others. Unfortunately, three of the four identified cysteine 
modifications are on peptides with more than one potential site. The simple case is Cys358, which 
exhibits about 20% depletion at 6 hours in its parent peptide. Much of the reaction appears to be 
complete in the 1st hour and this is confirmed in the accumulation plot. The modifications at 
Cys421 and Cys424 share the same peptide. Because both are part of the iron-sulfur cluster, 
distinguishing between them is not as critical. They exhibit over 60% depletion at 6 hours. The 
cysteines that share peptides with histidine modifications are more difficult to analyze. However, 
some insight can be gained by examining the kinetic profiles. For the peptides containing Cys99 
and Cys565, most of the observed depletion occurs in the first 2 hours. This is mirrored in the 
accumulation plots for the two modifications. In contrast, the accumulation plots for the 
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corresponding histidine modifications are more linear and substantial accumulation occurs 
between 2 hours and 6 hours (Figure 4-6b). The match of kinetic profiles (accumulation vs. 
depletion) for the cysteines strongly suggests that the majority of the depletion in the parent 
peptide is due to cysteine modification. It is likely that the histidines represent only a small 
fraction of the depletion at early times and play a greater role late in the kinetic studies. As a 
result, it is reasonable to assume that the depletion of the parent peptides of Cys99 and Cys565 is 
mainly caused by cysteine modifications at the 6 h time point.  
 
 
">
!">
">
+">
$">
">
*">
">
7">
6">
!"">
" !  + $  * 

	



+


	



8
9
:

	 8:
8	:, 		4 	
(66;&	67;!"!
(+7
($!;$$
(*;&	*6
  111
 
Figure 4-5. Effect of varying reaction duration, at a fixed HNE:ACO ratio of 10:1, on reaction 
progress measured using iTRAQ reporter ion intensity for targeted cysteine sites. The targeted 
mass list was used with Orbitrap/HCD measurement. Depletion plots are scaled to 100% for the 
control while normalized absolute intensities are given in the accumulation plots. Relative 
abundance measurements were not obtained for targeted site Cys424, although this site shares the 
same unmodified peptide with Cys421. 
 
Data for the histidines are presented in Figure 4-6. Seven of eight targeted modification sites 
were identified using the Orbitrap, with the exception being His101, which is located on the same 
tryptic peptide as His98. Two tryptic peptides containing two sites His(9/13) and His(98/101) were 
also detected. Modified and unmodified peptides for sites His(9/13) were both detected, with and 
without an oxidized methionine - the oxidized and non-oxidized forms had the similar 
contributions in constructing these plots. Figure 4-6a and 4-6b illustrate the depletion of parent 
peptides and the accumulation of modified peptides from Orbitrap measurements. As discussed 
above, it is likely that much of the depletion seen in peptides sharing a cysteine and histidine is 
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due to the cysteine. As a result, His460 stands out as an exceptionally reactive histidine. Only 
modest depletion is seen for the other histidines and the accumulation plots indicate that many of 
the histidines are far from reaching complete reaction at 6 hours; they still retain nearly peak 
reaction velocities. 
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Figure 4-6. Effect of varying reaction duration, at a fixed HNE:ACO ratio of 10:1, on reaction 
progress measured using iTRAQ reporter ion intensity for targeted histidine sites. The targeted 
mass list was used with Orbitrap/HCD measurement. Depletion plots are scaled to 100% for the 
control while normalized absolute intensities are given in the accumulation plots. Relative 
abundance measurements were not obtained for targeted site His101. 
 
Data for the listed lysines are presented in Figure 4-7. Three of the four targeted lysines were 
detected - the exception is Lys490. Figures 4-7a and 4-7b illustrate the depletion of the parent 
peptides and the accumulation of the modified peptides from Orbitrap measurements. In the 
depletion plots for the listed lysine series, the depletion for all parent peptides is very limited. 
The changes seen in the plot are at the uncertainty of the measurement and not meaningful. It 
indicates that the lysine reaction towards HNE is inefficient. In the accumulation plots, 
significant background modification is seen at time zero. This may represent a small 
concentration of the modification present in the starting aconitase or be background noise in the 
iTRAQ ion region of the spectrum. In either case, the plots in Figure 4-7 indicate that lysine 
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modifications are not significant under these conditions and only reach concentrations suitable 
for detection, but not quantification. 
 
 
 
Figure 4-7. Effect of varying reaction duration, at a fixed HNE:ACO ratio of 10:1, on reaction 
progress measured using iTRAQ reporter ion intensity for targeted lysine sites. The targeted 
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mass list was used with Orbitrap/HCD measurement. Depletion plots are scaled to 100% for the 
control while normalized absolute intensities are given in the accumulation plots. Relative 
abundance measurements were not obtained for targeted site His490. 
 
Enzymatic Assay 
Aconitase activity was determined using an established assay. This method is based on 
measuring the rate of NADPH generation at a wavelength of 340 nm (Scheme 4-2).211, 212  
 
 
Scheme 4-2. Generation of NADPH in aconitase enzymatic assay.211 
 
The activity of two preparations of modified aconitase was measured: One set was prepared from 
various molar ratios of HNE to aconitase (0:1, 1:1, 10:1 and 50:1) with a 2 h incubation (Figure 
4-8); another set was prepared from various incubation time frames (0h, 1h, 2h and 6h) at a 
molar ratio of 10:1 (Figure 4-9). Sample preparations were done in triplicate and the activity of 
each sample was measured three times. The average absorbance value from each sample was 
plotted as a function of time and the linear portion of the assay’ s calibration curve was used in 
the analysis. Relative activity was obtained after correcting for blank activity and normalizing 
against the rate of the aconitase positive control (activity of positive control was considered as 
100%).  
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Figure 4-8. Enzymatic assay of HNE modified m-aconitase. Samples were prepared at different 
molar ratios (0:1, 1:1, 10:1 and 50:1) with 2 h incubation. 
 
Figure 4-9. Enzymatic assay of HNE modified m-aconitase. Samples were prepared from 
different incubation time frames (0 h, 1 h, 2 h and 6 h) at a molar ratio of 10:1. 
 
The relative activity of the 0 to 1 molar ratio or the 0 h incubation time was around 100% as 
expected. It shows that the process of sample preparation does not cause enzyme activity to be 
lost. In both assay experiments, with the elevation of HNE amount or incubation time, aconitase 
activity dropped. In the molar ratios experiments, catalytic activity was at 70%, 45% and 40% of 
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original sample when the molar ratios were 1:1, 10:1 and 50:1 with a 2 h incubation. In the 
incubation time experiments, enzyme activity remained around 50%, 45% and 35% when the 
time frames were 1 h, 2 h, and 6 h at a 10:1 molar ratio. The two experiments overlapped at the 
10:1 molar ratio with a 2 h incubation, and results from the overlap measurements were quite 
consistent. The activity decline of modified aconitase in both sets did not drop off at a consistent 
rate and it appears that the modification stalled at long reaction times or high concentrations. At 
a 50:1 molar ratio or 6 h incubation, 35% - 40% of activity still remained. Higher molar ratios or 
longer incubation times cannot be examined due to the poor solubility caused by presumably 
cross-linking. 
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Discussion 
Method Development  
Porcine heart aconitase purchased from Sigma-Aldrich was used in this project. At the 
beginning, the project suffered from low coverage and poor signal in the tandem mass 
spectrometry, which limited our ability to detect modifications. Some experiments were 
attempted to improve the results. Various enzymes (Trypsin, GluC, Chymotrypsin and AspN) 
were combined. HNE was substituted by a more active carbonyl reagent, acrolein. A chelating 
reagent, bathophenanthroline disulfonic acid disodium salt (OBP), was added before enzymatic 
digestion to try to break ligation between the cysteines and the cluster. The coverage and number 
of detected modification could not be dramatically improved with these approaches.   
Analysis of the commercial sample using SDS-PAGE separation and mass spectrometry revealed 
the purity of aconitase is much lower than reported (Figure 4-10). The purchased sample is a 
mixture of various proteins. Porcine serum albumin in a large portion was added to stabilize 
aconitase. The low purity of aconitase made the identification of modification sites difficult by 
the method described in the previous HSA project. In this project, SDS-PAGE separation and 
in-gel digestion were applied after modification instead of gel-free digestion.  
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Figure 4-10. 10% SDS-PAGE running of Sigma-Aldrich aconitase and rat heart mitochondria. 
 
During the incubation of HNE with aconitase, the solution was observed to become cloudy with 
increased incubation time. This phenomenon was more obvious at higher molar ratios of HNE 
and finally caused smeared gel bands and poor tandem mass spectra. It was assumed to be due to 
intra and intermolecular cross-links involving Michael additions and Schiff base formations. To 
limit this problem, excess DTT was added after incubation of HNE with aconitase to consume 
the remaining HNE. Urea was then used to denature the modified proteins before adding 
reductant. This method was applied to possibly break down any imines involved in cross-linking. 
Analysis of samples with this approach showed a clearer gel band from the SDS-PAGE and 
improved tandem mass spectrum quantity at a 50:1 molar ratio (Figure 4-11). The drawback of 
this method is that the added DTT may compete for adducted HNE or impact the ligated 
cysteines. Additionally, it probably would be difficult to detect Schiff base formation under the 
conditions. However, product analyses from the two methods at a 10:1 molar ratio showed 
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similar modifications. This implies that the added DTT did not impact the modifications 
significantly at room temperature and pH 7.4.  
 
 
Figure 4-11. 10% SDS-PAGE running of modified aconitase (HNE:ACO=50:1) with or without 
adding DTT and urea before reduction. A: treated with DTT and urea; B: without DTT and urea 
added.  
 
Correlation between HNE Modifications and Enzyme Activity  
Superoxide anion (O2-), hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) have been shown 
to inactivate mitochondrial aconitase through disturbing the [4Fe-4S]2+ cluster.196, 204-207 
Aconitase activity may also be modulated by modifications of amino acids. Peroxynitrite 
(ONOO-) has been reported to modulate m-aconitase activity through modifications of cysteines 
and tyrosines.204, 205 In this project, some of the identified HNE modifications are in the active 
site region of aconitase. Cys358, Cys421 and Cys424 contribute ligands to the iron-sulfur cluster. 
The replacement of any of these cysteines with serine causes enzymatic activity to be lost. It has 
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been shown that Cys565 is the most reactive cysteine in aconitase towards electrophiles and can 
bind to various alkylation reagents, causing a decrease in aconitase activity.181, 213 Although this 
cysteine is not in the active site, modification of this residue could inhibit substrate entry to the 
cluster. His101 and His147 are also active sites in aconitase because they directly or indirectly 
provide protons when paired with Asp100 and Asp165 in hydrogen bonds with the substrate.182 The 
mutation of His101/Asp100 and His147/Asp165 pairs to Asn/Ser pairs shows varying-levels of 
decrease in aconitase activity.202 Our enzymatic assay results show reduced catalytic activities 
when the amount of HNE or incubation time increases. Before performing the assay, an effort 
was made to rebuild the [4Fe-4S]2+ cluster by providing the necessary components for the 
cluster. Assuming that the conditions used were favorable for cluster formation (near 100% 
activity was seen in the control samples subjected to the same procedures), it appears that protein 
modifications by the HNE must be the cause of the reduced aconitase activity. This could be a 
direct result of modification at active site residues or a result of poor folding due to cross-linking. 
The iTRAQ data provides evidence for the former. 
In this project, iTRAQ reagent labeling quantification was employed to measure the relative 
reactivity of targeted sites. There is evidence that critical residues are modified. The high degree 
of modification at the cysteines in the iron-sulfur cluster suggests that HNE would have a large 
impact on aconitase activity. The depletion plots for the unmodified peptides containing these 
cysteines are quite similar in profile to the aconitase activity plots. Each drops rapidly in the first 
2 hours to about 40-50% of the control value and then begins to level off in the 2-6 hour period. 
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This correlation strongly suggests that HNE modification of a cysteine in the iron-sulfur cluster 
leads to the elimination of aconitase activity. 
The enzyme activity assay as well as the cysteine modification analysis (iTRAQ) suggests that 
the HNE alteration of the protein does not go to completion. In each case, about 30% - 40% of 
the protein appears to resist alteration despite higher HNE concentrations or longer incubation 
times. This indicates that some portion of the protein is protected from reaction in the incubation 
process. There is not enough information from these studies to pinpoint the cause. A possible 
explanation is that some HNE modifications do not reduce function, but do alter the structure or 
solubility of aconitase in a way that inhibits reaction of HNE with active site residues. In such a 
scenario, the aconitase could retain activity and avoid critical cysteine modifications despite 
extended reaction times or greater HNE concentrations. 
  
Reactivity of Amino Acids 
As noted above, there are twelve cysteines, but no disulfide bridges in aconitase. Three cysteines, 
Cys358, Cys421 and Cys424, coordinate with the iron-sulfur cluster as ligands.189 In reactions with 
electrophiles, Cys565 has been reported as the most reactive site in the enzyme.213 All detectable 
cysteines, except Cys358, share the same tryptic peptides with other amino acids, which makes it 
hard to rank the reactivity of the cysteines using the iTRAQ quantification. If we assume that the 
cysteines are more reactive than the histidines in the peptides that contain both, the data in Figure 
5a suggest the following order of reactivity: Cys421/424 > Cys99 > Cys565 > Cys358. The high level 
  123 
of modification in the peptide containing Cys421/424 may be a result of it having two reactive 
cysteines. It is somewhat surprising that Cys99 reacts faster than Cys565, which had been 
identified in previous studies as being the most reactive with electrophiles. It is true that the 
peptide with Cys99 has contributions in its modification from His98/101, but as discussed earlier, 
these are expected to be small. In any case, the data suggest that all of these cysteines, Cys99, 
Cys421/424, and Cys565 have high reactivity. In the histidines, it is more difficult to identify an 
order of reactivity because His98/101 and His569 have their reactivity masked by the more reactive 
cysteines in the peptides that contain them. Excluding these, we are left with His460 > His46 ~ 
His9/13 > His519. Of these, His460 separates itself out as being significantly more reactive than the 
others. Based on their very limited reactivity, nothing can be stated about the relative lysine 
reactivity. 
A simple calculation of the SASA associated with the residues can be done.135, 136 It provides 
some insight into the environments of the reactive residues. Plots of side chain and backbone 
SASAs for the cysteines and histidines in aconitase can be generated using the GETAREA 
program137 (Figure 4-12). Lysines are excluded because we have no useful reactivity data for 
them. From the SASAs plots of cysteines and histidines, there seems to be no relationship 
between the SASA and reactivity other than the need for marginal surface accessibility. 
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Figure 4-12. SASA in Å2 for cysteines and histidines in aconitase. Red bars are the backbones 
and blue bars are the side chains. Green arrows indicate sites that were on the target list.  
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What the majority of the most reactive residues have in common is that they are physically close 
to the active site of the enzyme.200 All the cysteines from the iron-sulfur cluster are reactive with 
HNE, as well as a number of histidines that are in close proximity to the active site. In addition 
to the cysteines of the iron-sulfur cluster, many other reactive sites are near the cluster. His101 
and His147 are within 10 Å of the cluster and Cys99, His98, His460, and His569 are all within about 
20
Å of the cluster. This is an intriguing finding and suggests that features of the active site 
might direct HNE modification to residues in the vicinity. This would make aconitase very 
sensitive to HNE modification and potentially, active site residues might be catalyzing the HNE 
modification. This type of targeted modification was not seen in HSA and indicates that the local 
environment can play a strong role in directing HNE modification. 
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Conclusions 
The addition of a reactive α, -unsaturated aldehyde, HNE, to aconitase exhibits relatively high 
selectivity. The modification sites were determined at high confidence with various molar ratios 
of HNE to ACO (1:1, 2:1, 5:1 and 10:1) using mass spectrometry. In addition to the iron-sulfur 
cluster, other amino acids play a critical role in the enzymatic reaction and are considered as 
active site residues. Enzymatic assays of aconitase modified with HNE at various incubation 
times and molar ratios show decreased enzyme reactivity. iTRAQ quantification was applied to 
measure the relative reactivity of targeted amino acids towards HNE. The results suggest that 
cysteines have relatively high modification levels. The quantitation results for ligated cysteines 
(C358, C421 and C424) and an active site histidine (His101) are consistent with the enzymatic assay 
results, which quantitatively indicated that the decreased aconitase activity correlates with the 
extent of modification of active sites. Finally, the crystal structure of aconitase and plots of 
SASAs indicate that surface accessibility does not correlate with reactivity in aconitase. Instead, 
reactivity seems to be targeted at residues near the active site. 
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Chapter 5: Determine The Level and Nature of Protein Carbonylation in 
Oxidatively Stressed Mouse Heart Mitochondria 
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Background 
Mitochondria are a major source of ROS and target for oxidative damage. Mitochondria are 
involved in the production of ROS through one-electron carriers in the electron-transport chain 
(ETC), and mitochondria are also very susceptible to oxidative stress as evidenced by significant 
reports of LPO, protein oxidation and mitochondrial DNA (mtDNA) mutations. Mitochondria 
play a critical role in various apoptosis events since oxidative stress induced by ROS can cause 
apoptosis.214 However, exact mechanisms of increased ROS formation in mitochondria and their 
induction of apoptotic signals are not deeply understood.215 
The ETC is a powerful source of ROS during normal metabolism.216, 217 These ROS primarily 
are superoxide radical (O2.-) and hydrogen peroxide (H2O2). The latter is either as a product of 
SOD or spontaneous disproportionation of superoxide radical.214, 218 It is calculated that 1-4% of 
the oxygen entering the ETC is incompletely reduced to ROS.214, 219, 220 The ETC is composed of 
five multimeric complexes (Figure 5-1),215, 221 which are NADH dehydrogenase, succinate 
dehydrogenase, ubiquinol cytochrome c reductase, cytochrome c oxidase, and 
adenosine-5'-triphosphate (ATP) synthase. Electron transport between complex I (nicotinamide 
adenine dinucleotide (NADH) dehydrogenase) to complex IV (cytochrome c oxidase) is coupled 
to extrusion of protons from complex I, III (ubiquinol cytochrome c reductase) and IV into the 
intermembrane space, generating an electrochemical potential across the mitochondrial inner 
membrane.215 In this process, complex II (succinate dehydrogenase) only acts to transfer 
additional electrons into the quinone pool (Q) from succinate. Protons finally flow to complex V 
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(ATP synthase), which organizes the energy to synthesize ATP from adenosine diphosphate 
(ADP).222 Complex I and complex III are two major ROS-producing regions in the ETC under 
normal conditions.214 The rate of ROS generation from mitochondria is increased in various 
pathologic conditions including hypoxia, ischemia, aging, and chemical inhibition of ETC.216, 
223-228
 
 
 
Figure 5-1. Component of ETC in mitochondria.215 
 
Mitochondrial components are exposed to high concentrations of ROS because they are major 
producers of ROS, and may therefore be particularly susceptible to attack by ROS. Damage by 
oxidative stress to mitochondrial components includes LPO, protein oxidation and mtDNA 
mutations.214, 229 LPO might be particularly harmful in mitochondria, especially because there are 
some highly unsaturated lipids in the inner mitochondrial membrane.230 As a result of oxidative 
stress, protein oxidation may occur either directly or as a consequence of LPO. MtDNA is also 
highly susceptible to oxidative stress because it is located in the matrix and close to the major 
source of ROS. The damage to mtDNA is greater and lasts longer than that to nuclear DNA.214 
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Mitochondrial functional damage mostly impacts cells that have a high-energy demand, such as 
neurons and cardiac myocytes, because mitochondria play a critical role in cellular energy 
production by ETC dependent synthesis of ATP.215, 231 It has been suggested that ROS contribute 
to myocardial injury during ischemia and reperfusion.217, 232, 233 The rate of ROS generation from 
mitochondria is increased under ischemia and reperfusion conditions.228, 232-235 Some research 
has been done to support that ischemic damage to ETC increases the generation of ROS from 
mitochondria, which was measured by H2O2 release from ischemic damaged sub-sarcolemmal 
mitochondria (SSM) and inter-fibrillar mitochondria (IFM). The results show that ischemic 
damage to the ETC increases the generation of H2O2 from both complex I and complex III, and 
could be a potential mechanism of cardiac injury.228 
Although ischemic damage has been described to increase ROS by inhibiting ETC, there are not 
many details about how important proteins in mitochondria are impacted in this process. In this 
project, we are working with Dr. Edward J. Lesnefsky’ s group in the Department of 
Biochemistry at Virginia Commonwealth University. They provide the mouse heart 
mitochondrial samples. Our aim is to determine which mitochondrial proteins are oxidatively 
modified to give protein carbonyls during ischemic events in mouse hearts. Furthermore we will 
try to investigate the specific modification sites in these proteins. 
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Experimental Procedures 
Materials 
Isolated mouse heart mitochondria were provided by Dr. Lesnefsky’ s lab. They were prepared 
using standard techniques.228, 236 (+) Biotin-hydrazide, SDS, 2-(N-morpholino) ethanesulfonic 
acid (MES), NaBH3CN, IAM, DTT, and 10×PBS concentrate were purchased from 
Sigma-Aldrich (St. Louis, MO). Sequencing grade modified trypsin was from Promega 
(Madison, WI). HNE was obtained from Cayman Chemical (Ann Arbor, MI). Streptavidin 
magnetic beads were purchased from Invitrogen (Carlsbad, CA). Laemmli sample buffer was 
from Bio-Rad (Hercules, CA). The anti-HNE monoclonal antibody was purchased from Japan 
Institute for the Control of Aging (Haruoka, Japan). Enhanced chemiluminescence kits were 
obtained from GE Healthcare (Pittsburgh, PA) and oxyblot™ protein oxidation detection kits 
were obtained from Millipore (Billerica, MA). BCA Protein Assay kits, Imperial protein stain, 
streptavidin poly-HRP, and streptavidin resin were purchased from Thermo Scientific (Rockford, 
IL). iTRAQ reagent kits were obtained from Applied Biosystems (Foster City, CA). 
 
Experiments 
Biotinylation of protein carbonyls 
The fresh isolated ischemic mouse mitochondria sample and control were incubated with 5 mM 
biotin-hydrazide for 60 min at room temperature separately. The mitochondrial membrane was 
broken by adding 2% SDS at room temperature. The insoluble materials were discarded with 
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centrifugation at 12800 g and the supernatant was collected. The collected supernatant was 
diluted using labeling buffer (50 mM MES buffer, pH 5.5) to a final concentration of 1 mg/ml. 
Biotin hydrazide stock solution (50 mM in DMSO) was then added to a final concentration of 5 
mM. The mixture was incubated for 2 h at room temperature with gentle shaking. The hydrazone 
formed during labeling was stabilized by adding NaBH3CN to 15 mM and incubating for 60 min 
in an ice bath. Repeated washes employing centrifugal filter devices (Millipore, Billerica, MA) 
were used to remove reagents and to exchange to 200 ml 1×PBS buffer (pH 7.4) for enrichment; 
the molecular weight cut-off for the centrifugal filter devices used was 3 kDa. The protein 
concentration was determined using the BCA protein assay. 
 
Purification of biotinylated proteins 
After labeling, biotinylated proteins were enriched using streptavidin conjugated magnetic beads 
and streptavidin resins separately. The purification procedure was done according to the 
manufacturer’s protocol with slight adjustment. Briefly, the same amount biotin labeled sample 
and control were measured and incubated with pre-washed streptavidin magnetic beads or 
streptavidin resins for 60 min at room temperature. The incubation was carried out on a rotary 
machine using gentle rotation. For streptavidin magnetic beads, protein-coated beads were 
collected with a magnet for 3 min, and the supernatant was then removed completely. Coated 
beads were washed three times using 1×PBS buffer with 0.01% Tween 20 and 0.1% SDS (pH 7.4) 
to avoid unspecific binding. For the streptavidin resin, the protein-attached slurry was separated 
with centrifugation at 4000 g for 2 min, and the supernatant was carefully removed by pipette. 
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The slurry was washed three times using 1×PBS buffer with 0.01% Tween 20 and 0.1% SDS (pH 
7.4). Finally, the beads and slurry were collected for trypsin digestion.  
 
Enzymatic digestion 
1. Protein digestion after releasing from beads 
The collected coated beads from the enrichment were resuspended in100 µl 1% SDS in 1×PBS 
buffer and incubated at 95 °C for 5 min. The beads were separated with a magnetic separator for 
3 min and the supernatant containing enriched proteins was carefully collected. This step was 
repeated three times to completely collect the released proteins. The released proteins in the 
supernatant were reduced with DTT and alkylated with IAM. Repeated washes employing 
centrifugal filter devices (3 kDa molecular weight cut-off) were used to remove excess reagents 
and to exchange to a 50 mM ammonium bicarbonate buffer (pH 8.5) for digestion. The tryptic 
digestion was carried out overnight at 37°C. Digestion products were purified using a Waters 
(Milford, MA) Oasis MCX solid phase extraction cartridge. The final sample was dried using a 
centrifugal evaporator and then re-suspended in an HPLC equilibration mobile phase for 
LC-MS/MS analysis. 
2. Protein digestion on beads or resins 
The collected protein bound beads and resins were resuspended and washed with 50 mM 
ammonium bicarbonate buffer (pH 8.5) twice. Samples were subsequently reduced with DTT 
and alkylated with IAM. The streptavidin beads and resins were separated by magnetic separator 
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or subjected to centrifugation again, and then were washed with 50 mM ammonium bicarbonate 
buffer (pH 8.5) twice. The supernatant was removed and discarded during this process. The 
samples were treated with 0.5 µg trypsin. The reaction was carried out at 37 °C for 2 h with 
gentle shaking. The tryptic digestion was repeated twice and the final incubation time was 16 h. 
After every trypsin treatment, beads and resins were isolated and supernatants containing tryptic 
peptides were collected for mass spectrometry analysis and iTRAQ labeling.      
     
iTRAQ reagent labeling 
Enriched peptide mixtures were desalted using C18 MicroSpin columns (The Nest Group, 
Southboro, MA) and dried using a centrifugal evaporator. Solid peptide mixtures of both sample 
and control were then reconstituted in 25 ul of iTRAQ dissolution buffer. Two iTRAQ reagents 
were dissolved in 70 l of ethanol separately. Each iTRAQ reagent aliquot was added to one of 
the peptide mixtures in the following sequence: mass 114 for the enriched control using 
streptavidin magnetic beads; mass 116 for the enriched ischemic sample using streptavidin 
magnetic beads, mass 115 for the enriched control using streptavidin resin, and mass 117 for the 
enriched ischemic sample using streptavidin resin. After incubation for 2 h at room temperature 
with gentle shaking, the iTRAQ labeled sample and control were combined and then purified 
using a Waters (Milford, MA) Oasis MCX solid phase extraction cartridge. The final products 
from both enrichment methods were dried using a centrifugal evaporator and then re-suspended 
in the HPLC equilibration mobile phase for LC-MS/MS analysis. 
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Western Blot 
1. Detection of mitochondria carbonylation in vitro   
Fresh isolated mitochondria at a concentration of 1 mg/ml were treated with HNE at various 
concentrations (25 µM, 50 µM, 100 µM and 200 µM). All reactions were incubated at 37 °C for 
3 h. Modified mitochondria (100 µg) were mixed with a Laemmli sample buffer. After heating at 
95 °C for 5 min, the protein mixtures were separated on a 12% SDS-PAGE gel, and then 
transferred onto a PVDF membrane by electroblot. The membrane was blocked for 1 h at room 
temperature with a 5% fatty acid-free milk in TBST and incubated with anti-HNE diluted to 
1:500 in 5% BSA overnight at 4°C. Blocked membrane was then washed with TBST and 
incubated with HRP conjugated anti-mouse antibody in 5% BSA (1:5000 dilution) for 1 h at 
room temperature. Following washing with TBST, the membrane was developed with ECL 
detection reagents. 
2. Immunobloting of mitochondria carbonylation using streptavidin-conjugated HRP   
Equal amounts of biotinylated control and ischemic mitochondria samples (10 µg) were loaded 
on a 4-20% gradient polyacrylamide gel, and then transferred onto a PVDF membrane. The 
PVDF membrane was blocked overnight at 4 °C with 4% fatty acid-free BSA in PBST (pH 7.2). 
Blots were then incubated with streptavidin poly-HRP diluted to 0.02 µg/ml in 4% BSA at room 
temperature for 1 h. Following rinsing with PBST, the membrane was developed with ECL 
detection reagents.   
3. Identification of mitochondria carbonylation using Oxyblot   
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The procedure for the Oxyblot detection was taken directly from the manufacturer’s protocol. 
Briefly, fresh, isolated control and ischemic mitochondria samples (10 µg) were denatured by 
adding 12% SDS to a final concentration of 6% SDS, and then were derivatized by adding 10 µl 
of a 2,4-dinitrophenylhydrazine (DNPH) solution. The derivatization reaction was carried out at 
room temperature for 15 min. Samples were neutralized and reduced by adding 7.5 µl of 
neutralization solution and 1 µl of 2-mercaptoethanol. Mixtures were loated on 4-20% gradient 
polyacrylamide gel, and then transferred onto a PVDF membrane by electroblot. The membrane 
was blocked for 1 h at room temperature with 5% fatty acid-free BSA in PBST and incubated 
with anti-DNP diluted to 1:150 in 1% BSA/PBST at room temperature for 1 h. The blocked 
membrane was then washed with PBST and incubated with HRP conjugated anti-goat antibody 
in 1% BSA (1:2000 dilution) for 1 h at room temperature. Following washing with PBST, the 
membrane was developed with ECL detection reagents. 


LC-MS/MS analysis 
1. Mitochondria carbonylation identification 
Carbonylation identification was performed using a Thermo (San Jose, CA) LTQ XL linear ion 
trap mass spectrometer equipped with ETD. The LTQ XL was interfaced with a Thermo 
Surveyor capillary HPLC system. Peptides were separated on a reversed-phase, C18 column 
(150 m × 10 cm, 5 m particles, 300 Å pores; Column Technology, Fremont, CA) at a flow rate 
of ~1 l min−1 using 0.1% formic acid in water as mobile phase A and 0.1% formic acid in 
methanol as mobile phase B. Approximately 2 µg peptides were injected and a Michrom 
  137 
(Auburn, CA) CapTrap trapping column was used for rapid sample injection. The gradient 
started from 2% B, then increased to 15% B over 5 min, then increased to 80% B over 70 min, 
and finally increased to 95% B over 15 min. The eluted peptides were introduced into the LTQ 
XL with a nanospray source operating at a spray voltage of 2.1 kV, a capillary voltage of 21 V, 
and a capillary temperature of 200°C. A full scan in the m/z range 300-2000 was performed to 
obtain precursor ions, followed by four data-dependent CID MS/MS scans for the four most 
abundant precursor ions in the full scan. Dynamic exclusion was used-if the same precursor ion 
was picked for fragmentation twice within a 30 s window, it was excluded from further analysis 
for 180 s.  
2. iTRAQ reagent-labeled on-beads digests 
Analysis of iTRAQ reagent-labeled samples was performed only by a Thermo LTQ Orbitrap 
Velos mass spectrometer. Separations were performed on a Waters nanoACQUITY 
reversed-phase, C18 column (100 µm × 10 cm; 1.7 µm particles). Elution was achieved using a 
gradient of 0.1% formic acid in acetonitrile (B) versus 0.1% formic acid in water (A) at a flow 
rate of 0.4 µL min−1. Approximately 2 µg peptides were injected, with the loading and 
equilibration mobile phase being 1% B. The linear gradient ran to 15% B after loading at 1% B 
over 25 min, followed by an increase to 25% B over 35 min, followed by an increase to 35% B 
over 40 min, and followed by an increase to 85% B over 20 min. The nanospray ion source was 
operated at 3.5 kV. A full scan in the m/z range 400-7500 was performed to obtain precursor 
ions, followed by eight data-dependent HCD MS/MS scans for the eight most abundant 
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precursor ions in the full scan. Dynamic exclusion was used. For HCD, the normalized collision 
energy was 40 and the activation time was 0.1 ms. 

  
Database searching and data processing 
Peptide sequences and modifications were identified using the BioWorks version 3.3.1, SP1 
implementation of Sequest (Thermo). No scan grouping was performed in preparing peak lists 
for database searching. The protein sequence database used consisted of the NCBI RefSeq 
version of the complete mouse proteome and reversed versions of all sequences. Reversed 
sequences permit a false discovery rate estimation. Sequences were downloaded on June 27, 
2011, and the final database contained 70499 entries. Only fully-tryptic peptides were considered 
and up to three missed cleavage sites were allowed. Precursor ion tolerances were ±2 Da for 
linear ion trap measurments and ±15 ppm for Orbitrap measurements. Fixed mass shifts were 
applied for alkylated cysteines (+57 Da) while differential amino acid mass shifts were 
incorporated for biotin hydrazide labeled carbonylation at lysines (+241 Da), at arginines (+199 
Da), at proleins (+258 Da), at threonines (+240 Da), and oxidized methionines (+16 Da). A 
maximum of four variable modifications were permitted for each peptide. In searches with the 
iTRAQ labels present, fixed mass shifts of +144.102 Da were used for the peptide N-terminus 
and non-carbonylated lysine residues while differential amino acid mass shifts were incorporated 
for cysteines carboxyamidomethylation (+57.0513 Da) and methionines oxidation (+15.9994). 
Sequest output was refined using the Trans-Proteomic Pipeline (version 4.4; Institute for 
Systems Biology, Seattle, WA) software package. Specifically, PeptideProphet171 was used, in 
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semi-supervised mode172, to improve identification confidence. A PeptideProphet score threshold 
of 0.9 was applied. Intensity measurements for iTRAQ reporter ions (114-117) were processed 
using Microsoft Access.  
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Results 
In this project, fresh mitochondria samples were prepared by Dr. Lesnefsky’ s laboratory. Briefly, 
a mouse heart ischemia model was set up by submerging isolated hearts in saline within an 
Eppendorff tube. The tube was then incubated in a water bath at 37 °C for 30 min with shaking. 
Simultaneously, control hearts were kept in the same buffer on ice for the same period of time. 
Finally, mitochondria were isolated from both ischemic and control hearts following a standard 
procedure.228, 236  
DNPH derivatization was applied for protein carbonylation detection in this project. DNPH is 
often used to qualitatively identify carbonyl groups associated with aldehydes and ketones. 
DNPH can react with carbonyl groups of oxidized amino acid residues in proteins (Scheme 5-1). 
The formed hydrazone derivatives can be used to detect carbonyl functionality in the protein by a 
color change or by a western blot analysis with anti-DNP.237, 238  
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Scheme 5-1. Protein carbonylations labeling by DNPH. 
  
In addition, (+) biotin-hydrazide was used to label the carbonylated proteins.132 Biotinylated 
proteins were then purified using streptavidin-conjugated beads and resins. The interaction 
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between streptavidin and biotin is a non-covalent and highly specific biological binding. The 
binding between streptavidin and biotin is very tight, rapid and unaffected by pH or organic 
solvent.239, 240 The streptavidin-biotin interaction can only be broken under harsh conditions, 
which can often denature the proteins involved in the interaction. However, it has been reported 
recently a mild incubation at elevated temperatures in water can break the interaction.241 
Streptavidin is also widely applied in western blots; an immunoblotting can detect protein 
biotinylation when conjugated with reporter molecules.242, 243  
 
Western Blotting 
In vitro modification with HNE 
An in vitro experiment was designed to examine the possibility of mitochondrial protein 
modification by HNE. A monoclonal anti-HNE antibody was used to detect the HNE 
modifications. The anti-HNE is particularly sensitive to modified histidines in proteins. An 
increased modification level was observed at higher molar ratios of HNE to mitochondria 
(Figure 5-2). A band from the corresponding electrophoresis gel was cut out to perform in-gel 
trypsin digestion. One of the blotted proteins was identified as being aconitase by mass 
spectrometry analysis (see Figure 5-2). The western blot results indicate that HNE entered the 
mitochondria and modified a variety of proteins. Relatively high HNE concentrations were 
needed to observe wide spread modifications.  
  
  
Figure 5-2. Western blot of mitochondria modifications by HNE 
concentrations (0, 25, 50, 100 and 200 µM). One b
spectrometry analysis. 
 
Carbonylated proteins from ischemia model
Streptavidin conjugated poly-HRP was employed to detect biotinylated carbonylations in 
ischemia model mitochondria samples. The detection is based on the specific interaction between 
streptavidin and biotin.242, 243 Blotting detected multiple protein biotinylations from both 
biotin-hydrazide treated control (negative control 2, NC2)) and the ischemia sample (Figure 
The modified proteins from both samples appeared at the same general positions on the gel. 
There is slightly higher intensity in the ischemia model sample. The high background in NC2 
suggests either significant modification in the control or significant non
western blot. No blotting from the 
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Figure 5-3. Streptavidin conjugated poly-HRP identification of biotin-hydrazide treated control 
(NC2), ischemic mitochondria (IM), and buffer treated control (NC1) in Western blot. Protein 
molecular weight was decided by protein marker roughly. 
 
Oxyblot was also used to detect the carbonylated proteins in ischemic mitochondria. It is based 
on DNPH induced derivatization of carbonylated proteins.237, 238 Anti-DNP antibodies were used 
to detect the derivatization. Western blot results show specific, positive blotting from the 
ischemia model mitochondria sample. Limited signals of derivatization were found in the DNPH 
treated control (negative control 2, NC2) and none in the blank solution control (negative control 
1, NC1) were observed (Figure 5-4). A band from the corresponding gel electrophoresis analysis 
was cut out to perform in-gel trypsin digestion. Mass spectrometry analysis of this band at 
around 95 kDa showed the band contained aconitase.  
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Figure 5-4. Oxyblot of DNPH treated control (NC2), ischemic mitochondria (IM), and buffer 
treated control (NC1). One blotting was identified as aconitase by mass spectrometry analysis. 
 
The differences between Figure 5-3 and 5-4 suggest that the biotin-streptavidin strategy provides 
a greater amount of non-specific binding. The fact that patterns observed in this western blot are 
not reproduced in the Oxy blot is evidence of the non-specific binding. Careful comparison of 
the two methods shows that many of the bands with higher intensity in the Oxyblot of the 
ischemic model also give higher intensity in the biotin-streptavidin western blot, though 
somewhat obscured by the high degree of non-specific binding. 
 
Carbonylation Identification 
Our goal was to identify the carbonylated proteins from ischemia mitochondria. Fresh, isolated 
mouse mitochondria were treated with increasing amounts of HNE. Western blotting identified 
HNE modifications in the samples. The amount of apparent modification increased with 
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increasing amounts of HNE. Some blotted bands from the corresponding gel electrophoresis 
were subjected to in-gel trypsin digestion. The digests were analyzed by mass spectrometey and 
proteins were identified, such as aconitase and cytochrome c etc.. However, no peptides bearing 
HNE modifications were identified by mass spectrometry, even when the amount of HNE 
attained 200 µM. This concentration is higher than physiological HNE concentrations. 
Therefore, enrichment or other purification methods of the carbonylated proteins in the ischemia 
mitochondria sample was considered in this project. Streptavidin conjugated magnetic beads 
were primarily applied for the enrichment of potential protein carbonylation in this study. After 
releasing proteins from the beads and digestion, a very limited number of proteins were detected 
by mass spectrometry from both the control and the ischemia model mitochondria sample, and 
each protein was identified by only one peptide (Table 5-1). Also, no peptides bearing 
carbonylation sites were found. Comparing the search data from the control and the ischemia 
model mitochondria, the identified proteins were similar and it is hard to make any conclusions 
about which proteins were actually carbonylated. The limited detections probably were due to 
the very tight streptavidin-biotin binding, and as a result, carbonylated proteins were not 
efficiently released. Those that were identified were likely from non-specific binding on the 
beads. Next, the trypsin digestion was completed without releasing the proteins from the 
beads.244 Around three hundred proteins were identified by mass spectrometry from both the 
control and the ischemia model mitochondria sample (Table 5-1). Obviously no carbonylation 
sites will be detected in this protocol because the biotin-bearing peptide remains on the bead. 
Comparing search data from the control and the ischemia model mitochondria, the number of 
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identified proteins from the ischemia model was a little higher than the amount from control. 
However, the number of MS/MS spectra for specific proteins were quite similar and it is hard to 
identify a pattern of modification. Non-specific binding to the streptavidin conjugated beads, 
especially for the hydrophobic proteins in mitochondria, might be a problem in this experiment. 
To gain more information, a quantitative approach was taken. 
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Table 5-1. Protein identification from control and ischemic mitochondria samples with two 
digestion pathways. *: number of detected proteins. 
 
Relative Carbonylation Levels Based on iTRAQ Labeling 
In this project, the iTRAQ reagent labeling was used to measure the relative carbonylation levels 
of control and ischemia model mitochondria samples. The iTRAQ reagent-labeled samples were 
analyzed on a Thermo LTQ Orbitrap mass spectrometer. Peptide sequences were identified using 
tBioWorks, and the sequest output was refined using the Trans-Proteomic Pipeline software 
package. The ratios of iTRAQ reporter ions from the ischemia model and control mitochondria 
proteins were calculated and corrected by the ratio for trypsin peptides in the two samples. 
Because the same amount of trypsin was used in both digestions and no trypsin will be lost 
during the experiment, it can serve as an internal standard. Two batches of ischemia model 
mitchondria samples were quantified separately by applying the iTRAQ reagent after 
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streptavidin beads or resins. In the first preparation, all of the proteins enriched on the 
streptavidin magnetic beads showed significantly higher intensities for the iTRAQ ions in the 
ischemia model, as expected for a higher level of carbonylation. Table 5-2 lists the proteins that 
have the highest (>5) calculated ratios of ischemia model; control mitochondria proteins. In the 
Table 5-2, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 shows the highest ratio 
(8.32). Next are ATP synthase subunit B1 and cytochrome c oxidase subunit IV isoform 1. For 
ischemia model proteins purified on streptavidin resins, even more proteins show significant 
increases in carbonylation compared to the control sample (Table 5-3). Among these proteins, 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 also shows the highest ratio (21.43) 
and it is higher than the one from the streptavidin magnetic beads. The sample from the resin 
enrichment let to more proteins with quantifiable intensities and generally double the ratios of 
the ischemia model to control. This variation in ratios may reflect a difference in the levels of 
non-specific and specific binding on the two avidin products. In any case, both approach 
highlighted a similar set of proteins as having exceptional carbonylation levels in the ischemia 
model. It is interesting to note that most of these proteins are in the ETC. However, in the second 
batch, none of the protein modification levels were found to be significantly increased in the 
ischemia model. This is a surprising result and suggests problems in the preparation of the 
ischemia model mitochondria. For ischemia model proteins purified on streptavidin magnetic 
beads, only one protein, NADH dehydrogenase (ubiquinone) flavoprotein 2, showed a slightly 
higher amount of carbonylation compared to the control sample. For the streptavidin resin 
enriched ischemic sample, several proteins, NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
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NADH dehydrogenase (ubiquinone) Fe-S protein 7, isovaleryl-CoA dehydrogenase and 
enoyl-CoA delta isomerase, showed higher amounts of carbonylation compared to the control 
sample.  
 
Proteins iTRAQ intensity Ratios (Ischemic/Control) 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 8.32 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
B1 7.53 
cytochrome c oxidase subunit IV isoform 1 7.04 
ubiquinol-cytochrome c reductase, complex III subunit VII 6.32 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 6.26 
adenosine A3 receptor 6.00 
Table 5-2. Streptavidin magnetic beads purified proteins showing the significantly increased 
amount of carbonylation from first preparation.  
 
Proteins iTRAQ intensity Ratios (Ischemic/Control) 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 21.43 
cytochrome c oxidase subunit IV isoform 1 20.67 
ubiquinol-cytochrome c reductase, complex III subunit X 19.04 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
B1 16.00 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7 14.75 
adenosine A3 receptor 14.45 
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ubiquinol-cytochrome c reductase binding protein 14.37 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8 13.98 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 13.13 
solute carrier family 4, sodium bicarbonate transporter-like, member 
11 12.45 
ATP synthase, H+ transporting mitochondrial F1 complex, beta 
subunit 12.19 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
F2 11.48 
cytochrome c oxidase, subunit VIb polypeptide 1 10.68 
ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon 
subunit 10.38 
cytochrome c oxidase, subunit VIIa 2 10.01 
cytochrome c oxidase subunit VIIb 8.54 
succinate dehydrogenase complex, subunit C, integral membrane 
protein 8.27 
acyl-CoA thioesterase 2 7.85 
NADH dehydrogenase (ubiquinone) Fe-S protein 8 7.59 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14) 7.03 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10 6.91 
heat shock protein 1 (chaperonin) 6.62 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta 
subunit 
6.59 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 6.53 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
d 6.45 
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NADH dehydrogenase (ubiquinone) Fe-S protein 3 6.22 
aldehyde dehydrogenase 4 family, member A1 6.07 
Table 5-3. Streptavidin resins purified proteins showing the significantly increased amount of 
carbonylation from first preparation.  
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Discussion 
Method development 
In the first part of this project, mitochondria were modified with HNE at various molar ratios. 
HNE modifications were detected in Western blot using a monoclonal anti-HNE antibody. The 
level of modification increased with increasing HNE concentration. However, no modification 
sites were identified by mass spectrometry from in-gel digestion of the corresponding gel band, 
even at the highest HNE concentration (200 µM). No enrichment was used in these experiments 
and the absence of identified modifications is probably due to the low modification level, which 
does not allow modified peptides to compete with background signal from unmodified peptides. 
An enrichment process is necessary for purifying modified peptides in order to reduce the 
background and improve the probability of detecting the modifications. 
The frequently used strategies for isolating carbonylated proteins include Girard’ s reagent,245 
hydrazine-functionalized isotope-coded affinity tags,246, 247 aldehyde reactive probes and 
solid-phase hydrazides.248 In this project, we chose an aldehyde-reactive biotinylated derivative, 
biotin hydrazide, to tag the carbonylated proteins.132 Streptavidin conjugated magnetic beads and 
resins were used to isolate biotinylated proteins. The general procedure for streptavidin beads 
and resins is to incubate the biotinylated proteins with the beads, and then release attached 
proteins after washing.239, 240 The released proteins are then digested and the digested peptides 
are analyzed to identify modifications. During our experiment, we found that the bound proteins 
were very hard to release due to the strong interaction between the biotin tag and the 
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streptavidin. This is potentially more problematic in our system because the biotin-streptavidin 
conjugation point may be protected by the protein bearing the biotin tag. Therefore, we did the 
digestion on the beads. By choosing on-bead digestion, the proteins on the streptavidin are 
directly digested under relatively mild conditions. The digested peptides are easier to collect, and 
extra steps for sample purification before and after digestion are not necessary.244 The 
shortcoming of the on-bead digestion is that it precludes the identification of specific 
modification sites. 
We also applied iTRAQ reagents to quantify the streptavidin binding of control proteins and 
ischemia model mitochondria proteins. The quantitation by iTRAQ can eliminate the impact of 
non-specific binding caused by the very hydrophobic proteins in mitochondria. The total 
intensity ratio of the iTRAQ reporter ions from control and treated samples may give a measure 
of the enrichment provided by the streptavidin treatment and presumably the amount of 
carbonylation in each protein. 
 
Western Blotting 
In this project, Oxyblot was also used to detect the carbonylated proteins in ischemia model 
mitochondria. Oxy blotting results showed only one specific positive blotting from the ischemic 
mitochondria sample compared to negative controls. Although the blotted band appeared to 
contain aconitase, a more certain determination would require two-dimensional gel 
electrophoresis.249, 250  
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Streptavidin conjugated poly-HRP was employed to detect biotinylated carbonylations in 
western blotting too.242, 243 The Oxy blotting technique suffers from severe limitations when 
applied to tissue extracts from mammalian sources. Compared to Oxy blotting, streptavidin 
conjugated HRP displays the specificity of streptavidin detection chemistries and is insensitive to 
immunoglobulin contamination of samples.242 However, in this project, this method seems to 
have a relatively high background binding to the control sample. It is unclear if this was a result 
of non-specific binding or widespread oxidation in the control samples. 
 
iTRAQ Reagent Quantitation for Relative Carbonylation Levels 
For identifying the possible protein modifications, iTRAQ quantitation was used to measure the 
amount of biotin band binding in the control and treated samples. In one sample, large increases 
in carbonylation levels were seen in several proteins. Many of them are associated with the ETC. 
The two approaches of streptavidin enrichment gave similar general patterns, but the resin gave 
higher ratios. This may be related to the relative levels of non-specific binding. A second batch 
showed little difference in carbonylation levels between the ischemia model and control. This 
may be an issue in mitochondria preparation. Considering the two enrichment methods together, 
it seems the NADH dehydrogenase family proteins has the highest probability for modification, 
but more experiments are necessary. Overall, the quantification results from both sample 
purification methods are similar, but are dissimilar for different batches of ischemia michondria 
samples. More experiments for different ischemia sample preparations are demanded. 
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Nevertheless, the iTRAQ reagent based quantification method has been developed and can 
provide the comparison between treated and control samples. 
 
Future Direction 
The ultimate purpose of this project is to identify the specific modified sites from the ischemia 
model mouse heart mitochondria. Currently, we only could measure the relative protein 
carbonylation levels using iTRAQ reagent quantitation. In the future, we will try traditional 
two-dimensional gel electrophoresis to identify the carbonylated protein sites. We also will try 
different isolation methods, like Girard’ s P Reagent and SPH, for purifying the carbonylated 
proteins. Finally, we still could try the different experiment procedures, such as digestion before 
employing enrichment to capture the carbonylated peptides instead of proteins. 
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Conclusions 
In this project, protein carbonylation in the ischemia model mouse heart mitochondria was 
investigated. Oxyblot was applied to identify the carbonylated proteins. Only one band suggested 
obvious modification and was identified as containing aconitase. Biotin hydrazide derivatives 
and streptavidin conjugated magnetic beads and resins were used to purify the protein 
carbonylations. No specific modified sites were detected with mass spectrometry after releasing 
proteins from the beads and digestion. iTRAQ reagent induced quantitation was employed to 
measure the levels of proteins in the control and ischemic samples binding to the beads and 
resins. Several proteins have elevated ratios in the ischemia model sample. However, more 
experiments are needed to validate this result.  
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Appendices-I: Calculation 
Modification Description Modification Composition 
Monoisotopic 
Mass Shift 
Type 
Oxidation at Met +O +15.994915 Differential 
Iodoacetamide Alkylation at 
Cys 
+C2H3NO +57.021464 
Fixed or 
Differential 
Michael Addition of HNE at 
Cys, Reduced 
+C9H18O2 
−[acetamide cap] +101.109216 Differential 
Michael Addition of HNE at 
His, Reduced 
+C9H18O2 +158.130680 Differential 
Michael Addition of HNE at 
Lys, Reduced 
+C9H18O2 +158.130680 Differential 
Schiff Base Formation with 
HNE at Lys, Reduced 
+C9H16O +140.120115 Differential 
Michael Addition of HNE at 
Cys, Not Reduced 
+C9H16O2 
−[acetamide cap] +99.093566 Differential 
Michael Addition of HNE at 
His, Not Reduced 
+C9H16O2 +156.115030 Differential 
Michael Addition of HNE at 
Lys, Not Reduced 
+C9H16O2 +156.115030 Differential 
Schiff Base Formation with 
HNE at Lys, Not Reduced 
+C9H14O +138.104465 Differential 
Table A1. Precise modification mass shifts considered in non-iTRAQ experiments; note that 
while oxidation at Met and iodoacetamide alkylation at Cys were always included, reduced and 
non-reduced HNE modifications were considered in separate Sequest searches. 
 
 
Modification Description Modification Composition 
Monoisotopic 
Mass Shift 
Type 
Oxidation at Met +O +15.994915 Differential 
Iodoacetamide Alkylation at 
Cys 
+C2H3NO +57.021464 
Fixed or 
Differential 
iTRAQ Label at Lys +
12C513C21H1214N218O/ 
+
12C413C31H1214N15N16O 
+144.103991† Fixed 
iTRAQ Label at Peptide 
N-terminus 
+
12C513C21H1214N218O/ 
+
12C413C31H1214N15N16O 
+144.103991† Fixed 
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iTRAQ Label at Tyr‡ +
12C513C21H1214N218O/ 
+
12C413C31H1214N15N16O 
+144.103991† Differential 
Michael Addition of HNE at 
Cys, Reduced 
+C9H18O2 
−[acetamide cap] +101.109216 Differential 
Michael Addition of HNE at 
His, Reduced 
+C9H18O2 +158.130680 Differential 
Michael Addition of HNE at 
Lys, Reduced 
+C9H18O2 
−[iTRAQ label] +14.026689 Differential 
Schiff Base Formation with 
HNE at Lys, Reduced 
+C9H16O 
−[iTRAQ label] −3.983876 Differential 
Table A2. Precise modification mass shifts considered in iTRAQ experiments; † iTRAQ label 
mass shift value was the average for the four tags (separation between heavy pair and light pair is 
circa 0.004 Da, too small to resolve with available instrumentation); ‡ iTRAQ label addition at 
tyrosine only tested with Orbitrap data and found to be uncommon. 
 
Modified Peptide (with flanking residues) Modification 
Site or Sites 
(MA indicates 
Michael 
addition; SB 
indicates Schiff 
base formation) 
Counts of LC–MS/MS 
runs in which the 
modified peptide was 
identified using LTQ XL 
CID scans (maximum = 
12)/LTQ XL ETD scans 
(maximum = 12)/LTQ 
Orbitrap Velos CID scans 
associated with high 
mass accuracy Orbitrap 
precursor ion mass 
measurements 
(maximum = 3) 
1:1 HNE to 
HSA Ratio 
10:1 
HNE to 
HSA 
Ratio 
K.DLGEENFKALVLIAFAQYLQQC#PFEDHVK.L Cys-034 (MA) not detected 0/0/1 
K.ALVLIAFAQYLQQC#PFEDHVK.L Cys-034 (MA) 9/1/0 9/3/3 
K.SLH@TLFGDK.L His-067 (MA) 12/0/3 12/5/3 
K.SLHTLFGDK^LCTVATLR.E Lys-073 (MA) not detected 3/0/0 
R.NECFLQHK~DDNPNLPR.L Lys-106 (SB) not detected 0/1/0 
R.LVRPEVDVMCTAFH@DNEETFLK.K His-128 (MA) 0/2/0 2/3/0 
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K.K^YLYEIAR.R Lys-137 (MA) not detected 1/0/0 
R.RH@PYFYAPELLFFAK.R His-146 (MA) 12/11/0 12/12/3 
R.RH@PYFYAPELLFFAKR.Y His-146 (MA) not detected 1/0/0 
R.RH@PYFYAPELLFFAK^R.Y His-146 (MA) & 
Lys-159 (MA) 
not detected 0/2/1 
R.YK^AAFTECCQAADK.A Lys-162 (MA) not detected 12/2/2 
R.YK~AAFTECCQAADK.A Lys-162 (SB) not detected 10/1/0 
R.LK^CASLQK.F Lys-199 (MA) 6/0/2 11/0/3 
R.AFK^AWAVAR.L Lys-212 (MA) not detected 12/0/1 
K.AEFAEVSK^LVTDLTK.V Lys-233 (MA) not detected 9/4/0 
K.LVTDLTK^VH@TECCHGDLLECADDR.A Lys-240 (MA) & 
His-242 (MA) 
8/0/0 3/0/0 
K.VH@TECCHGDLLECADDR.A His-242 (MA) 0/7/0 0/7/0 
K.VH@TECCH@GDLLECADDR.A His-242 (MA) & 
His-247 (MA) 
not detected 9/4/0 
K.VH@TECCH@GDLLECADDRADLAK.Y His-242 (MA) & 
His-247 (MA) 
not detected 3/7/0 
R.ADLAK^YICENQDSISSK.L Lys-262 (MA) not detected 5/3/0 
K.SH@CIAEVENDEMPADLPSLAADFVESK.D His-288 (MA) 10/0/0 12/1/3 
K.SH@CIAEVENDEM*PADLPSLAADFVESK.D His-288 (MA) 1/0/0 11/1/1 
R.RH@PDYSVVLLLR.L His-338 (MA) 4/0/0 12/3/3 
R.H@PDYSVVLLLR.L His-338 (MA) not detected 2/0/0 
R.H@PDYSVVLLLRLAKTYETTLEK.C His-338 (MA) 0/6/0 1/9/0 
R.LAK^TYETTLEK.C Lys-351 (MA) 10/0/0 9/0/0 
R.LAK~TYETTLEK.C Lys-351 (SB) not detected 3/1/0 
K.TYETTLEK^CCAAADPHECYAK.V Lys-359 (MA) not detected 1/3/0 
K.CCAAADPH@ECYAK.V His-367 (MA) not detected 9/0/0 
K.VFDEFK^PLVEEPQNLIK.Q Lys-378 (MA) not detected 5/1/0 
K.QNCELFEQLGEYK^FQNALLVR.Y Lys-402 (MA) not detected 4/0/2 
K.K^VPQVSTPTLVEVSR.N Lys-414 (MA) not detected 11/1/3 
K.K~VPQVSTPTLVEVSR.N Lys-414 (SB) 8/0/0 12/1/3 
R.VTK^CCTESLVNR.R Lys-475 (MA) not detected 1/0/0 
K.EFNAETFTFH@ADICTLSEK.E His-510 (MA) 1/8/0 12/11/0 
K.EFNAETFTFHADICTLSEK^ER.Q Lys-519 (MA) not detected 1/0/0 
K.K^QTALVELVK.H Lys-525 (MA) not detected 0/1/3 
K.K~QTALVELVK.H Lys-525 (SB) 3/0/3 8/3/3 
K.EQLK^AVMDDFAAFVEK.C Lys-545 (MA) 4/7/0 11/11/3 
K.EQLK~AVMDDFAAFVEK.C Lys-545 (SB) not detected 4/7/0 
Table A3. Counts of LC–MS/MS runs in which the indicated modified peptide was identified. 
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The PeptideProphet score threshold was 0.9. Five independent preparations were made for each 
HNE:HSA ratio. For each ratio, four preparations were analyzed using a Thermo LTQ XL linear 
ion trap mass spectrometer and one preparation was analyzed using a Thermo LTQ Orbitrap 
Velos instrument. In all cases, three replicate LC–MS/MS runs were recorded for each 
preparation. For the LTQ XL runs, one collision-induced dissocation (CID) and one 
electron-transfer dissociation (ETD) MS/MS were recorded for each precursor ion selected for 
fragmentation; resulting CID and ETD spectrum counts are presented separately. For the LTQ 
Orbitrap Velos runs, only CID MS/MS were recorded. C# indicates HNE Michael addition at 
Cys followed by reduction; H@ indicates HNE Michael addition at His followed by reduction; 
K^ indicates HNE Michael addition at Lys followed by reduction; K~ indicates Schiff base 
formation with HNE at Lys followed by reduction; M* indicates oxidation at Met. 
 
Modification Site or 
Modification Site(s) 
Associated with 
Unmodified Peptide 
(MA indicates 
Michael addition; SB 
indicates Schiff 
base formation) 
Peptide Mass List Constituents 
[M+H]+ [M+2H]2+ [M+3H]3+ 
Cys-034 (MA) ALVLIAFAQYLQQC#PFEDHVK 2879.60 1440.31 960.54 
Cys-034-associated ALVLIAFAQYLQQCPFEDHVK 2778.49 1389.75 926.84 
His-067 (MA) SLH@TLFGDK 1463.88 732.44 488.63 
His-067-associated SLHTLFGDK 1305.74 653.38 435.92 
His-105 (MA) NECFLQH@K 1521.84 761.42 507.95 
His-105-associated NECFLQHK 1363.71 682.36 455.24 
Lys-162 (MA) YK^AAFTECCQAADK 2109.06 1055.04 703.69 
Lys-162-associated YKAAFTECCQAADK 2095.04 1048.02 699.02 
Lys-162-associated AAFTECCQAADK 1659.78 830.39 553.93 
Lys-199 (MA) LK^CASLQK 1393.87 697.44 465.30 
Lys-199-associated LKCASLQK 1379.85 690.43 460.62 
Lys-199-associated CASLQK 994.56 497.79 332.19 
Lys-212 (MA) AFK^AWAVAR 1321.81 661.41 441.28 
Lys-212-associated AFKAWAVAR 1307.79 654.40 436.60 
Lys-212-associated AWAVAR 817.48 409.25 273.17 
Lys-233 (MA) AEFAEVSK^LVTDLTK 2097.23 1049.12 699.75 
Lys-233-associated AEFAEVSKLVTDLTK 2083.21 1042.11 695.07 
Lys-233-associated AEFAEVSK 1168.65 584.83 390.22 
Lys-233-associated LVTDLTK 1077.68 539.34 359.90 
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His-242 (MA) VH@TECCHGDLLECADDR 2389.07 1195.04 797.03 
His-247 (MA) VHTECCH@GDLLECADDR 2389.07 1195.04 797.03 
His-242-associated & 
His-247-associated 
VHTECCHGDLLECADDR 2230.94 1115.97 744.32 
Lys-262 (MA) ADLAK^YICENQDSISSK 2388.26 1194.63 796.76 
Lys-262-associated ADLAKYICENQDSISSK 2374.23 1187.62 792.08 
Lys-262-associated ADLAK 805.51 403.26 269.17 
Lys-262-associated YICENQDSISSK 1731.85 866.43 577.96 
His-288 (MA) SH@CIAEVENDEM*PADLPSLAADFVE
SK 
3436.68 1718.84 1146.23 
His-288 (MA) SH@CIAEVENDEMPADLPSLAADFVES
K 
3420.68 1710.85 1140.90 
His-288-associated SHCIAEVENDEM*PADLPSLAADFVESK 3278.55 1639.78 1093.52 
His-288-associated SHCIAEVENDEMPADLPSLAADFVESK 3262.55 1631.78 1088.19 
Lys-351 (MA) LAK^TYETTLEK 1743.04 872.03 581.69 
Lys-351-associated LAKTYETTLEK 1729.02 865.01 577.01 
Lys-351-associated TYETTLEK 1272.70 636.85 424.90 
His-367 (MA) CCAAADPH@ECYAK 1998.94 999.97 666.98 
His-367-associated CCAAADPHECYAK 1840.81 920.91 614.27 
Lys-378 (MA) VFDEFK^PLVEEPQNLIK 2491.43 1246.22 831.15 
Lys-378-associated VFDEFKPLVEEPQNLIK 2477.41 1239.21 826.47 
Lys-378-associated VFDEFK 1072.60 536.80 358.20 
Lys-378-associated PLVEEPQNLIK 1567.93 784.47 523.32 
Lys-414 (MA) K^VPQVSTPTLVEVSR 1942.17 971.59 648.06 
Lys-414 (SB) K~VPQVSTPTLVEVSR 1924.16 962.59 642.06 
Lys-414-associated KVPQVSTPTLVEVSR 1928.15 964.58 643.39 
Lys-414-associated VPQVSTPTLVEVSR 1655.95 828.48 552.65 
His-510 (MA) EFNAETFTFH@ADICTLSEK 2706.36 1353.68 902.79 
His-510-associated EFNAETFTFHADICTLSEK 2548.23 1274.62 850.08 
Lys-525 (MA) K^QTALVELVK 1575.04 788.02 525.68 
Lys-525 (SB) K~QTALVELVK 1557.03 779.02 519.68 
Lys-525-associated KQTALVELVK 1561.01 781.01 521.01 
Lys-525-associated QTALVELVK 1288.81 644.91 430.28 
Table A4. List of targeted peptides and associated monoisotopic mass-to-charge ratios that were 
used as a targeted mass list for chosing parent ions for fragmentation. Mass-to-charge ratios in 
blue are outside the analyzed range (300-2000). Targeted peptides are grouped by modification 
site. C# indicates HNE Michael addition at Cys followed by reduction; H@ indicates HNE 
Michael addition at His followed by reduction; K^ indicates HNE Michael addition at Lys 
followed by reduction; K~ indicates Schiff base formation with HNE at Lys followed by 
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reduction; M* indicates oxidation at Met. Seventeen sites were targeted and both Schiff base 
formation and Michael addition were considered at two of these sites (Lys-414 and Lys-525). 
 
Modification Peptide Detection  
Count 
Averaged iTRAQ PQD 
Reporter Ion Intensity 
No 
HNE 
Added 
50:1 
HNE:
HSA 
100:1 
HNE:
HSA 
Cys-034-associated ALVLIAFAQYLQQCPFEDHVK 412 103 29 22 
Cys-034 (MA) ALVLIAFAQYLQQC#PFEDHVK 2 10 0 58 
His-067-associated SLHTLFGDK 795 15986 4323 2574 
His-105-associated NECFLQHK 345 8095 4837 3617 
His-242-associated 
& 
His-247-associated 
VHTECCHGDLLECADDR 239 184 73 54 
His-288-associated SHCIAEVENDEMPADLPSLAADFV
ESK 
433 198 40 19 
His-367-associated CCAAADPHECYAK 642 979 608 322 
His-510-associated EFNAETFTFHADICTLSEK 748 493 166 55 
His-067 (MA) SLH@TLFGDK 916 31 1963 1642 
His-105 (MA) NECFLQH@K 89 42 1681 2103 
His-367 (MA) CCAAADPH@ECYAK 326 9 351 465 
His-510 (MA) EFNAETFTFH@ADICTLSEK 126 13 239 397 
Lys-162-associated AAFTECCQAADK 527 1556 1053 679 
Lys-199-associated CASLQK 21 127 14 6 
Lys-233-associated AEFAEVSK 1018 2281 1729 1490 
Lys-233-associated LVTDLTK 313 6523 4854 4218 
Lys-262-associated ADLAK 6 542 337 353 
Lys-262-associated YICENQDSISSK 1195 886 678 527 
Lys-351-associated TYETTLEK 212 3714 1754 966 
Lys-378-associated VFDEFKPLVEEPQNLIK 895 718 610 389 
Lys-414-associated KVPQVSTPTLVEVSR 778 976 727 437 
Lys-414-associated VPQVSTPTLVEVSR 575 99 148 110 
Lys-525-associated KQTALVELVK 174 2206 480 151 
Lys-525-associated QTALVELVK 794 1789 430 259 
Lys-162 (MA) YK^AAFTECCQAADK 44 15 466 543 
Lys-199 (MA) LK^CASLQK 1 0 3965 5647 
Lys-233 (MA) AEFAEVSK^LVTDLTK 79 12 225 568 
Lys-262 (MA) ADLAK^YICENQDSISSK 2 0 16 96 
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Lys-351 (MA) LAK^TYETTLEK 43 44 1880 2210 
Lys-378 (MA) VFDEFK^PLVEEPQNLIK 43 34 43 48 
Lys-414 (MA) K^VPQVSTPTLVEVSR 248 7 66 56 
Lys-414 (SB) K~VPQVSTPTLVEVSR 118 28 134 127 
Lys-525 (MA) K^QTALVELVK 135 15 823 740 
Lys-525 (SB) K~QTALVELVK 12 83 1917 793 
Table A5. Change in relative abundance for HNE-modified and corresponding unmodified HSA 
peptides in response to HNE-exposure at stated HNE:HSA molar ratios. Averaged iTRAQ 
reporter ion intensities are given here; since the control was duplicated, the average of the two 
reporter ion signal averages is given here. iTRAQ reporter ion intensities were obtained using 
pulsed-Q dissociation (PQD) in a linear ion trap mass spectrometer. This dataset is the result of a 
single repeat preparation subjected to three replicate LC–MS/MS runs. Incubation time with 
HNE was 3 h. The mass list described in Table A4 was used and only mass list peptides are 
included in this table. Bolded entries were used in constructing Figure 3-4 while italicized entries 
were not used. For a peptide identification to be accepted, a PeptideProphet score of 0.9 or 
greater was required. MS/MS where all four iTRAQ reporter ion intensities were zero were 
discarded. C# indicates HNE Michael addition at Cys followed by reduction; H@ indicates HNE 
Michael addition at His followed by reduction; K^ indicates HNE Michael addition at Lys 
followed by reduction; K~ indicates Schiff base formation with HNE at Lys followed by 
reduction. 
 
 
Modification Peptide Detection
Count 
Averaged iTRAQ PQD Reporter 
Ion Intensity 
100:1 
HNE:
HSA 
for 0 h 
100:1 
HNE:
HSA 
for 1 h 
100:1 
HNE:
HSA 
for 3 h 
100:1 
HNE:
HSA 
for 24 
h 
Cys-034-associated ALVLIAFAQYLQQCPFEDHV
K 
342 212 121 122 100 
Cys-034 (MA) ALVLIAFAQYLQQC#PFEDH
VK 
70 2 24 17 38 
His-067-associated SLHTLFGDK 953 38165 20958 10653 4260 
His-105-associated NECFLQHK 437 5574 4126 3355 1806 
His-242-associated 
& 
His-247-associated 
VHTECCHGDLLECADDR 353 1289 319 548 346 
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His-288-associated SHCIAEVENDEM*PADLPSL
AADFVESK 
857 88 311 58 47 
His-288-associated SHCIAEVENDEMPADLPSL
AADFVESK 
866 1135 244 186 135 
His-367-associated CCAAADPHECYAK 966 861 738 508 259 
His-510-associated EFNAETFTFHADICTLSEK 2204 1787 1226 571 348 
His-067 (MA) SLH@TLFGDK 3622 78 7515 11990 10650 
His-105 (MA) NECFLQH@K 260 269 8992 9506 15905 
His-242 (MA) VH@TECCHGDLLECADDR 8 168 2451 4349 3510 
His-288 (MA) SH@CIAEVENDEM*PADLPS
LAADFVESK 
834 7 89 302 242 
His-288 (MA) SH@CIAEVENDEMPADLPS
LAADFVESK 
2751 4 79 279 223 
His-367 (MA) CCAAADPH@ECYAK 1401 39 999 2063 5379 
His-510 (MA) EFNAETFTFH@ADICTLSEK 1722 29 3947 7110 6686 
Lys-162-associated AAFTECCQAADK 1052 3085 3044 2769 1962 
Lys-199-associated CASLQK 29 251 24 17 36 
Lys-233-associated AEFAEVSK 1404 4820 5431 5262 4765 
Lys-233-associated AEFAEVSKLVTDLTK 1 93 591 364 439 
Lys-233-associated LVTDLTK 499 17374 22540 24120 21831 
Lys-262-associated ADLAK 5 109 97 84 105 
Lys-262-associated YICENQDSISSK 1803 2797 3167 2985 2982 
Lys-351-associated TYETTLEK 344 5530 4297 3405 2725 
Lys-378-associated VFDEFKPLVEEPQNLIK 6292 5231 6216 6091 5124 
Lys-414-associated KVPQVSTPTLVEVSR 1293 8162 7017 6430 5426 
Lys-414-associated VPQVSTPTLVEVSR 1052 209 487 330 215 
Lys-525-associated KQTALVELVK 270 7350 2056 2005 1670 
Lys-525-associated QTALVELVK 1020 7644 3075 3230 3415 
Lys-162 (MA) YK^AAFTECCQAADK 210 155 5208 7024 4866 
Lys-199 (MA) LK^CASLQK 33 1720 26535 39406 32742 
Lys-212 (MA) AFK^AWAVAR 48 941 1771 2392 5858 
Lys-233 (MA) AEFAEVSK^LVTDLTK 355 73 961 2437 8534 
Lys-262 (MA) ADLAK^YICENQDSISSK 120 62 817 1777 4669 
Lys-351 (MA) LAK^TYETTLEK 222 295 17008 28787 32302 
Lys-378 (MA) VFDEFK^PLVEEPQNLIK 357 1000 1783 2071 3483 
Lys-414 (MA) K^VPQVSTPTLVEVSR 501 53 393 363 529 
Lys-414 (SB) K~VPQVSTPTLVEVSR 145 199 879 539 289 
Lys-525 (MA) K^QTALVELVK 345 128 2947 6102 8845 
Lys-525 (SB) K~QTALVELVK 1 0 0 141 556 
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Table A6. Change in relative abundance for HNE-modified and corresponding unmodified HSA 
peptides in response to HNE-exposure time at a 100:1 HNE:HSA molar ratio. Averaged iTRAQ 
reporter ion intensities are given here. iTRAQ reporter ion intensities were obtained using 
pulsed-Q dissociation (PQD) in a linear ion trap mass spectrometer. This dataset is the result of a 
three repeat preparations subjected to three replicate LC–MS/MS runs each. The same set of 
three repeat preparations was analyzed using the LTQ Orbitrap Velos system (see Table A7). The 
mass list described in Table A4 was used and only mass list peptides are included in this table. 
Bolded entries were used in constructing Figures 3-5 and 3-6 while italicized entries were not 
used. For a peptide identification to be accepted, a PeptideProphet score of 0.9 or greater was 
required. MS/MS where all four iTRAQ reporter ion intensities were zero were discarded. C# 
indicates HNE Michael addition at Cys followed by reduction; H@ indicates HNE Michael 
addition at His followed by reduction; K^ indicates HNE Michael addition at Lys followed by 
reduction; K~ indicates Schiff base formation with HNE at Lys followed by reduction; M* 
indicates oxidation at Met. 
 
 
Modification Peptide Detection 
Count 
Averaged iTRAQ HCD Reporter Ion 
Intensity 
100:1 
HNE:H
SA for 
0h 
100:1 
HNE:H
SA for 
1 h 
100:1 
HNE:H
SA for 
3 h 
100:1 
HNE:H
SA for 
24 h 
Cys-034-associated ALVLIAFAQYLQQCPFEDH
VK 
587 78,624 32,756 33,334 30,214 
Cys-034 (MA) ALVLIAFAQYLQQC#PFED
HVK 
42 33 5,327 6,193 8,584 
His-067-associated SLHTLFGDK 415 13,952,
918 
6,539,4
86 
3,337,2
88 
1,158,34
2 
His-105-associated NECFLQHK 136 5,832,9
64 
4,849,9
06 
4,391,3
49 
2,830,56
3 
His-242-associated 
& 
His-247-associated 
VHTECCHGDLLECADDR 165 3,822,6
06 
320,141 888,666 562,688 
His-288-associated SHCIAEVENDEM*PADLPS
LAADFVESK 
427 21,440 3,763 2,908 2,669 
His-288-associated SHCIAEVENDEMPADLPS
LAADFVESK 
447 136,119 12,148 13,123 7,753 
His-367-associated CCAAADPHECYAK 242 1,956,9
60 
1,843,1
65 
1,439,0
56 
795,689 
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His-510-associated EFNAETFTFHADICTLSEK 3968 200,464 98,380 44,679 27,313 
His-067 (MA) SLH@TLFGDK 1726 13,109 2,156,9
87 
3,519,6
15 
3,131,64
2 
His-105 (MA) NECFLQH@K 144 4,630 3,374,6
03 
4,273,3
92 
10,184,1
20 
His-242 (MA) VH@TECCHGDLLECADD
R 
1 0 644,631 2,910,2
21 
7,530,89
6 
His-288 (MA) SH@CIAEVENDEM*PADLP
SLAADFVESK 
432 94 989 6,542 5,691 
His-288 (MA) SH@CIAEVENDEMPADLP
SLAADFVESK 
517 89 1,456 22,830 15,411 
His-367 (MA) CCAAADPH@ECYAK 300 16,192 1,406,2
53 
3,027,3
19 
8,318,95
5 
His-510 (MA) EFNAETFTFH@ADICTLSE
K 
1709 489 429,024 762,804 720,107 
Lys-162-associated AAFTECCQAADK 326 27,423,
946 
22,733,
690 
20,503,
814 
13,714,2
38 
Lys-199-associated CASLQK 3 12,243,
954 
80,833 770,411 1,208,51
4 
Lys-212-associated AWAVAR 18 2,489,8
80 
2,801,7
77 
2,890,1
15 
2,396,50
1 
Lys-233-associated AEFAEVSK 1405 8,509,2
80 
8,504,3
45 
8,576,0
27 
7,285,14
5 
Lys-233-associated LVTDLTK 83 33,314,
060 
34,218,
062 
37,033,
153 
31,241,0
85 
Lys-262-associated ADLAK 33 169,516 187,289 204,700 204,112 
Lys-262-associated YICENQDSISSK 433 12,043,
353 
11,924,
154 
11,293,
278 
10,678,9
32 
Lys-351-associated LAKTYETTLEK 3 304,390 176,579 176,468 98,190 
Lys-351-associated TYETTLEK 318 31,796,
143 
21,735,
695 
17,967,
937 
12,827,9
25 
Lys-378-associated VFDEFKPLVEEPQNLIK 3490 1,155,9
07 
1,208,7
14 
1,181,8
20 
1,022,52
5 
Lys-414-associated KVPQVSTPTLVEVSR 2689 927,400 585,347 594,473 546,458 
Lys-414-associated VPQVSTPTLVEVSR 335 1,889,1
70 
2,012,3
82 
2,697,3
08 
3,472,85
5 
Lys-525-associated KQTALVELVK 105 11,562,
546 
2,307,6
65 
2,613,5
92 
1,917,80
2 
Lys-525-associated QTALVELVK 337 33,508,
017 
10,231,
592 
12,479,
695 
12,615,5
64 
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Lys-162 (MA) YK^AAFTECCQAADK 109 5,108 1,294,6
83 
1,862,6
66 
1,353,26
7 
Lys-199 (MA) LK^CASLQK 82 148,821 4,099,2
55 
6,318,5
18 
4,813,05
5 
Lys-212 (MA) AFK^AWAVAR 183 15,885 328,737 750,455 2,543,72
4 
Lys-233 (MA) AEFAEVSK^LVTDLTK 259 213 166,208 442,734 1,710,77
5 
Lys-262 (MA) ADLAK^YICENQDSISSK 221 3,918 108,763 200,239 483,669 
Lys-351 (MA) LAK^TYETTLEK 358 9,234 2,853,5
76 
4,711,1
45 
5,505,77
7 
Lys-378 (MA) VFDEFK^PLVEEPQNLIK 222 315,488 476,860 591,517 970,454 
Lys-414 (MA) K^VPQVSTPTLVEVSR 168 53,292 194,219 214,435 329,460 
Lys-414 (SB) K~VPQVSTPTLVEVSR 139 102,784 383,309 269,070 142,050 
Lys-525 (MA) K^QTALVELVK 269 13,297 811,364 1,779,8
72 
2,629,18
3 
Lys-525 (SB) K~QTALVELVK 150 1,202 4,346,2
72 
3,215,1
59 
753,301 
Table A7. Change in relative abundance for HNE-modified and corresponding unmodified HSA 
peptides in response to HNE-exposure time at a 100:1 HNE:HSA molar ratio. Averaged iTRAQ 
reporter ion intensities are given here. iTRAQ reporter ion intensities were obtained using 
higher-energy C-trap dissociation (HCD) in an Orbitrap mass spectrometer. This dataset is the 
result of a three repeat preparations subjected to three replicate LC–MS/MS runs each. The same 
set of three repeat preparations was analyzed using the LTQ XL system (see Table A6). The mass 
list described in Table A4 was used and only mass list peptides are included in this table. Bolded 
entries were used in constructing Figures 3-5 and 3-6 while italicized entries were not used. For a 
peptide identification to be accepted, a PeptideProphet score of 0.9 or greater was required. 
MS/MS where all four iTRAQ reporter ion intensities were zero were discarded. C# indicates 
HNE Michael addition at Cys followed by reduction; H@ indicates HNE Michael addition at His 
followed by reduction; K^ indicates HNE Michael addition at Lys followed by reduction; K~ 
indicates Schiff base formation with HNE at Lys followed by reduction; M* indicates oxidation 
at Met. 
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Modified Peptide (with flanking residues) Modification 
Site or Sites 
(T indicates 
trypsin 
digestion; C 
indicates 
chymotrypsin 
digestion) 
Counts of LC–MS/MS runs in which the 
modified peptide was identified using 
LTQ XL CID scans (maximum = 3) and 
LTQ Orbitrap Velos CID scans 
associated with high mass accuracy 
Orbitrap precursor ion mass 
measurements (*) 
1:1 HNE 
to ACO 
Ratio 
2:1 HNE 
to ACO 
Ratio 
 
10:1 
HNE to 
ACO 
Ratio 
 
50:1 
HNE to 
ACO 
Ratio 
 
K.VAM(#)SH^FEPHEYIR.Y His-009 (T) not 
detected 
not 
detected 
not 
detected 
1 
K.VAM(#)SHFEPH^EYIR.Y His-013 (T) 1 1 3* 3* 
K.VAM(#)SH^FEPH^EYIR.Y His-009 & 
His-013 (T)  
not 
detected 
not 
detected 
not 
detected 
1 
R.YDLLEK~NIDIVR.K Lys-023 (T) not 
detected 
not 
detected 
1 2 
K.IVYGH^LDDPANQEIER.G His-046 (T) not 
detected 
not 
detected 
3* 3* 
Y.GH^LDDPANQEIERGKTY.L His-046 (C) not 
detected 
not 
detected 
3* 3* 
K.VAVPSTIH^C*DHLIEAQLGGEK.D His-098 (T) 1 1 2 1 
K.VAVPSTIHC@DHLIEAQLGGEK.D Cys-099 (T) not 
detected 
1* 1* 1 
K.VAVPSTIHC*DH^LIEAQLGGEK.D His-101 (T) not 
detected 
not 
detected 
3 1* 
K.VAVPSTIH^C@DHLIEAQLGGEK.D His-098 & 
Cys-099 (T) 
not 
detected 
not 
detected 
not 
detected 
1 
K.VAVPSTIH^C*DH^LIEAQLGGEK.D His-098 & 
His-101 (T) 
not 
detected 
not 
detected 
1 3* 
K.VAVPSTIHC@DH^LIEAQLGGEK.D Cys-099 & 
His-101 (T) 
not 
detected 
not 
detected 
not 
detected* 
1 
K.VAVPSTIH^C@DH^LIEAQLGGEK.D His-098 & 
Cys-099 & 
His-101 (T) 
not 
detected 
not 
detected 
not 
detected 
2 
R.AK~DINQEVYNFLATAGAK.Y Lys-117 (T) not 
detected 
not 
detected 
3* 3* 
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W.RPGSGIIH^QIILENY.A His-147 (C) not 
detected 
not 
detected 
not 
detected 
1 
K.LTGSLSGWTSPK~DVILK.V Lys-218 (T) not 
detected 
not 
detected 
1 2 
F.KDHLVPDPGC@HY.D Cys-305 (C) not 
detected 
1 2 0 
Y.DQVIEINLSELKPH^INGPF.T His-321 (C) not 
detected 
0 2* 3* 
R.VGLIGSC@TNSSYEDM(#)GR.S Cys-358 (T) 3* 3* 3* 3* 
K.QALAH^GLK.C His-379 (T) not 
detected 
not 
detected 
not 
detected* 
not 
detected* 
R.DVGGIVLANAC@GPC*IGQWDR.K Cys-421 (T) 2 1 1 not 
detected 
R.DVGGIVLANAC*GPC@IGQWDR.K Cys-424 (T) not 
detected 
not 
detected 
1 not 
detected* 
R.DVGGIVLANAC@GPC@IGQWDR.K Cys-421 & 
Cys-424 (T) 
not 
detected 
not 
detected 
3* 1* 
R.NDANPETH^AFVTSPEIVTALAIAGTLK.F His-460 (T) not 
detected 
1* 3* 3* 
F.TGRNDANPETH^AF.V His-460 (C) not 
detected 
not 
detected 
3 3* 
K.FNPETDFLTGK~DGK.K Lys-490 (T) not 
detected 
not 
detected 
not 
detected 
3 
K.FK~LEAPDADELPR.A Lys-496 (T) not 
detected 
not 
detected 
2 3 
R.AEFDPGQDTYQH^PPK.D His-519 (T) not 
detected 
not 
detected 
3 3* 
K.C@TTDHISAAGPWLK.F Cys-565 (T) 3* 3* 3* 3* 
K.C*TTDH^ISAAGPWLK.F His-569 (T) not 
detected 
not 
detected 
2 2 
K.C@TTDH^ISAAGPWLK.F Cys-565 & 
His-569 (T) 
not 
detected 
not 
detected 
2 2* 
R.IH^ETNLK.K His-668 (T) not 
detected 
not 
detected 
1* 2* 
K.K~QGLLPLTFADPADYNK.I Lys-674 (T) not 
detected 
not 
detected 
not 
detected 
1* 
K.H^PNGTQETILLNHTFNETQIEWFR.A His-717 (T) not 
detected 
not 
detected 
1 not 
detected 
K.HPNGTQETILLNH^TFNETQIEWFR.A His-729 (T) not 
detected 
not 
detected 
not 
detected 
not 
detected* 
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K.H^PNGTQETILLNH^TFNETQIEWFR.A His-717 & 
His-729 (T) 
not 
detected 
not 
detected 
not 
detected 
1 
Table A8. Counts of LC–MS/MS runs in which the indicated modified peptide was identified. 
Four independent preparations were made for each HNE:ACO ratio. For each ratio, three 
preparations were analyzed using a Thermo LTQ XL linear ion trap mass spectrometer and one 
preparation was analyzed using a Thermo LTQ Orbitrap Velos instrument. In all cases, only one 
LC–MS/MS run was recorded for each preparation. For the LTQ XL and the LTQ Orbitrap Velos 
runs, only collision-induced dissocation (CID) MS/MS were recorded for each precursor ion 
selected for fragmentation. C* indicates carboxyamidomethylation at Cys; C@ indicates HNE 
Michael addition at Cys followed by reduction; H^ indicates HNE Michael addition at His 
followed by reduction; K~ indicates HNE Michael addition at Lys followed by reduction; M# 
indicates oxidation at Met. 
 
 
Modification Site or 
Modification Site(s) 
Associated with 
Unmodified Peptide 
Peptide Mass List Constituents 
[M+H]+ [M+2H]2+ [M+3H]3+ 
His-009 VAMSH^FEPHEYIR 1918.00 959.50 640.01 
His-009 VAM#SH^FEPHEYIR 1934.00 967.50 645.34 
His-013 VAMSHFEPH^EYIR 1918.00 959.50 640.01 
His-013 VAM#SHFEPH^EYIR 1934.00 967.50 645.34 
His-009 & His-013  VAMSH^FEPH^EYIR 2076.13 1038.57 692.72 
His-009 & His-013 VAM#SH^FEPH^EYIR 2092.13 1046.57 698.05 
His-009-associated & 
His-013-associated 
VAMSHFEPHEYIR 1759.87 880.44 587.30 
His-009-associated & 
His-013-associated 
VAM#SHFEPHEYIR 1775.87 888.44 592.63 
His-046 IVYGH^LDDPANQEIER 2171.15 1086.08 724.39 
His-046-associated IVYGHLDDPANQEIER 2013.02 1007.01 671.68 
His-098 VAVPSTIH^C*DHLIEAQLGGEK 2720.49 1360.75 907.50 
Cys-099 VAVPSTIHC@DHLIEAQLGGEK 2663.47 1332.24 888.49 
His-101 VAVPSTIHC*DH^LIEAQLGGEK 2720.49 1360.75 907.50 
His-098 & Cys-099 VAVPSTIH^C@DHLIEAQLGGEK 2821.60 1411.30 941.20 
His-098 & His-101 VAVPSTIH^C*DH^LIEAQLGGEK 2878.62 1439.81 960.21 
Cys-099 & His-101  VAVPSTIHC@DH^LIEAQLGGEK 2821.60 1411.30 941.20 
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His-098 & Cys-099 & 
His-101 
VAVPSTIH^C@DH^LIEAQLGGEK 2979.73 1490.37 993.91 
(His-098 & Cys-099 & 
His-101)-associated 
VAVPSTIHC*DHLIEAQLGGEK 2562.36 1281.68 854.79 
Lys-117  AK~DINQEVYNFLATAGAK 2399.34 1200.17 800.45 
Lys-117-associated AKDINQEVYNFLATAGAK 2385.31 1193.16 795.78 
Lys-117-associated DINQEVYNFLATAGAK 2042.08 1021.54 681.37 
Cys-358 VGLIGSC@TNSSYEDMGR 2091.02 1046.01 697.68 
Cys-358 VGLIGSC@TNSSYEDM#GR 2107.02 1054.01 703.01 
Cys-358-associated VGLIGSC*TNSSYEDMGR 1989.91 995.46 663.98 
Cys-358-associated VGLIGSC*TNSSYEDM#GR 2005.91 1003.46 669.31 
Cys-421 DVGGIVLANAC@GPC*IGQWDR 2403.23 1202.12 801.75 
Cys-424 DVGGIVLANAC*GPC@IGQWDR 2403.23 1202.12 801.75 
Cys-421 & Cys-424 DVGGIVLANAC@GPC@IGQWDR 2504.34 1252.67 835.45 
Cys-421-associated & 
Cys-424-associated 
DVGGIVLANAC*GPC*IGQWDR 2302.12 1151.56 768.04 
His-460 NDANPETH^AFVTSPEIVTALAIAGTLK 3226.78 1613.89 1076.27 
His-460-associated NDANPETHAFVTSPEIVTALAIAGTLK 3068.65 1534.83 1023.56 
Lys-490 FNPETDFLTGK~DGK 2015.09 1008.05 672.37 
Lys-490-associated FNPETDFLTGKDGK 2001.07 1001.04 667.69 
Lys-490-associated FNPETDFLTGK 1556.82 778.91 519.61 
Lys-496  FK~LEAPDADELPR 1803.00 902.00 601.67 
Lys-496-associated FKLEAPDADELPR 1788.97 894.99 597.00 
Lys-496-associated LEAPDADELPR 1369.71 685.36 457.24 
His-519 AEFDPGQDTYQH^PPK 2176.12 1088.56 726.04 
His-519-associated AEFDPGQDTYQHPPK 2017.99 1009.50 673.33 
Cys-565 C@TTDHISAAGPWLK 1946.07 973.54 649.36 
His-569  C*TTDH^ISAAGPWLK 2003.09 1002.05 668.37 
Cys-565 & His-569 C@TTDH^ISAAGPWLK 2104.20 1052.60 702.07 
Cys-565-associated & 
His-569-associated 
C*TTDHISAAGPWLK 1844.96 922.98 615.66 
Lys-674  K~QGLLPLTFADPADYNK 2337.33 1169.17 779.78 
Lys-674-associated KQGLLPLTFADPADYNK 2323.30 1162.15 775.11 
Lys-674-associated QGLLPLTFADPADYNK 2051.10 1026.06 684.37 
Internal Standard WVVIGDENYGEGSSR 1811.87 906.44 604.63 
Table A9. List of targeted peptides and associated monoisotopic mass-to-charge ratios that were 
used as a targeted mass list for chosing parent ions for fragmentation. Mass-to-charge ratios in 
blue are outside the analyzed range (300-2000). Targeted peptides are grouped by modification 
site. C* indicates carboxyamidomethylation at Cys; C@ indicates HNE Michael addition at Cys 
  185 
followed by reduction; H^ indicates HNE Michael addition at His followed by reduction; K~ 
indicates HNE Michael addition at Lys followed by reduction; M# indicates oxidation at Met. 
Seventeen modifications at twelve residues were targeted. 
 
Modification Peptide Detection 
Count 
Averaged iTRAQ HCD Reporter Ion 
Intensity 
10:1 
HNE:A
CO for 
0h 
10:1 
HNE:A
CO for 
1 h 
10:1 
HNE:A
CO for 
2 h 
10:1 
HNE:A
CO for 
6 h 
Internal Standard WVVIGDENYGEGSSR 551 6,053,1
61 
4,809,6
68 
4,558,0
96 
4,050,52
0 
Cys-099 VAVPSTIHC@DHLIEAQLG
GEK 
121 2,551 229,961 222,621 168,247 
Cys-358 VGLIGSC@TNSSYEDMG
R 
156 5,135 429,106 470,003 518,706 
Cys-358 VGLIGSC@TNSSYEDM#G
R 
65 17,928 253,054 282,361 349,781 
Cys-421 DVGGIVLANAC@GPC*IG
QWDR 
1 0 23,485 26,098 28,031 
Cys-565 C@TTDHISAAGPWLK 92 15,842 575,998 580,750 599,727 
Cys-565 & His-569 C@TTDH^ISAAGPWLK 145 2,757 123,904 252,470 517,238 
(Cys-099 & His-098 & 
His-101)-associated 
VAVPSTIHC*DHLIEAQLGG
EK 
87 1,237,6
39 
609,098 527,023 385,229 
Cys-358-associated VGLIGSC*TNSSYEDMGR 80 2,909,9
94 
1,878,8
45 
1,712,8
91 
1,444,20
3 
Cys-358-associated VGLIGSC*TNSSYEDM#G
R 
60 2,748,4
82 
1,883,4
93 
1,828,8
87 
1,605,90
5 
Cys-421-associated & 
Cys-424-associated 
DVGGIVLANAC*GPC*IGQ
WDR 
159 329,860 160,120 116,568 80,479 
Cys-421-associated & 
Cys-424-associated 
DVGGIVLANAC*GPC*IGQ
WDRK 
2 6,804 5,449 0 0 
Cys-565-associated & 
His-569-associated 
C*TTDHISAAGPWLK 42 1,370,0
57 
782,015 660,115 540,467 
His-009 VAMSH^FEPHEYIR 1 0 324,755 519,955 828,189 
His-009 VAM#SH^FEPHEYIR 2 298,354 430,856 508,790 828,993 
His-013 VAMSHFEPH^EYIR 1 10,971 122,396 156,688 240,192 
His-013 VAM#SHFEPH^EYIR 13 95,116 171,191 232,407 371,270 
His-009 & His-013  VAMSH^FEPH^EYIR 11 21,608 43,299 73,096 191,010 
  186 
His-009 & His-013 VAM#SH^FEPH^EYIR 13 15,945 27,321 46,278 126,248 
His-046 IVYGH^LDDPANQEIER 107 17,499 437,198 838,855 1,926,07
0 
His-098 VAVPSTIH^C*DHLIEAQLG
GEK 
1 0 101,458 126,504 186,825 
His-098 & His-101 VAVPSTIH^C*DH^LIEAQL
GGEK 
1 3,942 12,086 28,348 114,005 
His-460 NDANPETH^AFVTSPEIVT
ALAIAGTLK 
111 236 1,029 2,372 5,178 
His-519 AEFDPGQDTYQH^PPK 40 39,327 560,843 947,504 1,898,11
9 
His-519 AEFDPGQDTYQH^PPKDS
SGQR 
1 20,404 27,054 62,686 60,425 
His-569  C*TTDH^ISAAGPWLK 40 17,885 229,398 363,520 585,296 
His-009-associated & 
His-013-associated 
VAMSHFEPHEYIR 38 2,577,3
48 
1,828,0
28 
1,586,1
02 
1,415,13
2 
His-009-associated & 
His-013-associated 
VAM#SHFEPHEYIR 99 1,279,8
80 
919,430 816,214 636,920 
His-046-associated IVYGHLDDPANQEIER 1639 906,002 654,302 597,641 486,893 
His-460-associated NDANPETHAFVTSPEIVTA
LAIAGTLK 
701 9,080 5,798 4,569 3,856 
His-519-associated AEFDPGQDTYQHPPK 212 2,213,6
58 
1,613,4
71 
1,523,5
37 
1,252,20
5 
His-519-associated AEFDPGQDTYQHPPKDS
SGQR 
2 19,736 14,520 6,822 8,022 
Lys-117  AK~DINQEVYNFLATAGAK 16 19,730 18,468 19,772 20,138 
Lys-496  FK~LEAPDADELPR 27 442,284 327,440 322,685 310,301 
Lys-674  K~QGLLPLTFADPADYNK 5 19,626 23,054 27,547 29,413 
Lys-117-associated AKDINQEVYNFLATAGAK 271 294,401 219,102 188,939 172,933 
Lys-117-associated DINQEVYNFLATAGAK 1077 288,322 222,843 221,252 192,174 
Lys-490-associated FNPETDFLTGKDGK 19 3,096,6
22 
2,299,7
55 
2,093,2
06 
1,889,29
2 
Lys-490-associated FNPETDFLTGK 444 22,326,
359 
17,711,
126 
17,319,
620 
15,758,7
37 
Lys-496-associated FKLEAPDADELPR 678 994,196 754,689 690,847 642,682 
Lys-496-associated LEAPDADELPR 71 14,709,
109 
11,753,
477 
11,930,
606 
11,084,5
31 
Lys-674-associated KQGLLPLTFADPADYNK 112 393,637 326,304 300,272 257,119 
Lys-674-associated QGLLPLTFADPADYNK 692 570,630 428,138 417,142 370,419 
  187 
Table A10. Change in relative abundance for HNE-modified and corresponding unmodified 
ACO peptides in response to HNE-exposure time at a 10:1 HNE:ACO molar ratio. Averaged 
iTRAQ reporter ion intensities are given here. iTRAQ reporter ion intensities were obtained 
using higher-energy C-trap dissociation (HCD) in an Orbitrap mass spectrometer. This dataset is 
the result of only one preparation subjected to three replicate LC–MS/MS runs. The mass list 
described in Table A9 was used and only mass list peptides are included in this table. All entries 
were used in constructing Figures 4-5, 4-6 and 4-7. For a peptide identification to be accepted, a 
PeptideProphet score of 0.9 or greater was required. MS/MS where all four iTRAQ reporter ion 
intensities were zero were discarded. C* indicates carboxyamidomethylation at Cys; C@ 
indicates HNE Michael addition at Cys followed by reduction; H^ indicates HNE Michael 
addition at His followed by reduction; K~ indicates HNE Michael addition at Lys followed by 
reduction; M# indicates oxidation at Met. 
  
  188 
Appendices-II: Spectra 
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